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ABSTRACT OF DISSERTATION

QUANTIFICATION OF FACTORS GOVERNING DRUG RELEASE KINETICS
FROM NANOPARTICLES: A COMBINED EXPERIMENTAL AND MECHANISTIC
MODELING APPROACH
Advancements in nanoparticle drug delivery of anticancer agents require
mathematical models capable of predicting in vivo formulation performance from in vitro
characterization studies. Such models must identify and incorporate the physicochemical
properties of the therapeutic agent and nanoparticle driving in vivo drug release. This
work identifies these factors for two nanoparticle formulations of anticancer agents using
an approach which develops mechanistic mathematical models in conjunction with
experimental studies.
A non-sink ultrafiltration method was developed to monitor liposomal release
kinetics of the anticancer agent topotecan. Mathematical modeling allowed simultaneous
determination of drug permeability and interfacial binding to the bilayer from release
data. This method also quantified the effects of topotecan dimerization and surface
potential on total amount of drug released from these liposomal formulations. The pHsensitive release of topotecan from unilamellar vesicles was subsequently evaluated with
this method. A mechanistic model identified three permeable species in which the
zwitterionic lactone form of topotecan was the most permeable. Ring-closing kinetics of
topotecan from its carboxylate to lactone form were found to be rate-limiting for
topotecan drug release in the neutral pH region.
Models were also developed to non-invasively analyze release kinetics of
actively-loaded liposomal formulations of topotecan in vivo. The fluorescence excitation
spectra of released topotecan were used to observe release kinetics in aqueous solution
and human plasma. Simulations of the intravesicular pH in the various release media
indicated accelerated release in plasma was a consequence of increased intravesicular pH
due to ammonia levels in the plasma instead of alterations in bilayer integrity. Further

studies were performed to understand the roles of dimerization, ion-pairing, and
precipitation on loading and release kinetics obtained from actively-loaded topotecan.
Extension of this type of modeling for other types of nanoparticles was illustrated
with doxorubicin-conjugated polymeric micelles.
Mathematical modeling of
experimental studies monitoring doxorubicin release identified conjugation stability
during storage, hydrazone hydrolysis kinetics, and unconjugated doxorubicin partitioning
affected micellar doxorubicin release. This work identifies several of the key parameters
governing drug release from these liposomal and micellar nanoparticles and lays the
framework for future development of in vivo release models for these formulations.
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CHAPTER ONE
Statement of Aims
Much has been made of the potential of nanoparticles as drug delivery vehicles due to
their unique properties (e.g. size, shape, surface chemistry); however, few nanoparticle
formulations have been approved for clinical use.

The low percentage of approved

nanoparticle formulations is partially due to the current trial-by-error approach generally
used in the development of these formulations. Such a haphazard way to develop successful
nanoparticle formulations is time-consuming and expensive and must be improved to
increase the success of nanomedicines. Furthermore, most in vitro characterization studies
of nanoparticle release kinetics do not critically evaluate the factors governing observed
release let alone provide any idea whether these studies are able to predict release in vivo.
The application of mechanistic mathematical models supported by experimental studies
is necessary to rationally optimize nanoparticle drug delivery systems and begin the critical
task of correlating in vitro release characteristics to in vivo performance. To this end, the
use of mechanistic models to characterize in vitro release kinetics must incorporate
thermodynamic (e.g. drug ionization state, self-association, interfacial binding) and kinetic
(e.g. drug species’ permeability and/or kinetics of drug degradation of drug, particle, and/or
drug-particle linkages) properties inherent to the drug/particle system. Furthermore, these
models must also account for the specific effects of the method used to monitor release,
such as drug transport through a dialysis membrane or sink vs. non-sink conditions. This
thesis focuses on developing an approach that combines experimental studies with
supporting mechanistic mathematical models capable of identifying the factors governing
nanoparticle drug release.

The aims outlined below were pursued to advance

understanding of factors which affect nanoparticle drug release kinetics and provide

1

examples for future approaches to analyzing drug release kinetics and developing models
capable of predicting drug release.
I.

Develop and validate a non-sink method to simultaneously determine both
liposomal release kinetics and apparent binding coefficients of topotecan to
the lipid bilayer using mathematical modeling.
An ultrafiltration method was developed and validated to separate encapsulated
from free drug to monitor liposomal release kinetics under non-sink conditions.
Using a mathematical model that considered both drug permeability and binding to
the bilayer-solution interface allowed for both constants to be determined
simultaneously from the same experiment. With modification, the model could also
describe release kinetics under sink conditions maintained by dynamic dialysis.

II.

A mechanistic model to assess the pH-sensitive release of liposomal topotecan
was developed and experimentally validated
Using the developed non-sink method, experimental studies were conducted to
observe the pH-dependent release of passively-loaded liposomal topotecan. Based
on these profiles, further studies were conducted to analyze the pKa governing
topotecan ionization in the low-to-neutral pH region. The kinetics of reversible, pHdependent, ring-opening/closing interconversion of the drug between its lactone
and ring-opened carboxylate forms was also assessed to clearly determine the
contribution of the various topotecan species contributing to drug release.

III.

A non-invasive method was developed to monitor liposomal release kinetics
in human plasma and reveal the effect of ammonia levels on intravesicular pH
and accelerated release
A spectroscopic fluorescence method was developed to monitor liposomal
release kinetics of topotecan in plasma in real-time. A mathematical model was
2

developed to compare the release kinetics obtained from this fluorescence method
with those determined by HPLC. Lastly, the accelerated release seen in plasma was
correlated with the ammonia concentration in plasma using simulations to account
for the effects of transbilayer ammonia transport on intravesicular pH.
IV.

Mechanistic mathematical models were developed to identify the factors
contributing to experimentally observed loading and release kinetics of
actively-loaded liposomal formulations of topotecan
The kinetics of topotecan active loading was monitored at 37 °C and a
mechanistic model was developed which incorporated transport of ion pairs of
topotecan with excess chloride in solution. The model was validated with studies
that showed slowed release in the absence of excess chloride. Further studies
focusing on release from these formulations corroborated these factors using
mechanistic models developed to describe release. Lastly, differences in release
kinetics between formulations loaded at 37 and 60 °C were assessed. Mechanistic
modeling of these release profiles implicated precipitation of a HCl salt of topotecan
as the primary cause of the extended release kinetics observed from liposomal
topotecan formulations actively-loaded at 60 °C.

V.

A mechanistic model was constructed to characterize the experimental
release kinetics of doxorubicin-conjugated polymeric micelles using an
approach similar to that used to characterize liposomal drug release kinetics
The approach used to developed mechanistic models for liposomal drug release
was extended to characterize drug release from polymeric micelle nanoparticles.
Experimental release studies of doxorubicin conjugated to block copolymers via a
pH-sensitive hydrazone linkage were mechanistically modeled.

As a result of

modeling, instability of the hydrazone linkage during storage and partitioning of
3

unconjugated doxorubicin into the micellar phase were identified as important
factors in the release kinetics as determined by dynamic dialysis.

Copyright © Kyle Daniel Fugit
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CHAPTER TWO
Introduction
2.1 Nanotechnology and chemotherapy
Treating cancer with conventional therapeutic agents presents many challenges from
both a clinical and physicochemical standpoint. Many chemotherapeutics result in high
systemic toxicity due to their nonspecific actions upon DNA repair and/or cell replication.1
Such toxicity limits the therapeutic doses possible. High systemic clearance and protein
binding also limit tumor exposure to many of the anticancer agents already approved or
currently under development. Improving clinical efficacy of these chemotherapeutic agents
requires increasing tumor exposure while reducing systemic toxicity. From a formulation
standpoint, strategies to increase drug solubility, shield drugs from rapid clearance (e.g.
extend release), and/or target the tumor vasculature would increase the effectiveness of
chemotherapeutic agents.

Nanoparticle delivery systems satisfy many of these

requirements.
A wide array of nanoparticles has been extensively explored as drug carriers for the
treatment of cancer.2-4 These nanoparticulate systems are attractive for pharmaceutical
applications due to their ability to entrap and release drug payloads in a manner capable of
altering pharmacokinetics via increased drug solubility or extended release from the
particle.3, 5 Their unique size is also advantageous for passively targeting the particles and
their drug payloads to solid tumors due to the enhanced permeation and retention (EPR)
effect. This effect is a result of the leaky vasculature within the tumor environment
produced by rapid tumor angiogenesis. Fenestrations between endothelial junctions allow
nanoparticles that cannot penetrate healthy vasculature to reach tumor tissue.6-9

In

addition to the benefits of nanoparticle size, a multitude of chemical surface modifications
may further reduce systemic toxicity through active targeting. Modifying the surface of
5

these particles with various oligomers that are recognized by receptors overexpressed or
unique to cancer cells provides the means to actively target cancer cells.3-5, 10-13

Active

targeting in this context has the potential to increase drug accumulation at the tumor site; 5,
14, 15

it may also allow drugs to bypass efflux transporters overexpressed in drug resistant

cancer cells.7, 16-19
Many types of nanoformulations have been developed to take advantage of these
properties but few have had clinical success.20 Part of this low success rate may be
attributable to differences in release rates observed during in vitro characterization studies
and those occurring in vivo. This is supported by investigations that have shown antitumor
efficacy of drug-loaded nanoparticle formulations is linked to drug release rates.21-24 Many
physiological factors (i.e. age, gender, dose regimen, type or location of cancer, mononuclear
phagocyte system)25 have been hypothesized to contribute to a disparity between in vitro
drug release and the pharmacokinetics (PK) and pharmacodynamics (PD) frequently seen
with nanoparticle formulations of anticancer agents.

However, correlations between

nanoparticle efficacy and these proposed factors remain untested.26, 27 Understanding the
contributions of these various factors to alterations in drug release kinetics from
nanoparticles will require a combined approach of experimental techniques and
mechanism-based mathematical models. Such an understanding will ultimately aid in the
design of models capable of reliably predicting in vivo formulation performance and offer
insights into ways to minimize these physiological effects on nanoformulations.

2.2 Liposomes
Liposomal formulations offer several potential advantages for the intravenous delivery
of antitumor agents due to their ability to increase drug solubility, reduce drug toxicity, and
prolong drug release.3

These liposomes are generally composed of an aqueous core
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surrounded by one or more lipid bilayers. Most liposomes range between 50 and 600 nm in
diameter. Large unilamellar vesicles (LUV’s) (i.e. liposomes with only a single bilayer)
typically range between 50 and 200 nm in diameter (Figure 2.1). LUV’s are advantageous
for developing controlled release strategies and ideal for modeling and studying release
kinetics because: 1) a single bilayer provides a single barrier domain as opposed to the
heterogeneous barrier properties of multilamellar vesicles;28 and 2) the bilayer properties
are minimally altered by curvature effects that reduce chain order in the bilayer.28, 29

Figure 2.1. An illustration of a liposome used in this thesis. The liposome of
radius R forms a single bilayer composed of phospholipids. The phospholipids
comprising the inner and outer leaflet of the bilayer (green and purple,
respectively) are composed of a hydrophobic fatty acid tail and a hydrophilic
phosphatidylcholine headgroup.
Pegylated liposomes have the added benefit of longer systemic circulation due to
reduced clearance by the mononuclear phagocytic system. 3, 30-32 This prolonged circulation
time when combined with an appropriate particle size provides enhanced delivery of
liposomes to solid tumors due to the EPR effect. 3, 8, 31 These properties have led to the FDAapproved liposomal formulation of doxorubicin (DOXIL ®) as well as other drug products,
7

including several currently in clinical trials.33-40 Functionalization of the liposome surface
with specific moieties also makes possible active targeting strategies utilizing receptors that
are highly expressed and specific to various cancer types.3, 7, 16, 40-42

2.2.1 Factors governing liposomal drug release
The release of drugs from liposomes is dependent upon a multitude of factors. These
factors can be divided into two major categories: properties associated with the bilayer
structure and those associated with the aqueous compartments.
The structure of the bilayer is quite complex, with various regions of hydrophobicity
and 3-dimensional order that may interact with drug molecules in specific ways; however,
the hydrophobic domain of the inner bilayer is typically viewed as the rate-limiting barrier
governing drug permeability in bilayers.43-46 The bulk solubility-diffusion model described
over a century ago by Overton was one of the earliest attempts to account for the properties
of bilayers that govern permeability47,

48

and is still sometimes used. The model relates

permeability, Pm, to the oil-water partition coefficient of the solute, K, the diffusion
coefficient of said solute through this oil phase, and the thickness of the bilayer, h. This
relationship is illustrated by the equation below.
𝑃𝑚 =

𝐾𝐷
ℎ

(1)

This equation clearly illustrates the dependence of permeability upon both the ability of the
solute to partition into the bilayer and its diffusivity through the bilayer. The dependence
on partitioning qualitatively explains why ionized compounds are generally impermeable to
bilayer membranes as the free energy for charged species to partition into the bilayer are
much higher than those of neutral compounds.28, 49-51
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This model is overly simplistic, however. It fails to account for the differences in
permeability seen with different bilayer compositions and the drastic reductions in
permeability seen as the size of the solute increases. The bulk solubility-diffusion model is
unable to capture the effects of the ordered structure of the bilayer’s fatty acid tails. This
chain ordering effect provides an additional resistance to drug diffusion and an entropic
barrier to solute (i.e. drug) partitioning, which is also required for transport across the
bilayer.28, 51, 52 This free-surface-area theory explains why lipids that form rigid gel phases
(and higher surface densities) result in lower permeabilities for larger molecules.49, 52 Even
the sudden and large increases seen in transport when the bilayer undergoes a phase
transition from its more rigid gel phase to a liquid crystalline environment with increases in
temperature may be explained by the more loosely-packed structure of the bilayer..50,

53

The longer-chain phospholipids used here (see Figure 2.2) exist in the gel phase under
physiological conditions and are used to slow release.49,

50

Further study of the bilayer

properties was not a focus of this thesis.

Figure 2.2 Phospholipids used for liposomal formulations used within this
thesis.
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When considering release kinetics, determination of the various drug species that are
permeable and subsequently their respective permeabilities is crucial.

As mentioned

previously, the ionization state of drugs and small molecules has been shown to alter
release kinetics,49, 50, 52 Permeability determinations for each ionization state of the drug are
therefore crucial to developing mechanistic models governing liposomal drug release. The
populations of these ionization states and other equilibria or kinetic events in solution may
alter the driving force governing the kinetics of drug release. These factors may include
drug self-association, complexation, precipitation, and/or kinetic events which reduce the
amount of permeable specie(s) present in solution. The studies conducted in this thesis
focus heavily on the physiochemical properties of the drug in the aqueous compartments.
In addition to these physicochemical properties, physiological processes and/or
conditions may also affect liposomal drug release. Bilayer integrity may be compromised
by the particles’ interactions with proteins (e.g. vesicle binding and particle opsonization) 5457

or osmotic stresses58, 59 while in circulation or at the tumor site. Other factors such as the

influx of other permeable species may alter the conditions of the aqueous compartment in
vivo and accelerate release.60 Some of these effects are observed and identified within this
thesis.
With a thorough understanding of the physiochemical and biological phenomena that
affect liposomal drug release, predictable and tunable drug release may be engineered for
these types of formulations. Developing models that incorporate these properties and
mechanistically describe their effect on drug release kinetics is vital to a rational
development process and one of the principal subjects of this thesis.
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2.2.2 Loading Strategies
Implementation of mechanistic models requires an understanding of the loading
methods used to entrap drug within the intravesicular compartment. This is important as
the environmental conditions dictating drug loading (i.e. loading solution) may have vastly
different effects on the intravesicular environment and consequently result in different drug
release kinetics. Two of the main methods used to entrap or load drug within a liposome
(both used within this thesis) are passive and active loading. Passive loading is quite
simple. The lipid films used to form the bilayer are hydrated with a solution containing the
drug of interest. Drug loading efficiencies can vary greatly using this method as highly
lipophilic drugs will have a great affinity for the bilayer 49, 61 while more hydrophilic drugs
will mostly remain within the aqueous phase, leaving much of the drug unencapsulated. 62, 63
Active loading of drug is more complex, as illustrated in Figure 2.3. Many liposomal
formulations of amine-containing (or weakly basic) anticancer agents are actively-loaded by
establishing an acidic intravesicular compartment relative to the extravesicular pH of the
loading solution. This pH gradient is generated by the release of a small, highly permeable
base (ammonia in this case) once it has been removed from the extravesicular solution. As
ammonia is released, protons are generated in the intravesicular compartment and the pH
is lowered. When a weakly basic drug is exposed to this low intravesicular pH, the drug
ionizes and typically becomes impermeable. This maintains the gradient for the permeable
form of the drug to continue driving the loading process. This process results in high drug
loading efficiencies that often prolong drug retention in aqueous buffers.23, 62, 64 However,
many of these formulations may exhibit accelerated release in vivo or ex vivo.23,

62

A

mechanistic understanding of the loading process should aid in deciphering the factors that
contribute to these differences in release kinetics and are investigated in this thesis.
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Figure 2.3 An illustration of the active loading process for weakly basic drugs.
The rates of drug and ammonia transport are governed by their permeabilities
𝑚
𝑚
𝑃𝐷𝑟𝑢𝑔
and 𝑃𝑁𝐻
, respectively.
3

2.3 Polymeric micelles
Polymeric micelles are amphipathic block copolymers which self-associate to form a
hydrophobic core surrounded by a hydrophilic shell when dispersed in aqueous solutions.5,
65

This is illustrated by Figure 2.4. One of the most common examples of these formulations

are Pluronic block copolymer micelles. These triblock copolymers possess a hydrophobic
poly(propylene oxide) chain sandwiched between more hydrophilic poly(ethylene oxide)
chains.65, 66 The ratio of these copolymers may be changed to improve the partitioning of a
particular drug.66 These types of micelles are generally between 10-100 nm in diameter,
allowing them to take advantage of passive targeting due to the EPR effect 65 and overcome
multidrug resistant cancers.19,

65

These initial polymer micelle formulations primarily

focused upon increasing the solubility of many highly lipophilic anticancer agents while
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reducing the systemic toxicities encountered using other excipients as solubilizing agents.6770

Figure 2.4 An illustration of a polymeric micelle. The nanoparticle forms as the
amphipathic block copolymers self-associate in aqueous solution. The more
hydrophobic polymer block resides in the core and the more hydrophilic
polymer block forms the shell.
Further development of polymeric micelles using more elaborate copolymers has led to
many more exotic versions. These more advanced delivery systems are designed to possess
unique structures capable of providing a plethora of characteristics exploitable for altering
drug release. Some of these designs alter characteristics intrinsic to the formulation (e.g.
particle size, charge, hydrophobicity). While these properties may be advantageous for
altering drug release kinetics, they may also result in a complicated drug release
mechanism. The partitioning of drug payloads may be due to the drug’s affinity for a micelle
with a highly-charged core rather than the typical hydrophobic core.5, 65, 66 Over time, drug
may be released from these various polymeric micelles due to a combination of kinetic
factors (i.e. drug diffusion and/or stability of drug-polymer linkage) and thermodynamic
factors (i.e. complexation/absorption to the micelle core, CMC) intrinsic to the
drug/polymer system and independent of the release environment. 5, 66 Further complexity
13

is added when nanoparticles are engineered to respond to external stimuli such as heat,
electromagnetic waves, enzymatic activity, or pH 5, 63, 65, 71-79 while active targeting strategies
to alter the micelle surface may subsequently alter the mechanism or kinetics of release. 5, 19,
65, 68, 70

Chemically conjugating drugs to the block copolymers is another way to alter drug
release kinetics and adds another dimension to the mechanism of drug release. In several
instances, these drug-conjugated micelles exhibit a biphasic drug release pattern (i.e. burst
drug release followed by an extremely slow drug release phase) that varies depending upon
the pH of the release medium.80-83 This thesis examines the factors governing release from
this type of polymer micelle formulation.

2.4 Topoisomerase inhibitors
2.4.1 Topotecan
Topotecan (TPT) is a topoisomerase I inhibitor currently approved to treat cervical,
ovarian, and small cell lung cancers as an oral capsule or an injectable solution.
Furthermore, TPT is also used in multiple clinical trials as the sole medication or in
conjunction with other medications and/or radiation.84-88

TPT is one of several

camptothecin analogues which stabilize single-strand breaks produced by the DNAtopoisomerase I complex, preventing further DNA replication and eventually resulting in
cell death.89

Due to its dimethylethylamine group, TPT is also weakly basic and

subsequently its active lactone conformation is highly soluble under mildly acidic
conditions.90 As such, an injectable solution of the hydrochloride salt is readily made and
approved for use;88, 91 however, TPT undergoes pH-dependent ring-opening hydrolysis from
its active lactone to a less-active carboxylate form as pH is increased (see scheme 2.5).92
This results in the carboxylate form dominating at physiological pH. The ring-opening
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combined with base-catalyzed degradation and binding of the carboxylate to serum
albumin90, 91, 93 significantly lowers TPT’s effectiveness upon systemic administration.

pH

Figure 2.5. TPT undergoes reversible, pH dependent interconversion between
its lactone (left) and carboxylate (right) forms that results in the lactone form
dominating under acidic conditions while the carboxylate form dominates at
neutral or basic pH.
These issues may be circumvented upon TPT encapsulation in liposomes with a low
intravesicular pH.94 Like other weakly basic drugs, TPT can achieve high encapsulation
efficiency in liposomal formulations utilizing active loading strategies to generate a
transbilayer gradient of lower intravesicular pH relative to the extravesicular loading
solution.21, 42, 61, 73, 95-97 Considerable work has focused on such loading strategies for TPT;
however, the subsequent release of TPT from these formulations is poorly understood.24, 42,
62, 64, 97

Moreover, observations of accelerated release from studies conducted in plasma

have not been explained.62 Part of the work in this thesis focuses on mechanistically
determining the critical parameters attributable to liposomal TPT loading and release
kinetics.

2.4.2 Doxorubicin
Doxorubicin (DOX) is a topoisomerase II inhibitor currently approved to treat several
hematological malignancies in addition to many solid tumors including gastric, ovarian,
thyroid, and small cell lung cancers as an injectable solution.98 DOX is also extensively used
15

in preclinical and clinical trials with a wide array of nanoparticle formulations.36, 40, 99-104
The weakly basic anthracycline stabilizes the topoisomerase II cleavage complex (Top2cc)
formed during unwinding of supercoiled DNA during replication. In the case of DOX, both
single and double strand breaks formed by the Top2cc prevent DNA replication and
eventually triggers cell death.105 At higher DOX concentrations, DOX may suppress Top2cc
altogether by altering DNA structure.105, 106 DOX may be administered as its hydrochloride
salt as a soluble injection due to the weakly basic nature (pKa ~ 8.2) 107 of the
anthracycline’s aminogylcosidic side chain (see Scheme 2.6); however, cardiotoxicity
typically occurs in over half the patients that receive chronic treatment. 108 The generation
of free oxygen radicals in response to DOX is the likely cause 108-110 (although the
mechanisms leading to this are numerous and still debated).108

Figure 2.6. The ionization states of DOX are governed by its acid dissociation
constant (KA) and the pH of the solution. At higher pH, the neutral base form
dominates (left) while its cationic form (right) dominates at lower pH.
Reducing this cardiotoxicity through formulation is of great clinical interest. 110 The
nanoparticle formulation marketed as DOXIL (liposomal doxorubicin) reduces DOX’s
cardiotoxicity due to its slow release from liposomes and preferential accumulation of these
nanoparticles in solid tumors.30, 73, 111-113 Even so, the liposomal formulations have led to
other side effects including hand-foot syndrome (i.e. blistering and skin necrosis typically in
16

the extremities), likely due to a combination of the prolonged circulation and slow DOX
release from the liposome delivery vehicle in combination with the rich capillary beds of the
skin.30, 114 This has led to much research on other nanoparticle formulations with various
release rates in an attempt to find formulations which may not share in this same toxicity.
The factors governing DOX release from a polymeric micelle formulation are explored as
part of this thesis.

2.5 Characterization of nanoparticle drug release
The characterization of nanoparticle drug release requires methods to monitor either
the loss of drug from the nanoparticle or the accumulations of drug in the release media.
There are many methods employed to monitor nanoparticle drug release under these
constraints;115-117 however, few consider the impact of environmental conditions (particular
to the selected characterization method) which may alter observed in vitro drug release
kinetics. One popular method used to monitor in vitro drug release from nanoparticles that
exhibits several of these method-specific effects is dynamic dialysis. Dynamic dialysis uses
a large reservoir in an attempt to provide the sink conditions necessary to drive release to
completion. Meanwhile, the nanoparticles remain concentrated within a small volume
compartment separated from the reservoir by a semi-permeable membrane.19, 60, 63, 64, 118-120
A large reservoir volume, however, does not necessarily ensure sink conditions within the
dialysis chamber itself. Depending on the nanoparticle release kinetics and the extent of
drug binding to the nanoparticle, transport across the dialysis membrane may become ratelimiting.3,8 Corrections for drug binding to the nanoparticles and the barrier properties of
the dialysis membrane are therefore crucial when interpreting kinetic data collected with
dynamic dialysis.49, 61, 63, 118
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Most other methods used to monitor nanoparticle drug release typically use a physical
separation
differences78,

(e.g.
79

size-exclusion

chromatography,

ultrafiltration) 51,

between free and entrapped drug.

121

or

spectral

Validation of the separation

efficiency/recovery or spectral deconvolution63 is obviously required for interpretation of
release kinetics using these methods. Just as important as this validation and frequently
overlooked during release characterization is evaluation of “sink” or “non-sink” conditions.
If non-sink conditions are present, evaluation of release kinetics becomes problematic. For
example, changes in the extent of release from nanoparticle formulations due to changes in
pH or temperature do not necessarily translate into differences in release rates (i.e.
thermodynamics vs. kinetics).81,
effect.

122, 123

Figure 2.7 provides a general illustration of this

Without a way to quantify these distinctions, assessing the eventual in vivo

performance becomes challenging.

Figure 2.7

An illustration of the effect of non-sink conditions on release

profiles. In this illustration, the initial rate of release is the same; however, the
final % of drug released is different due to a different equilibrium. Interpreting
both factors during nanoparticle release characterization is necessary to
evaluate the effect of different conditions (e.g. pH and/or temperature) on
altering the rate of release rather than the equilibrium.
18

Mathematical modeling of release profiles obtained from these methods may provide
the ability to validate such release methods and subsequently determine release
parameters intrinsic to the drug/nanoparticle system of interest. At a minimum, these
models can distinguish the kinetic and thermodynamic quantities intrinsic to the
drug/particle system and those from the experimental environment contributing to the
observed release profiles.49, 60, 63, 124-126 This thesis provides validation of several non-sink
methods with the aid of mathematical models capable of quantifying the kinetics and
approach to equilibrium exhibited by release studies conducted with such methods.
With validated methods, studies that systematically examine release kinetics under a
variety of conditions can be used for the development of mechanistic models which will
provide insights on further optimization and control of drug release from these
nanoparticle drug delivery systems.

These mechanistic models will contain the

physicochemical principles governing drug release from the nanoparticle of interest. They
may require other studies in conjunction with release studies to validate the
physicochemical principles affecting release kinetics.49, 53, 60, 63, 124
Once these mechanistic models are capable of describing nanoparticle drug release in
vitro, the incorporation of in vivo conditions will be possible and ultimately lead to accurate
in vitro/in vivo correlations. Such correlations would reduce much of the costs incurred
during preclinical development due to extensive animal testing and unguided formulation
optimization. Mathematical models for assessing in vitro drug release and predicting in vivo
drug release from nanoparticle formulations would be useful both in the design phase and
during preclinical testing where avoiding the extensive use of animals would be highly
desirable. Such models would facilitate the design of formulations with adjustable and
predictable drug release rates for patient-specific treatment regimens. The work within

19

this thesis is intended to develop mechanistic models that are adequate enough to describe
drug release kinetics from nanoparticle formulations in vitro. The approach used here along
with its subsequent findings will guide the design of future studies used to characterize
nanoparticle drug release kinetics, optimize the loading and release of the formulations
studied, and explore the mechanistic changes in release kinetics due to various
physiological factors.

Copyright © Kyle Daniel Fugit
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CHAPTER THREE
Dynamic Non-sink Method for the Simultaneous Determination of Drug
Permeability and Binding Coefficients in Liposomes
3.1 Introduction
Mathematical models for assessing drug permeability and predicting in vivo drug
release from nanoparticle formulations would be useful both in the design phase and during
preclinical testing where avoiding the extensive use of animals would be highly desirable.
Such models would facilitate the design of formulations with adjustable and predictable
drug release rates for patient-specific treatment regimens.

Mechanism-based models

applicable to liposomal systems would need to account for three main factors affecting drug
release: 1) the escaping tendency or effective concentration of the entrapped (permeable)
drug species which serves as the driving force for liposomal release; 2) drug speciation and
species permeability-area products for lipid bilayer transport;44, 49, 52, 53, 63, 127, 128 and 3) the
environmental conditions in which drug release occurs both during the in vitro release
characterization and in vivo.49,

118

The intraliposomal driving force for transport likely

depends on such factors as pH-dependent drug speciation, self-association, complexation,
precipitate formation, membrane binding, and drug degradation/interconversion kinetics.
The driving force for liposomal release and the membrane permeability-area product are
closely linked and dependent on which drug species account for the release.49, 60, 129, 130 The
environmental conditions (e.g., temperature, pH, sink conditions or lack thereof, presence of
permeable buffer species, lipid-bilayer perturbing components, etc.) also impact both the
driving forces and permeability coefficients. Thus, robust mechanism-based models for
predicting liposomal drug release may be quite complex. Translation of release parameters
generated in vitro to the prediction of drug release in vivo may be particularly challenging.
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The necessary corrections will likely vary depending on the in vitro method employed to
study drug release.
A number of methods currently exist to monitor in vitro drug release from
nanoparticles115,

117, 131

but extrapolation to predict in vivo release often requires an

adjustment for the absence of sink conditions in the in vitro experiments as well as other
possible environmental differences. For example, one popular method to monitor in vitro
drug release from nanoparticles is dynamic dialysis. Dynamic dialysis uses a large reservoir
in an attempt to provide the sink conditions necessary to drive the process to completion.
Meanwhile, the nanoparticles remain concentrated within the small volume compartment
and separated from the reservoir by a semi-permeable membrane.19,

60, 63, 64, 118-120

Unfortunately, a large reservoir volume does not ensure sink conditions within the dialysis
chamber itself. Depending on the nanoparticle release kinetics and the extent of drug
binding to the nanoparticle, transport across the dialysis membrane may become ratelimiting.3,8 Corrections for drug binding to the nanoparticles and the barrier properties of
the dialysis membrane are therefore crucial when employing dynamic dialysis for
predictive modeling.49, 61, 63, 118 In some cases, incomplete release has been observed even
though approximate sink conditions (based on overall drug concentration gradients) were
maintained due to factors such as pH differences or drug binding phenomena. Such factors
reduce the thermodynamic activity gradient for the permeable species, resulting in the
achievement of equilibrium and subsequently incomplete release. 72,

132-134

Finally, even if

the above concerns relating to sink conditions are properly taken into account, a separate
set of experiments in addition to dynamic dialysis would be needed. These additional
experiments would be required to quantify the species-dependent membrane binding of the
drug and its influence on observed release kinetics for the construction of a mechanismbased release model. 63, 119
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A method to evaluate drug release kinetics under well-defined non-sink conditions when
combined with the appropriate mechanistic release model would allow simultaneous
determination of the kinetic and thermodynamic parameters governing release kinetics.
This method would also provide a more robust assessment of nanoparticle formulations.
This study demonstrates the utility of a novel ultrafiltration method to analyze drug release
from nanoliposomal formulations under non-sink conditions using the model anti-cancer
agent topotecan (TPT). With the appropriate mathematical models, the liposomal drug
release parameters generated under non-sink conditions were shown to be comparable
with those obtained from dynamic dialysis.

This non-sink method was also used to

simultaneously characterize membrane binding of the drug and its dependence on both
drug and lipid concentrations in suspension.

3.2 Experimental
3.2.1 Materials
Powders of 1,2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC, >99% purity) and
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000]
(m-PEG DSPE, MW = 2806, >99% purity) were purchased from Avanti Polar Lipids
(Alabaster, AL). Topotecan hydrochloride was purchased from AK Scientific (Union City,
CA). Float-A-Lyzer® G2 dialysis tubes (100,000 MWCO) were purchased from Spectrum
Labs (Rancho Dominguez, CA). Millipore semi-micro ultrafiltration centrifugation devices
(regenerated cellulose, NMWL: 30,000), 100 nm pore size Nuclepore polycarbonate
membranes, solvents, and buffer salts were purchased from Fisher Scientific (Florence, KY).
All solvents were HPLC grade.
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3.2.2 Preparation and characterization of DSPC/m-PEG DSPE liposomes
Large unilamellar vesicles were formed using a film hydration and extrusion process as
reported previously with slight modifications.28, 49, 62 Briefly, DSPC and m-PEG DSPE (95:5
mol:mol) lipids were weighed, dissolved in chloroform, and aliquots of the resulting
solutions were distributed into separate vials. Chloroform was subsequently evaporated
under a stream of nitrogen gas and the residue was vacuum-dried at 40°C for 6 hours. For
release studies, TPT was passively loaded into liposomes by hydrating the dried lipid film
with TPT solutions (0.25 mM in pH 4.0, 50 mM formate buffer adjusted to an ionic strength
of 0.3 with NaCl) to achieve 40 or 90 mg lipid/mL suspensions. These suspensions were
extruded 10 times through two stacked 100 nm pore size Nuclepore® polycarbonate
membranes using a Liposofast® extrusion device at 60°C to obtain unilamellar vesicles with
encapsulated TPT in the intra-vesicular solution. Blank liposome suspensions (40 mg
lipid/mL) used in spiking experiments for dynamic dialysis and ultrafiltration validation
were made under the same conditions as passively loaded liposomes without TPT present
in the hydrating solution.
Liposome characterization included particle size measurements by dynamic light
scattering (DLS) and lipid content analyses using HPLC with evaporative light scattering
detection (ELSD) as previously reported.130

Particle size data were used to monitor

liposome stability and in combination with information on the number of vesicles in
suspension (based on lipid content) and bilayer surface density data from the literature to
calculate liposomal volumes necessary for the mathematical models.49, 50, 84, 135

3.2.3 Release of TPT from DSPC/m-PEG DSPE liposomes
All release studies were conducted in a water-jacketed incubator maintained at 37 °C.
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3.2.3.1 Sephadex® column removal of unencapsulated drug from passively loaded liposome
suspensions
To compare release studies using dynamic dialysis (sink conditions) and ultrafiltration
(non-sink conditions), 0.7 mL of 40 mg lipid/mL suspensions was passed through a
Sephadex® PD-10 column to separate liposomes from unencapsulated drug. The first 4.75
mL was collected and diluted to 15 mL of suspension using the same buffer used for lipid
hydration (without drug). Next, 4.5 mL of this suspension was either transferred to dialysis
tubes or 7 mL glass vials with a rubber stopper. Release studies under either sink or nonsink conditions were performed in triplicate. Additional studies of the concentration
dependence of binding to the DSPC bilayer utilized 90 mg lipid/mL suspensions and 0.25 or
0.7 mL aliquots passed through a Sephadex® column. In these instances, the first 1.5 mL of
eluent was discarded and the next 3.25 mL containing the liposome suspension was
collected and transferred to 7 mL glass vials with a rubber stopper.
3.2.3.2 Non-sink release studies measured by ultrafiltration
Glass vials containing the liposome suspensions were placed on a Thermo Cimerac iPoly
15 multipoint stirrer insulated with 1.5 inches of Styrofoam® to minimize heating from the
stir plate and subsequently maintained a suspension temperature of 37.4 ± 0.6 °C.
Liposome suspensions were stirred at 200 rpm over the time course of the release study (~
96 hours) using 10 x 5 mm Teflon® stir bars. Encapsulated drug was monitored by ultrafiltration
of 100 µL samples taken throughout the duration of the release studies.
Ultrafiltration was chosen as it has been used in previous studies with liposomes as a
method in which encapsulated drug may be separated from released drug. 121,

130

Each

sample was diluted with chilled (4 °C) buffer to 450 µL to quench drug release and ultrafiltered
using an Amicon® Ultra 0.5 mL centrifugal filter device with a 30,000 MWCO Ultracel®
membrane. Samples were centrifuged in these cartridges at 14,000 rpm for 10 minutes in an
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Eppendorf 5417R maintained at 4 °C. During centrifugation, liposome integrity was maintained
as suspensions were concentrated but not dried completely due to the conical geometry of the
ultrafiltration membrane. Concentrated suspensions (26 ± 2 µL) were recovered by inverting and
centrifuging the cartridge at 2000 rpm for another 2 minutes. After recovery of the concentrate,
400 µL of chilled buffer was added and the process was repeated to ensure complete removal of
membrane-bound extravesicular drug. The final concentrate from this second cycle was analyzed
by HPLC after dilution into the calibration range of TPT standards. Chilled methanol (-20 °C)
was used to disrupt the vesicles and minimize solvent evaporation during sample dilution.
Samples that had not been ultrafiltered (20–100 uL) were also taken and immediately
diluted in chilled methanol to determine the total amount of TPT and any extravesicular
drug present at the beginning of the release study.
3.2.3.3 Dynamic dialysis under sink conditions
Dialysis tubes (Float-A-Lyzer® G2, 100,000 MWCO) containing 4.5 mL of liposome
suspension were placed in 900 mL reservoirs containing pH 4.0 formate buffer preequilibrated at 37 °C. Aliquots (20 uL) were removed from the dialysis tube over a 48 hour
period and immediately diluted in chilled methanol for TPT analysis by HPLC.

3.2.4 Dialysis tube swelling studies
Changes in the suspension volume within the dialysis tube during release studies may
produce errors in the observed loss of drug during dynamic dialysis. To correct for this, the
rate of swelling as measured by the volume of sample within the dialysis tubes at
equilibrium must be determined. Fresh dialysis tubes of the same make as those used in
dynamic dialysis studies were filled with 4 mL of the same buffer as that in the reservoir.
These tubes were then allowed to sit in reservoirs at the same conditions used in dynamic
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dialysis studies. The volume in these tubes was monitored over time using a 10 mL
graduated cylinder.

3.2.5 TPT dimerization
Several reports have indicated that TPT self-associates to form dimers,136-138 the tendency
of which may be pH dependent.138

Self-association of TPT may result in liposomal

membrane binding coefficients that are concentration dependent if only the monomeric
form is involved in binding. Since previous characterization of TPT self-association has
been in the neutral pH range,136-138 studies were conducted to assess TPT dimerization at
the conditions release studies were performed. Apparent extinction coefficients were
calculated for varying concentrations of TPT (1 – 250 µM) dissolved in the same buffer
employed for release studies. Absorbance was measured at wavelengths of 360, 376, 378,
380, 382, 384, 386, and 388 nm using a Varian Cary 50 UV-Vis spectrophotometer. NSG
quartz cuvettes (NSG Precision Cells, Farmingdale, NY) with 2 and 10 mm path lengths were
used to stay within the analytical range of the instrument.

3.2.6 HPLC analyses
Samples from release and validation studies were analyzed for TPT and lipid
concentration by HPLC as reported previously.49,

130

TPT samples were analyzed with a

previously developed HPLC method utilizing fluorescence detection. 130

TPT lactone

standards were prepared in chilled, acidified methanol over a concentration range of 20200 nM. Samples were diluted to within this concentration range using chilled methanol.
Samples were either immediately injected or stored at -20 °C for no more than 48 hours
before analysis.
Lipid analysis was performed using an HPLC coupled to an ELSD (Sedere, Inc.,
Lawrenceville, NJ) as previously reported.49, 130 DSPC standards and samples were dissolved
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in 80% chloroform:19.5% methanol:0.5%(v/v) of 30% (vol) NH4OH solution. Standards
spanned the concentration range of 0.05 – 0.3 mg DSPC/mL. Lipid samples from release
studies (50 – 150 µL) were dried at room temperature under N 2. Once dried, samples were
redissolved in the above-mentioned solvent mixture to be within the calibration range of
DSPC standards.

3.2.7 Model Development and Data Analysis
Previously, mechanistic models for liposomal release have been developed to account for
the additional resistance contributed by the dialysis membrane in dynamic dialysis
studies.49,

60, 118

The general concepts applicable to liposomal systems are depicted in

Scheme 3.1. By developing appropriate models, the rate of drug release applicable to sink
conditions can be extracted from a variety of release methods. Such a case is illustrated
here by using mathematical models to analyze and compare the kinetics of liposomal
release of TPT under sink and non-sink conditions. All fitting of release kinetics and
dimerization data was performed using Micromath® Scientist® non-linear regression
software utilizing a weighting factor of two.

28

Scheme 3.1. Illustration of the relevant kinetic and equilibrium processes
applicable in developing a mathematical model for liposomal drug release as
determined by dynamic dialysis. The volume compartments of a liposome with
radius, r, are highlighted along with the kinetic and binding components
governing drug release. The blue core is the inner aqueous volume, 𝑽𝒘
𝒊 , while
𝒎
the green and purple sections refer to the inner, 𝑽𝒎
𝒊 , and outer, 𝑽𝒐 , membrane

volumes, respectively. The rate of liposomal drug release depends on the rate
constant, km’, and the difference in the unbound inner and outer aqueous drug
concentrations, Tiw and Tow, respectively, while the apparent intravesicular, Ki’,
and extravesicular, Ko’, binding coefficients govern the equilibrium between
drug bound to the inner or outer lipid membrane, Tim and Tom, respectively, and
the corresponding unbound drug in the intravesicular or extravesicular
compartments, respectively. The rate constant kd reflects the diffusion of drug
across the dialysis membrane driven by the concentration gradient Tow -Tr. All
notations in red refer to aspects unique to dynamic dialysis conditions.
3.2.7.1 Mathematical model of TPT release from unilamellar liposomes: non-sink conditions
A mechanistic, mathematical model is required to obtain both drug permeability and
membrane- binding from release studies. Several models describing drug loading and
release have already been developed;49, 60, 124, 127, 128, 139, 140 however, only a few have been
tested and these studies have only examined release under sink conditions.49, 60, 124
The apparent rate constant governing drug release from a liposome is a function of the
drug’s apparent permeability coefficient, 𝑃𝑚 ′, through the bilayer and the radius, r, of the
particle. This is shown below in equation 1.49, 50
3

′
𝑘𝑚
= 𝑟 𝑃𝑚 ′

(1)

′
While 𝑘𝑚
may be dependent on the respective permeabilities of each species of drug

present in solution, such a distinction cannot be made here as multiple conditions (e.g. pH)
′
must be explored to determine each specie’s contribution. Therefore, the 𝑘𝑚
determined
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here applies to the specific pH chosen for these experiments (which is satisfactory for
comparing these different release methods).
Liposomal drug release is dependent on the driving force developed by the effective
concentration gradient between unbound, intra- and extra-vesicular drug concentrations
(𝑇𝑖𝑤 and 𝑇𝑜𝑤 , respectively). This is expressed by equations 2a and b.
𝑑𝑇𝑖
𝑑𝑡
𝑑𝑇𝑜
𝑑𝑡

=

𝑛𝑉𝑖𝑇
𝑉0𝑇

′ ( 𝑤
= −𝑘𝑚
𝑇𝑖 − 𝑇𝑜𝑤 )

′ ( 𝑤
′ ( 𝑤
𝑘𝑚
𝑇𝑖 − 𝑇𝑜𝑤 ) = 𝑓𝑣 𝑘𝑚
𝑇𝑖 − 𝑇𝑜𝑤 )

(2a)
(2b)

These differential equations describe bilayer-limited Fickian diffusion at a pseudo steadystate. The term 𝑓𝑣 symbolizes the ratio of total entrapped volume (the product of the total
number of vesicles, n, and intravesicular volume of a single liposome, 𝑉𝑖𝑇 ) to total
extravesicular volume, 𝑉0𝑇 , thus accounting for the difference in volumes of the inner and
outer compartments. Derivation of the concentrations of unbound drug in the intra- and
extra-vesicular compartments in terms of total intra- and extra-vesicular drug
concentrations (𝑇𝑖 and 𝑇𝑜 , respectively) will be described in a later section.
For non-sink release studies, both the initial concentrations of intra- and extra-vesicular
drug were determined by analyzing total suspension concentration of drug, T, and drug
concentration after ultrafiltration of suspension when the release study began, Ti,0. This is
shown by the equations below:
𝑇𝑖 (0) = 𝑇𝑖,0
𝑇𝑜 (0) = 𝑇𝑜,0 = 𝑇 − 𝑓𝑣 𝑇𝑖,0

(3a)
(3b)

3.2.7.2 Dynamic dialysis model of drug release from unilamellar liposomes: sink conditions
Dynamic dialysis is advantageous for maintaining sink conditions as it provides a large
reservoir capable of maintaining the driving force for drug release. Because nanoparticles
cannot cross the dialysis membrane, significant dilution of the nanoparticle suspension
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during drug release is avoided and the concentration of drug remaining in the suspension
versus time can be quantified. This is depicted in Scheme 1. Mathematically, the differential
equation governing transport in the vesicle is the same as equation 2a, where 𝑇𝑜𝑤 refers to
the unbound extravesicular TPT within the dialysis tube. A release rate constant for
transport of liposomally-released drug from the dialysis tube, 𝑘𝑑 , must be added to eqn. 2b
to describe transport from the extravesicular compartment of the dialysis tube into the
reservoir compartment. This is expressed by equation 4 with portions in red identifying the
term unique to dynamic dialysis.
𝑑𝑇𝑜
𝑑𝑡

′
= 𝑘𝑚
𝑓𝑣 (𝑇𝑖𝑤 − 𝑇𝑜𝑤 ) − 𝑘𝑑 𝑇𝑜𝑤

(4)

In these studies, the suspension concentration of TPT within the dialysis tube at any time
(𝑇𝑑 ) is sampled.

This concentration would naturally be composed of intra- and

extravesicular TPT as shown by equation 5.
𝑇𝑑 = 𝑓𝑣 𝑇𝑖 + 𝑇𝑜

(5)

Derivation of the unbound drug concentrations in dynamic dialysis is the same as in the
non-sink condition case (see next section).
For sink conditions using the dynamic dialysis method, the initial conditions are
dependent on the loading condition of the liposome suspension. For passively-loaded
liposomes, the initial conditions are as follows:
𝑆

𝑇𝑖 (0) = 𝑓

(6a)

𝑇𝑜 (0) = 0

(6b)

𝑣

where S is the initial suspension concentration of TPT within the dialysis tube.

To

accurately discern the rate of transport of drug through the dialysis membrane, a
suspension of blank liposomes spiked with free TPT was used. While the rate equations are
the same as for passively-loaded drug, the initial conditions are not and are expressed
below:
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𝑇𝑖 (0) = 0

(7a)

𝑇𝑜 (0) = 𝑆

(7b)

3.2.7.3 Derivation of unbound drug concentration for modeling of release studies at sink and
non-sink conditions
Binding of drug to the phospholipid membrane interface has been reported previously
with other chemotherapeutics and lipophilic drugs.49, 53, 61, 63, 118, 141 Such binding will reduce
the driving force for drug transport, resulting in the need for a mathematical model that
includes this effect on release kinetics. Such a model was developed based on previous
models (which account for drug binding) to describe the concentration of unbound drug in
terms of total intra-and extravesicular drug concentration and its subsequent effect on
release kinetics.49, 60 The relationship is the same for release studies conducted under nonsink and sink conditions and is derived below.
The total amount of drug inside (𝑀𝑖,𝑇 ) and outside (𝑀𝑜,𝑇 ) the vesicle can be expressed in
terms of the contributions of aqueous and membrane bound components. Equations 8a and
b express these mass balances.
𝑤
𝑚
𝑀𝑖,𝑇 = 𝑀𝑖,𝑇
+ 𝑀𝑖,𝑇

(8a)

𝑤
𝑚
𝑀𝑜,𝑇 = 𝑀𝑜,𝑇
+ 𝑀𝑜,𝑇

(8b)

In these equations and from this point on, the superscripts “w” and “m” represent
unbound drug in the aqueous compartment and membrane bound drug, respectively; the
subscripts i, and o, refer to the intra- and extra-vesicular compartments. These mass
balance equations can be expressed in terms of concentrations using the ratios of the
aqueous to membrane volume in the inner and outer compartments defined in equations
9a-e (see Scheme 1)
𝑎=

𝑉𝑖𝑤
𝑉𝑖𝑇

,𝑏 =

𝑉𝑖𝑚
𝑉𝑖𝑇

,𝑐 =

𝑉𝑜𝑤
𝑉𝑜𝑇
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,𝑑 =

𝑛𝑉𝑜𝑚
𝑉𝑜𝑇

, 𝑓𝑣 =

𝑛𝑉𝑖𝑇
𝑉𝑜𝑇

(9a-e)

thus producing equations 10a & b for total drug concentration within, 𝑇𝑖 , and outside, 𝑇𝑜 ,
the vesicles:
𝑇𝑖 = 𝑎(𝑇𝑖𝑤 ) + 𝑏(𝑇𝑖𝑚 )

(10a)

𝑇𝑜 = 𝑐 (𝑇𝑜𝑤 ) + 𝑑(𝑇𝑜𝑚 )

(10b)

Next, the concentration gradient of aqueous, unbound drug must be solved in terms of
total drug encapsulated. This is done by incorporating an apparent volume-normalized
membrane binding coefficient describing the equilibrium between TPT bound at the
interface of the bilayer membrane and that in solution for the intravesicular, Ki’, and
extravesicular, Ko’, compartments. These binding constants may differ if there are
differences in the intra- versus extra-vesicular environments (e.g. pH gradients, ionic
strength differences, etc.) or prior to equilibrium when drug concentrations may differ
dramatically between the inner and outer compartments. In the present study of passively
loaded liposomes, the intravesicular and extravesicular compartments were at the same pH
and buffer concentration throughout the experiment. At equilibrium both compartments
contained the same drug concentration. Under these conditions we found that a single K’
could be assumed (Ki’= Ko’) without diminishing the quality of the fit of the model to the
data.
With this assumption, the model may refer to both as K’ and,Tiw and Tow may be described
by equations 11a and b
1

(11a)

1

(11b)

𝑇𝑖𝑤 = 𝑓𝑖𝑤 𝑇𝑖 ; 𝑓𝑖𝑤 = 𝑎+𝑏𝐾′
𝑇𝑜𝑤 = 𝑓𝑜𝑤 𝑇𝑜 ; 𝑓𝑜𝑤 =

𝑐+𝑑𝐾′

with 𝐾 ′ = 𝑇 𝑚 ⁄𝑇 𝑤 . Using these substitutions, equations 2a, 2b, and 4 can be rewritten in
terms of total intra- and extra-vesicular drug concentration.
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3.2.7.4

Concentration corrections for ultrafiltration recovery and dialysis compartment

volume
For non-sink release studies, the recovery of intra- and extra-vesicular drug after
ultrafiltration must be accounted for to accurately assess release kinetics. In dialysis
experiments under sink conditions, the volume of the nanoparticle suspension within the
dialysis tubes may fluctuate.
The concentration of TPT determined by HPLC analysis of ultrafiltered samples, while
mostly composed of intravesicular TPT, may require corrections due to the ultrafiltration
process. The observed concentration obtained from ultrafiltration, 𝑇𝑢 , must be interpreted
correctly to accurately model drug release. This can be accomplished by expressing 𝑇𝑢 with
equation 12.
𝑇

𝑇𝑢 = 𝜔 𝑓𝑖 + 𝜑𝑇𝑜
𝑣

(12)

Here, the % of intravesicular (𝜔) and extravesicular drug (𝜑) recovered in the
ultrafiltrate were determined with validation studies.
Ideally, the concentration in samples from dynamic dialysis studies at any sample time, n,
would be dependent upon only diffusive transport process. This suspension concentration,
′
Td,n, can be determined from the observed concentration within the dialysis tube, 𝑇𝑑,𝑛
, by

accounting for volume changes due to sample removal and dialysis bag shrinking/swelling.
These effects are expressed by equation 13.
′
𝑇𝑑,𝑛 = 𝑥𝑣,𝑛 𝑥𝑠,𝑛 𝑇𝑑,𝑛

(13)

The factors 𝑥𝑣,𝑛 and 𝑥𝑠,𝑛 correct for volume swelling in the dialysis tube and the mass
removed due to sample collection since the previous time point, respectively.
The correction factor for volume change in the dialysis tube, 𝑥𝑣,𝑛 , is:
𝑥𝑣,𝑛 =
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𝑉𝑛−1
𝑉𝑛

(14)

where 𝑉𝑛 is the volume present in the dialysis tube at sample time, n, and 𝑉𝑛−1 is the
volume present after removing sample for analysis at the previous time point (n-1). The
following equation describes the volume change occurring between time points:
𝑉𝑛 = 𝑉𝑛−1 + (𝑉𝑒𝑞 − 𝑉𝑛−1 )(1 − 𝑒 −𝑘𝑣 𝑡𝛥𝑛 )

(15)

where 𝑘𝑣 is the rate constant and 𝑉𝑒𝑞 is the volume in the dialysis tube at hydrostatic
equilibrium. 𝑉𝑛−1 is the volume at the previous sampling time and 𝑡𝛥𝑛 is the time interval
between the samples.
In addition to swelling, the mass removed with each sample, while small, could
cumulatively result in a substantial amount of lipid removal and subsequently encapsulated
drug removed from the dialysis tube. Because of volume swelling, the amount of mass
taken from the previous sampling must be accounted for at each sampling. The correction
factors for the first, second, and any later sample (𝑥𝑠,1 , 𝑥𝑠,2 , and 𝑥𝑠,𝑛 , respectively) are:
𝐿0

𝑥𝑠,1 =
𝐿

𝑥𝑠,2 = 𝐿0 −
0

𝐿

𝑥𝑠,𝑛 = 𝐿0 − (
0

𝐿𝑠,1𝑉𝑠,1
𝐿0𝑉0

+

(16a)

𝐿0
𝐿𝑠,1 𝑉𝑠,1

(16b)

𝐿0 𝑉0

𝐿𝑠,2𝑉𝑠,2
𝐿0𝑉0

+⋯

𝐿𝑠,𝑛−1 𝑉𝑠,𝑛−1
𝐿0 𝑉0

)

(16c)

Here, 𝐿0 is the lipid concentration in the initial suspension in the dialysis tube, 𝐿𝑠 and 𝑉𝑠
are the lipid concentration and volume of sample taken, respectively (at the denoted sample
number), and 𝑉0 is the initial volume of suspension added to the dialysis chamber.
3.2.7.5 Determination of TPT dimerization constant (K2)
Self-association of TPT in solution has been previously reported 137,

138

and may affect

observed binding due to the different binding affinities of the drug in its monomeric (T1)
and dimeric (T2) forms and the effects of binding on the bilayer surface charge. The two
forms of TPT in solution can be related by a dimerization constant, K2, as shown by equation
17.
35

𝑇

𝐾2 = 𝑇 22

(17)

1

The two forms may also be related by mass balance in which the total concentration of TPT
in solution, T, may be written as the sum of these species as shown in equation 18.
𝑇 = 𝑇1 + 2𝑇2

(18)

Using these equations, the fraction of monomer present in solution, 𝑓1 , can be solved as
expressed by equation 19.
𝑓1 =

−1+√1+8𝐾2 𝑇

(19)

4𝐾2 𝑇

In solution, both monomeric and dimeric forms of TPT have their own unique extinction
coefficients (𝜀1,𝑖 and 𝜀2,𝑖 , respectively) at any wavelength, i, which contribute to the
apparent extinction coefficient, 𝜀𝑎𝑝𝑝 . This is shown by equation 20.
𝜀𝑎𝑝𝑝,𝑖 = 𝑓1 𝜀1,𝑖 + 𝑓2 𝜀2,𝑖 = 𝑓1 𝜀1,𝑖 + (1 − 𝑓1 )𝜀2,𝑖

(20)

Using equations 19 and 20, the concentration dependence of 𝜀𝑎𝑝𝑝,𝑖 was fit at multiple
wavelengths simultaneously to determine K2, 𝜀1,𝑖 and 𝜀2,𝑖 .

3.3 Results
3.3.1

Validation

of

Analytical

Methods

and

Liposome

Particle

Characterization
TPT concentrations were analyzed using a previously validated HPLC method with
fluorescence detection.130 A linear response for TPT lactone (4.5 min retention time) was
observed between 20 and 200 nM using excitation and emission wavelengths of 380 nm
and 550 nm, respectively. TPT concentrations in samples taken from release studies and
size exclusion experiments ranging from 0.2 - 2 µM were determined by diluting samples
with chilled methanol into the concentration range of standards.
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Phospholipid content was determined using an HPLC method previously developed and
validated.49, 130 ELSD was employed due to the lack of a chromophore/fluorophore in the
lipid molecules. A peak retention time of 7.9 minutes and a linear relationship between the
logarithm of peak area and DSPC concentration was observed from 0.05 – 0.3 mg
DSPC/mL,similar to that previously reported.49, 130
Separation of passively-loaded TPT liposomes from unencapsulated drug was achieved
with a Sephadex® size exclusion column. Figure 3.1 compares the elution profiles of an
aqueous solution of TPT in the absence of liposomes and a suspension of passively-loaded
TPT-containing liposomes.

Both TPT and liposomes detected using HPLC and DLS,

respectively, were present in the peak eluting in the 2.5- 5mL range while the solution of
TPT in the absence of liposomes did not produce a peak in this range.

[TPT] (nM) or DLS (kcps)

400

300

200

100

0
2.5

5

10

20

Elution Volume (mL)
Figure 3.1. Elution profiles of free (

) or liposomal TPT (

HPLC. The DLS intensity profile generated by liposomes (
indicate separation of free from entrapped drug.
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) analyzed by

) is also shown to

Particle size was determined by DLS for the liposomes before and after the conclusion of
release studies. The average particle size in five independent release studies (with 95 %
confidence interval) was 98 ± 2 nm before studies began and 100 ± 3 nm after release
studies were concluded. Because phospholipids undergo acid-catalyzed ester hydrolysis,
142-144

the stability of the phospholipid bilayer under acidic conditions for extended periods

of time could lead to lipid loss during the release study and alter release kinetics.143 Lipid
stability was evaluated by monitoring lipid content in solution using HPLC with an ELSD.
Figure 3.2 demonstrates that liposomal suspensions employed in release studies conducted
under non-sink conditions exhibited no lipid loss during the 96 hour period in which
release was monitored.
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Figure 3.2. Lipid content was monitored during non-sink release studies. The
line indicates the average of all measured lipid concentrations and shows lipid
content remained constant throughout the release experiments. Error bars
represent 95% confidence intervals.
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3.3.2 Recovery from ultrafiltration and volume changes in dynamic dialysis
Corrections were required to obtain the true release profiles from changes in drug
concentration observed by both ultrafiltration and dynamic dialysis methods. Values for
the % of TPT and lipid recovered after ultrafiltration have been reported previously under
similar conditions.130 The % of lipid recovered was used to determine the actual amount of
intravesicular drug present in samples as trace amounts of extravesicular TPT still present
after separation by Sephadex®118 would lead to a lower % of TPT recovered.130
Additionally, any extravesicular drug still present after ultrafiltration could also lead to an
overestimation in the binding coefficient observed. To determine the % of extravesicular
drug present in the retentate after ultrafiltration, blank liposome suspensions were spiked
with TPT followed by immediate ultrafiltration. Using similar drug and lipid concentrations
as those employed in release studies, the % of extravesicular TPT recovered during
ultrafiltration was determined to be 1.5 ± 0.2 %. This recovery was similar to the 1.4 % that
would be expected based on the 26 µL of ultrafiltrate suspension that was retained after
ultrafiltration. For non-sink release studies, the initial concentration of extravesicular drug
was never more than 0.2% of the drug concentration used to load the liposomes.
Dynamic dialysis studies also required corrections in drug concentration due to increases
or decreases in volume within the dialysis tube. Additionally, the effect of sample removal
also needed to be taken into account. For these dynamic dialysis studies, 4.5 mL of solution
was initially observed to fill the dialysis tubes to the top of the dialysis membrane.
However, these tubes swelled during release studies. To correct for the effect of observed
volume changes on drug concentration, the rate of volume swelling was determined. This
was achieved by filling a fresh set of dialysis tubes initially with 4 mL (Vo) of buffer solution,
then monitoring volume changes over 72 hours at the same conditions used in dynamic
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dialysis release studies. The rate of swelling, kv, and tube volume at equilibrium, Veq, could
be determine using the equation below.
𝑉 = 𝑉0 + (𝑉𝑒𝑞 − 𝑉0 )(1 − 𝑒 −𝑘𝑣 𝑡 )

(21)

The resulting swelling profile of the dialysis tubes is shown by Figure 3.3a and resulted in
a kv of 0.13 ± 0.02 hr-1 while Veq varied greatly between dialysis tubes (ranging from 4.8 –
5.3 mL. Using this rate constant and the Veq determined for each dialysis tube, the loss of
lipid observed in dynamic dialysis studies could be accounted for using the correction
factors described by equations 13 – 16 and is illustrated by Figure 3.3b. These equations
were then applied to TPT concentrations obtained during dynamic dialysis studies to reflect
drug loss due only to liposomal release.
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Figure 3.3. The rate of dialysis tube swelling was monitored and used to
determine a swelling rate constant for the dialysis tubes used in dynamic
dialysis studies (A). Using this swelling rate and accounting for the volume of
sample removed over time, the loss in lipid observed over time in dynamic
dialysis studies (

) could be accounted for (
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) (B).

3.3.3 Comparison of release studies under non-sink and sink conditions
In addition to these corrections, the parameters calculated in Table 3.1 which describe the
ratio of aqueous and membrane volumes for the intravesicular compartment (a and b
respectively) and the extravesicular compartment (c and d respectively) along with the
ratio of entrapped and external volume (fv) were required for model fitting (see Appendix
for a more detailed explanation) and calculated using previously reported values and
equations.50, 135 With this information, the kinetic parameters for drug release under nonsink and sink conditions could be compared. For simplicity and because equilibrium is
nearly reached in these non-sink studies, Ki’ and Ko’ are assumed to be equivalent at the end
of these studies and thus referred to from this point on as K’. Fitting of release profiles from
0.48 mg lipid/mL suspensions under non-sink conditions as shown in Figure 3.4a resulted
in a k’m of 0.51 ± 0.05 hr-1 and K’ of 73 ± 2. For dialysis studies, drug transport across the
dialysis membrane may affect observed drug release.49, 118 As such, release profiles from
passively loaded liposome suspensions and blank liposome suspensions spiked with TPT
were simultaneously fit to determine both k’m and the rate constant for TPT transport
across the dialysis membrane (kd). Because K’ cannot be determined from dynamic dialysis
studies, it was held constant at the value determined from the non-sink studies. Using this
value and the parameters listed in Table 1, k’m and kd were simultaneously fit as shown by
Figure 3.4b, resulting in values of 0.50 ± 0.04 hr-1 and 0.79 ± 0.13 hr-1 respectively. The
release profile of passively-loaded liposomes in Figure 3b also exhibits a lag time consistent
with accumulation of released drug within the dialysis tube caused by the noninstantaneous rate of drug transport across the dialysis membrane.49, 118 The values of k’m
determined from both methods are nearly identical and show that non-sink studies can
simultaneously provide accurate release rate constants along with drug binding
information.
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Table 3.1. Volume parameters used when comparing release studies of liposome
suspensions under non-sink and sink-conditions
Lipid Suspension Concentrations

a

b

c

0.48 mg/mL (non-sink)

0.85

0.15

0.99982

0.00018 0.00122

0.51 mg/mL (dialysis)

0.85

0.15

0.99980

0.00020 0.00135

A.

43

d
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1.0

B.
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0.0
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Figure 3.4. A comparison of the release profiles of TPT from DSPC/mPEG-DSPE
liposomes obtained from ultrafiltration (A) and dynamic dialysis (B) methods at
pH 4.0, 37 °C. A) The release profiles of TPT under non-sink conditions are
shown for suspensions of 0.48 (

),

5.44 (

), and 15.3 (

) mg lipid /mL

along with the fits of these data to the mathematical model describing release
under non-sink conditions (represented by the lines of corresponding color).
The inset at the top right compares the approach to equilibrium occurring under
non-sink conditions to a simulated profile of release under sink conditions (
). B) The release profiles of TPT using dynamic dialysis. After correcting for
volume swelling and sampling of the dialysis tube, TPT release from passively
loaded liposomes
drug (
(

and

(

) and blank liposome suspensions spiked with free

) were fit simultaneously, producing their respective release profiles
). Error bars indicate the standard deviation at each time point of

triplicate release experiments.
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3.3.4 Drug and lipid concentration effects on drug partitioning probed by nonsink method
Further validation of the non-sink method to examine release kinetics was performed by
varying the suspension concentration of lipid.

For these studies, the same initial

concentration of TPT was used to passively load the three different lipid suspensions. This
was done to avoid drug self-association effects on release kinetics (i.e., to maintain the same
intravescicular driving force between the studies).
Because equilibrium is achieved with a different extent of drug released due to changes in
membrane binding of drug, the effects of membrane binding (K’) in addition to TPT
permeability (k’m) on release may be observed by calculating the half-life to equilibrium
(𝑡1/2 ) from these non-sink release studies. This calculation starts by solving for 𝑡1/2 with
the rearrangement of equation 2a and substituting for 𝑇𝑜 using the mass balance 𝑇𝑜 =
𝑓𝑣 (𝑇𝑖,0 − 𝑇𝑖 ).
−

𝑑𝑇𝑖
𝑑𝑡

′
′ 𝑤
= 𝑘𝑚
𝑇𝑖 (𝑓𝑖𝑤 + 𝑓𝑜𝑤 𝑓𝑣 ) − 𝑘𝑚
𝑓𝑜 𝑓𝑣 𝑇𝑖,0

′ 𝑤
Next, the term 𝑘𝑚
𝑓𝑜 𝑓𝑣 𝑇𝑖,0 may be solved for by assuming equilibrium where

(22)
𝑑𝑇𝑖
𝑑𝑡

= 0 and

𝑇𝑖 = 𝑇𝑖𝑒𝑞 and 22 becomes equation 23.
′ 𝑤
′ 𝑒𝑞 ( 𝑤
𝑘𝑚
𝑓𝑜 𝑓𝑣 𝑇𝑖,0 = 𝑘𝑚
𝑇𝑖 𝑓𝑖 + 𝑓𝑜𝑤 𝑓𝑣 )

(23)

Substituting 23 back into 22 and rearrangement provides equation 24.
𝑑𝑇𝑖
𝑑𝑡

′ 𝑤
′ 𝑤 )
= −(𝑘𝑚
𝑓𝑖 + 𝑘𝑚
𝑓𝑜 𝑓𝑣 (𝑇𝑖 − 𝑇𝑖𝑒𝑞 )

(24)

Equation 24 takes on the general form of a first order reaction. Upon integration and
substituting equations A11a & b for 𝑓𝑖𝑤 and 𝑓𝑜𝑤 respectively, equation 25 is produced by
solving for 𝑡1/2 as the time at which the amount of drug encapsulated is halfway to
equilibrium (𝑇𝑖 − 𝑇𝑖𝑒𝑞 = 0.5(𝑇𝑖,0 − 𝑇𝑖𝑒𝑞 )).
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𝑡1/2 =

ln (2)
1
𝑓
+ 𝑣 )
𝑎+𝑏𝐾′ 𝑐+𝑑𝐾′

𝑘′𝑚 (

(25)

The fitted release profiles for the three suspensions at varying lipid concentration in
Figure 3.4a resulted in similar release half-lives (see Table 3.2), indicating this method is
useful over a wide range of lipid concentrations. Altering the suspension concentration of
lipid to validate the non-sink method’s ability to determine release kinetics also allowed
critical evaluation of the membrane binding coefficient determined from these release
studies.

The apparent binding coefficients (K’) were observed to vary depending on the

lipid concentration (spanning a 30-fold range). The resulting fits of K’ were 73 ± 2, 46 ± 6,
and 23 ± 3 for the 0.48, 5.44, and 15.3 mg lipid/mL suspensions, respectively.
Because this release model accounts for the differences in aqueous and membrane
volumes encountered under the various conditions studied, the apparent binding
coefficients should not be different between these studies. However, the cationic charge of
TPT at pH 4.0 in conjunction with the varying suspension concentrations of TPT may have
an effect on observed binding coefficients. Both of these variables may be accounted for
with the consideration of drug self-association and the change in bilayer surface potential
due to binding of cationic drug. To assess whether either or both effects contribute toward
the variation in K’ observed experimentally, TPT dimerization in solution and the varying
surface potential at the lipid membrane-solution interface were evaluated and used to
determine intrinsic binding coefficients for the monomeric and dimeric forms of TPT
binding to the DSPC/m-PEG DSPE bilayer.
In general, the intrinsic binding coefficient, 𝐾𝑖0 , for any species “i” (in this case TPT)
capable of binding to the lipid membrane may be expressed by equation 26.
𝑇𝑚

𝐾𝑖0 = 𝑇𝑖→0
𝑤
𝑖→0
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(26)

Essentially, 𝐾𝑖0 represents the equilibrium partition coefficient at infinitely dilute
𝑚
𝑤
concentrations within the membrane and aqueous phases (𝑇𝑖→0
and 𝑇𝑖→0
, respectively)

when the membrane surface charge is zero. These intrinsic partition coefficients can be
related to the observed partition coefficient at higher TPT concentrations as illustrated by
equation 27.
𝐾 ′ = 𝑓1 𝛿1 𝐾10 + 𝑓2 𝛿2 𝐾20 = 𝑓1 𝛿1 𝐾10 + (1 − 𝑓1 )𝛿2 𝐾20

(27)

Here, f1 and f2 account for the fractions of total TPT in the monomeric and dimeric forms,
respectively, as defined by equation 19. Values of f1 corresponding to the conditions at the
end of each release study were calculated from the dimerization constant (K2) obtained by
fitting the dependence of the TPT extinction coefficient on concentration (Figure 3.5a) to
the dimer model described by equations 19 and 20. The estimated value of K2 is 6700 ± 600
M-1.
Table 3.2. Values used to calculate the intrinsic DSPC bilayer/water
partition coefficients for TPT species at pH 4 and 37 °C.
Lipid suspensions
Parameters
0.48 mg/mL

5.44 mg/mL

15.3 mg/mL

Total TPT (µM)

0.94

4.99

15.44

t1/2 (hrs)

17 ± 2

19 ± 2

19 ± 3

𝐾′

73 ± 2

46 ± 4

23 ± 3

𝑓1

0.99

0.95

0.83

∑ 𝐶𝑖

0.6

0.6

0.6

𝛿1

1.3 ± 0.1

1.8

2.3

𝛿2

1.6 ± 0.3

3.2

5.3

𝑖

95% confidence intervals are shown where applicable
The 𝛿 values account for the effects of changes in membrane surface potential on species
binding with increasing drug concentration. Because TPT is primarily cationic at pH 4, its
47

ability to bind to the bilayer surface will also depend on the membrane surface potential.
Using the Gouy-Chapman theory as previously described by Austin and coworkers,141 this
effect may be calculated for any partitioned species with charge z using the correction factor
𝛿𝑧 . This correction factor is calculated with the following equation.141
𝛿𝑧 = [

𝛼+∑𝑖 𝐶𝑖+√𝛼 2+2𝛼 ∑𝑖 𝐶𝑖
]
∑𝑖 𝐶𝑖

𝑧

(28)

Here, 𝛼 = 𝜎/(2000𝑅𝑇𝜖0 𝜖𝑟 ) where 𝜎 is the surface charge density due to the
concentration of TPT bound to the bilayer, 𝜖0 is the permittivity of a vacuum and 𝜖𝑟 is the
relative permittivity of water.

This correction is also dependent upon the bulk

concentration of all electrolytes in solution, ∑𝑖 𝐶𝑖 , and the charge of the TPT species of
interest as both monomer (1+) and dimer (2+) forms are present in the concentration range
studied.138
Using the values reported in Table 3.2 to account for dimerization and the membrane
surface potential, 𝐾10 was determined to be 80 ± 20 while the partition coefficient for the
dimer, K20, was found to be negligible. In Figure 3.5b, the profile generated by equation 27
using the fitted value of 𝐾10 along with the dimer constant, K2, correlates well with the
experimentally-observed apparent binding constants, K’. The inset in 4b also demonstrates
the non-linearity observed in the plot of bound drug-to-lipid ratio, Tm/L, versus unbound
monomeric drug concentration conforms to the Gouy-Chapman theory.
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Figure 3.5. A) The apparent extinction coefficients of TPT as a function of
concentration at pH 4 were simultaneously fit to the dimer equations (19 and
20) to determine a dimerization constant, K2. The plot shows extinction
coefficients at 380 (blue), 376 (red), 386 (purple), and 388 (green) nm
wavelengths along with lines of the corresponding color to represent the fit of
the data to the dimerization model. Only four of the eight wavelengths used are
shown above for clarity. B) Using K2 and correcting for the changes in bilayer
surface potential described by the Gouy-Chapman theory, the apparent binding
coefficient, K’, observed at the three lipid concentrations used in non-sink
release studies ( ) was used to determine the intrinsic binding coefficient, 𝐾10
with equation 27, and the values provided in Table 3.2. The resulting fit of K’ to
equation 27 is shown (solid line) and correlates with the reduction in binding
experimentally observed with the three TPT suspension concentrations studied.
The inset to the top right compares the non-linear relationship of bound drugto-lipid ratio, Tm/L, with increasing concentration of unbound, monomeric drug,
f1Tu, predicted by the Gouy-Chapman equation (dotted line) with that
determined from non-sink release studies ( ).

3.4 Discussion
3.4.1 Effect of experimental parameters on extent of drug release under nonsink conditions
For the non-sink experiments, the extent of drug release is highly dependent upon two
primary factors: fraction of volume encapsulated ( 𝑓𝑣 ) and the apparent membrane binding
of drug to the liposomal bilayer (𝐾 ′ ). The effect of these factors can be appreciated by
examining the percentage of total drug released as defined by the following equation.
𝑋=

𝑀𝑜,∞
𝑀𝑇

× 100%

(29)

Here, Mo,∞ refers to the total mass of extravesicular drug at equilibrium and MT is the total
mass of drug in the suspension.
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Using the non-sink model, X can be simulated under a variety of experimental conditions
(e.g. different lipid concentrations, particles sizes, drug binding coefficients etc.). Figures
3.6a and b illustrate two of the main experimental parameters affecting the total amount of
drug released. Here simulations were conducted to determine the expected % of drug
released, X, for varying values of binding coefficients, K’, in Figure 3.6a and as a function of
the ratio of entrapped volume, fv (i.e. liposome concentration), in Figure 3.6b. In Figure
3.6a, the plot shows that increasing values of K’ result in less drug released into the
extravesicular compartment due to a higher amount bound to the membrane leaflet. For
Figure 3.6b, the increasing values of fv result in less drug released because a larger fraction
of the total volume is within the intravesicular compartment.
It would also be convenient to generalize these relationships so that the extent of drug
release from liposomes under non-sink conditions could be estimated for a wide array of
experimental conditions. Such a relationship is illustrated by Figure 3.6c. This nomograph
was constructed by noting that at equilibrium, the concentrations of unbound, aqueous
drug in the intra- and extra-vesicular solution will be equal.
𝑇𝑖𝑤 = 𝑇𝑜𝑤

(30)

This relationship can then be rewritten in terms of total concentration of intra- and extravesicular drug using the previous derived fraction of unbound intra- and extra-vesicular
drug (eqns. 11a & b) and rearranged to the following ratio.
𝑇𝑖
𝑇𝑜

𝑓𝑤

𝑎+𝑏𝐾 ′

= 𝑓𝑜𝑤 = 𝑐+𝑑𝐾′
𝑖

(31)

Furthermore, one can specify the percent of drug released, 𝑋, in terms of the total
suspension concentration of drug present in solution, 𝑇, for 𝑇𝑖 and 𝑇𝑜 as expressed by
equations 32a and b.
𝑇𝑖 =

(100−𝑋)𝑇
𝐸
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(32a)

𝑇𝑜 = (1 − 𝐸)𝑋𝑇

(32b)

Here, the fraction of total volume entrapped, E, may be expressed in terms of the
previously defined ratio of entrapped to external volume, 𝐸 = 𝑓𝑣 ⁄(1 + 𝑓𝑣 ). These equations
can be substituted into equation 31 and rearranged into the following equation.
(100−𝑋)
𝑋

=[

𝑎+𝑏𝐾 ′

]

𝐸

𝑐+𝑑𝐾 ′ 1−𝐸

(15)

This relationship is linear as shown in Figure 3.6c with 𝐸⁄(1 − 𝐸) providing the slope.
Here, the slopes of lines are shown based on varying values of E, and the horizontal lines
indicate the percent of drug which would be released at equilibrium.
The above calculations and simulations assumed that all released drug, whether
membrane-bound or free in extravesicular solution, was removed during ultrafiltration due
to the low binding observed in these studies. This assumption can be assessed based on the
dilutions made during ultrafiltration and drug binding coefficients. Based on the highest
binding coefficient obtained during these experiments (73), there would be less than a 2.5%
change in the total amount of drug removed over the range of lipid concentrations (0.48 –
15.3 mg lipid/mL) used in these studies. For drugs with higher membrane binding, a
similar analysis shows that a 0.5 mg lipid/mL suspension would have less than a 3% change
in the amount of drug removed for a lipophilic compound having a binding coefficient of
2400.

52

50 nm
100 nm
150 nm
200 nm

100%

90%

X

80%

70%

60%

50%
1

A.

10

100

1000

10000

K'

50 nm
100 nm
150 nm
200 nm

100%

X

90%

80%

70%

60%

B.

50%
0.0001

0.001

0.01

fv

53

0.1

𝐸 = 0.01

0.5

𝐸 = 0.003

𝐸 = 0.001

(𝟏𝟎𝟎 − 𝑿)

𝑿

0.4

0.3

𝑋 = 80%
0.2

𝑋 = 90%
0.1

𝑋 = 95%
𝑋 = 99%
0

C.

0

125

250

𝒂 + 𝒃𝑲′
𝒄 + 𝒅𝑲′

375

500

Figure 3.6. The effect of experimental parameters on total drug release at
equilibrium. A) Keeping the suspension concentration constant at 0.5 mg/mL,
simulations using the equations describing the non-sink model were used to
determine the % of released drug, X, as a function of varying values of drug
binding coefficients, K’. These simulations are plotted for several common
diameters of liposomes. B) To illustrate the effect entrapped volume, fv , has on
the amount of drug released under non-sink conditions, simulations were
conducted in which K’ was held constant at 90. The plot shows increasing fv (i.e.
increasing amount of liposomes) reduces the amount of drug released as the
volume fraction entrapped increases (i.e. the number of liposomes in the
suspension increase). The lines illustrate this trend for liposomes of different
diameters indicated by the legend in the upper right corner of plot. C) This
nomograph provides a general method for estimating the amount of released
drug. The plot relates all experimental conditions affecting the amount of drug
released during a non-sink release study including the drug binding coefficient,
K’, and the volume compartments present in the suspension (a and b for
intravesicular aqueous and membrane compartments, and c and d for
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extravesicular aqueous and membrane compartments), to X (as indicated by the
labeled, horizontal lines).

This relationship is highly dependent upon the

fraction of entrapped volume, E, as the slope steepens dramatically with
increasing E (and subsequently higher lipid concentration).

3.4.2 Applicability to drug release characterization for other drugs and/or
nanoparticle formulations
The mathematical model described here should be adaptable to other drugs and
nanoparticle formulations. For every drug-nanoparticle combination, careful consideration
should be given to which components of the current model are relevant and whether
additional terms are necessary. For example, an evaluation of the effect of pH on release
requires consideration of drug speciation as the ionization of the drug may have an effect on
observed release.49,

130

Other effects such as drug precipitation, complexation, or

degradation may be taken into account by including relevant equilibrium equations to solve
for the fraction of total drug free to permeate the membrane or by adding relevant kinetic
terms (e.g. degradation/ineterconversion130 or dissolution rate constant) into the rate
equation. More generally, the non-sink method and model may be applicable to other
agents as well as other types of nanoparticles (e.g., a current application of similar
methodology underway in this laboratory involves doxorubicin-conjugated polymeric
micelles).
Validation of the % recovery and % of free drug removed is critical when considering
the use of ultrafiltration to isolate drug remaining within the nanoparticle. Significant
binding of drug to the ultrafiltration membrane may interfere with removal of released drug
by a washing step. In such cases, other methods that can separate (e.g. size-exclusion) or
distinguish (e.g. spectroscopic techniques) entrapped from released drug may be more
appropriate yet still amenable to the non-sink mathematical model used here.
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3.5 Conclusions
The liposomal release kinetics and lipid bilayer partitioning of the anticancer agent TPT
were simultaneously determined by ultrafiltering liposomal suspensions under non-sink
conditions at various times. . Dynamic dialysis was used to validate these findings by
providing a nearly identical release rate constant. The non-sink method was also able to
probe the concentration dependence of TPT binding to the bilayer and revealed that
binding was dependent on the surface potential at the bilayer interface and TPT
dimerization. The non-sink method provides a reliable way to obtain both kinetic and
thermodynamic descriptors. This method may also be useful in future mechanistic studies
of liposomal drug release kinetics where dynamic dialysis studies are complicated by drug
binding to the dialysis membrane or observed release is rate-limited by drug transport
through the dialysis membrane. The parameter values and methodology provided may
have utility in the development of models capable of providing in vitro - in vivo correlations;
however, environmental in vivo factors that may alter release rates would have to be
investigated and incorporated into mechanistic models to yield useful, predictive
relationships for liposomal formulations.

Copyright © Kyle Daniel Fugit
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CHAPTER FOUR
The Role of pH and Ring-opening Hydrolysis Kinetics on Liposomal
Release of Topotecan
4.1 Introduction
Liposomal formulations offer several potential advantages for the intravenous delivery
of antitumor agents due to their ability to increase drug solubility, reduce drug toxicity, and
prolong drug release.3 Pegylated liposomes have the added benefit of longer systemic
circulation due to reduced clearance by the mononuclear phagocytic system.

3, 30-32

This

prolonged circulation time when combined with an appropriate particle size provides
preferential delivery of liposomes to solid tumors, a result of the well-known enhanced
permeability and retention of nanoparticles in tumors. 3, 8, 31 These properties have led to
the FDA-approved liposomal formulation of doxorubicin (DOXIL ®) as well as other drug
products, including several currently in clinical trials.33-40
When investigated systematically, the antitumor efficacy of drug-loaded liposomal
formulations has been closely linked to the drug release rate.21-24 Such investigations imply
that the ability to tailor liposomal drug release rates could enable clinicians to optimize
efficacy for a specific tumor by selecting the delivery system that produces the optimal
tumor concentration profile. Protracted or metronomic dosing regimens have shown such
promise with enhanced antitumor agent efficacy,1, 145, 146 but these approaches are unable to
take advantage of the localized intratumoral drug release afforded by liposomes and other
nanoparticulate systems. Liposomal systems that provide predictable drug release rates
would reduce the frequent visits and monitoring currently necessary due to the narrow
therapeutic window and rapid clearance of many chemotherapeutics.
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While many models have been developed to describe drug loading,124, 127, 139, 140 few have
considered release kinetics 49, 60, 128 and even fewer have been validated experimentally. 49, 60,
124

Mechanistic models that incorporate physicochemical properties of the drug in solution

including the drug species present as a function of intraliposomal pH, their interactions
with the lipid bilayer, and their membrane permeabilities would be essential to release rate
design and optimization.
Liposomal formulations of topotecan (TPT) serve as a prime example of the need for
mechanistic models to reliably predict drug release rates under a variety of loading and
release conditions. TPT is a topoisomerase I inhibitor currently approved to treat cervical,
ovarian, and small cell lung cancers as an injectable solution and in multiple clinical trials as
the sole medication or in conjunction with other medications and/or radiation.84-88 Like
other weakly basic drugs, TPT exhibits high encapsulation efficiency in liposomal
formulations utilizing active loading strategies.21, 42, 61, 73, 95-97 Previous work with liposomal
TPT has mainly focused on encapsulation strategies, while the emphasis on controlled or
extended release has been limited.24, 42, 62, 64, 97
Studies that systematically examine various formulation and releasing-media
parameters are necessary to develop a model capable of understanding and controlling
release. Since the generation of a low-intravesicular pH is a prerequisite for active loading
of weak bases while drug release occurs under physiological conditions near a neutral pH,
64, 73, 96

evaluating the sensitivity of TPT release to both the intra- and extravesicular pH is

critical to the development of a mechanistic model having practical utility. Over this pH
range, TPT is assumed to exist in solution as one of four major species as illustrated in
Scheme 4.1.
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Scheme 4.1. The major species of TPT in solution in the low to neutral pH
range. Two lactone forms are present (𝐿𝑝 and 𝐿𝑛 ) differing in the state of
ionization of the phenol on ring A. Reversible hydrolysis of the lactone E-ring
may transform these species to their carboxylate counterparts (𝐶𝑛 and 𝐶𝑎
respectively).
The aim of the present work was to determine the pH sensitivity of TPT release from
unilamellar liposomes and develop a mechanism-based mathematical model to account for
the observed transport rates. To completely account for the pH-permeability profiles
obtained experimentally, the mathematical model had to include the effects of TPT
speciation via ionization, membrane-binding equilibria, drug species’ permeability
coefficients, and the kinetics and pH dependence of TPT lactone ring-opening/closing.

59

4.2 Materials and Methods
4.2.1 Materials
Powders of 1,2-Distearoyl-sn-glycero-3-phosphatidylcholine (DSPC, >99% purity) and
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000]
(m-PEG DSPE, MW = 2806, >99% purity) were purchased from Avanti Polar Lipids
(Alabaster, AL). Topotecan hydrochloride was purchased from AK Scientific (Union City,
CA). Millipore ultrafiltration cartridges (Amicon® Ultra 0.5 mL centrifugal filter device with
30,000 MWCO Ultracel® membrane), Nuclepore polycarbonate membranes (0.1 µm),
solvents, and buffer salts were purchased from Fisher Scientific (Florence, KY). All solvents
were HPLC grade.

4.2.2 Preparation and characterization of DSPC/m-PEG DSPE liposomes for
lactone-carboxylate interconversion and release studies
Large unilamellar vesicles were formed using the film hydration and extrusion process
described in several previous reports with slight modifications.49, 62 Briefly, DSPC and mPEG DSPE (95:5 mol:mol) lipids were weighed into borosilicate vials, then dissolved in
chloroform. The chloroform was subsequently evaporated under a stream of N2 and the
residue was vacuum-dried at 40°C for 6 hours to form a thin lipid film. Films were hydrated
and passed 10 times through two stacked Nuclepore polycarbonate membranes (100 nm
pore) using a Liposofast® extrusion device at 60°C to obtain unilamellar vesicles. All
solutions for film hydration were made with a buffer concentration of 50 mM and adjusted
to an ionic strength of 0.3 with NaCl. The reported pH was measured at 37 °C. Liposomes
used in lactone-carboxylate interconversion studies were composed of lipid films hydrated
with pH 6.33 (2-(N-morpholino)ethanesulfonic acid (MES)) and pH 7.67 (Tris) to achieve a
final lipid concentration of 50 mg/mL. Liposomes for release studies were hydrated with
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solutions of pH 3.35 (chloroacetate), 4.01 (formate), 5.01 (acetate), 5.92 and 6.33 (MES),
7.04 and 7.39 (phosphate), and 7.67 (Tris) containing 50 µM TPT, yielding a lipid
concentration of 40 mg/mL.
For the calculation of vesicle volume parameters, particle size and lipid content were
determined. Liposome particle size was analyzed using a Beckman Delsa™ Nano C Particle
Sizer with a 70 second accumulation time. Particle size before and after release studies was
determined using Cumulants analysis. Liposome suspensions were diluted by a factor of 10
before analysis to obtain intensity readings within the detection range of the instrument.
To avoid interference from dust and other artifacts during size analysis, the buffers used in
liposome hydration and subsequent release studies were filtered with a 0.22 µm
nitrocellulose filter.

Samples were stored at 4°C until analysis.

Lipid content was

determined using HPLC and is described in further detail in the analyses section.

4.2.3 Fluorescence measurements of aqueous TPT solutions
The acid dissociation constant of the TPT A-ring phenol was determined using changes
in fluorescence excitation spectra with pH. Solutions of 500 nM TPT were prepared at
various pH with buffers of formate (pH 3.50), acetate (4.50 and 5.50), MES (pH 6.00 and
6.27) and phosphate (pH 6.50, 6.80, 7.20, and 7.50) at concentrations of 50 mM while ionic
strength was kept at 0.3 by adjustment with sodium chloride. Solutions were scanned with
a FluoroMax-3 (Jobin Yvon Inc., Edison, NJ). Excitation scans were made over a range of 300
– 470 nm using an emission wavelength of 560 nm. The temperature of the sample
chamber was maintained at 37 °C, and fluorescence intensity was recorded using a 0.5
second integration time and a 3 nm band pass width.
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4.2.4 TPT interconversion studies
Kinetic studies of the reversible and pH dependent ring-opening/closing of TPT were
conducted with 0.4-0.6 µM TPT solutions at pH 5.92, 6.33, 7.04, 7.39, and 7.67 using the
same buffers used to hydrate liposomes. At pH 5.92 and 6.33, solutions were spiked with a
50 µM stock solution of the ring-opened TPT carboxylate dissolved in 0.1 N NaOH. Studies
at higher pH used a 50 µM stock of lactone TPT in DMSO. To determine the effect (if any) of
TPT binding to the bilayer, interconversion studies were also conducted in 50 mg/mL
liposome suspensions at pH 6.33 and 7.67 and compared with profiles obtained in aqueous
solution.
At various times, 150 µL samples were withdrawn and interconversion was quenched
using 300 µL of a chilled (-20 °C) 2:1 (v:v) acetonitrile: methanol solution. Samples were
immediately injected and analyzed by HPLC for both ring-opened carboxylate and lactone
content. All studies were conducted in a water-jacketed incubator maintained at 37 °C and
stirred at 200 rpm with a 10 x 5 mm Teflon stir bar using a Thermo Cimerac iPoly 15
multipoint stirrer.

4.2.5 Release of TPT from DSPC/DSPE-PEG-2K liposomes
Release studies were conducted in a similar manner as reported previously.147
Unencapsulated TPT present in passively loaded liposome suspensions was removed by
passing suspensions through a Sephadex G-25 column equilibrated with the same buffer as
the liposome suspension. Aliquots of liposome suspension (0.2–0.5 mL) were passed
through the column and the drug-loaded liposome fraction eluting between 2.5–5 mL was
collected, yielding liposome suspensions for release studies having lipid concentrations of
1.0-4.5 mg/mL. Liposome suspensions were transferred to glass vials capped with a rubber
stopper and stirred at the same conditions used for interconversion studies within a water62

jacketed incubator maintained at 37 °C.

Suspension temperature was monitored daily

using a digital thermometer over the time span of release studies.
Encapsulated drug was monitored by ultrafiltration of 50–150 µL aliquots of liposome
suspension taken at various time points. Each aliquot was diluted with chilled (4 °C) buffer
to 425 µL and ultrafiltered using an Amicon® Ultra 0.5 mL centrifugal filter device with
30,000 MWCO Ultracel® membrane. Cartridges were then centrifuged at 14,000 rpm for 10
minutes in an Eppendorf 5417R maintained at 4 °C. The concentrated suspension (50 µL)
was recovered by inverting the cartridge and centrifuging at 2000 rpm for another 2
minutes. Recovered concentrate was resuspended in another 400 µL of chilled buffer and
the process was repeated. The final concentrate was dissolved in acidified methanol and
diluted within the calibration range for HPLC analysis.

4.2.6 HPLC analyses
Samples from interconversion studies were analyzed for TPT concentration by HPLC.148
A Waters Alliance 2695 separation system coupled to a Waters fluorescence detector
(M474) was employed with excitation and emission wavelengths at 380 and 560 nm,
respectively. Interconversion studies measured both lactone and carboxylate forms of TPT
using a Supelcosil™ ABZ+ column (250 x 4.6 mm, 5 µm) and guard column (20 x 4.0 mm, 5
µm) with a mobile phase (14% acetonitrile: 86% (v/v) of 5% (pH = 5.5) triethylamine
acetate, 50 mM tetrabutylammonium hydrogen sulfate (TBAHS) buffer) flow rate of 1.5
mL/min. Lactone TPT standards were prepared in chilled, acidified methanol (-20 °C) and
carboxylate standards were prepared in 10 mM sodium carbonate buffer (pH 10.1) at 20200 nM concentrations. Lactone and carboxylate retention times were 5.5 and 2.1 min,
respectively.
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For release studies, samples were diluted in chilled, acidified methanol (0.001 N HCl for
studies at pH ≤ 5.01 and 0.02 N HCl for studies conducted at higher pH) to convert all TPT to
its lactone form. Samples were stored at -20 °C until analysis. TPT lactone was then
analyzed using a Waters Symmetry® C18 column (4.6×150 mm, 5 µm) and guard column
(3.9 x 20 mm) with a mobile phase (16% acetonitrile: 84% (v/v) of 5% (pH = 5.5)
triethylamine acetate buffer) flow rate of 1 mL/min. Sample compartment and column
were kept at ambient temperature. The retention time for TPT lactone was 4.5 min and
response was linear between 20 and 200 nM.
Lipid analysis was performed with HPLC using an evaporative light scattering detector
(ELSD, Sedere, Inc., Lawrenceville, NJ) based on a previously described method using an
Allsphere (Alltech Associates, Inc., Deerfield, IL) silica column (4 x 150 mm, 5 µm) and
guard column (20 x 4.0 mm, 5 µm). The elution method employed a linear gradient
composed of 100% mobile phase A (80% chloroform:19.5% methanol:0.5%(v/v) NH4OH)
changing to 80% mobile phase A and 20% mobile phase B (80% methanol:19.5%
water:0.5% (v/v) NH4OH) at 3 min which was maintained until 7 min, and returned to
100% mobile phase A at 14 min at a flow rate of 1 mL/min.49 Samples (100 µL) were dried
at room temperature under N2, then dissolved in chilled mobile phase A before analysis.

4.2.7 Mechanism-based mathematical model development
4.2.7.1 Mathematical model for liposomal TPT release including kinetics of lactone ringopening/closing
Scheme 4.2 depicts the equilibria and rate constants that influence the rate of liposomal
release of TPT as a function of pH. While the mechanistic approach is similar to those
employed previously for other compounds,49,

60, 124

the species present and parameter

values will obviously differ. Using this scheme, a mathematical model that accounted for
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the various species of TPT as a function of pH was developed and described in the following
section.
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Symbols and description
KA1
Phenol ionization
w
Aqueous species
m
Membrane-bound species
i
Intravesicular
o
Extravesicular
Partition coefficients
KL,p
Binding for species Lp
KC,n
Binding for species Cn
Release constants (hr-1)
km,p For species Lp
km,n For species Cn
km,c
For species Cn
Interconversion kinetics
kcl
Ring-closing rate constant (hr-1)
kop
Ring-opening rate constant (hr-1)
fCOOH Carboxylate fraction
Scheme 4.2. A schematic of the associated equilibria and kinetics governing liposomal release of TPT. The liposome depicted
with radius, r, highlights the volume compartments described in the mathematical model. The different volume compartments
are color coded with blue highlighting the inner aqueous volume, 𝑉𝑖𝑤 , while the green and violet sections refer to the inner,
𝑉𝑖𝑚 , and outer, 𝑉𝑜𝑚 , membrane volumes, respectively. The transport pathways and binding/ionization equilibria for all species
illustrated in Scheme 4.1 are also depicted and described in the accompanying table (right).

Based on Scheme 4.2, the total amount of drug inside and outside liposomes consists of
various solution and membrane-bound species (Equations 1a and b):
𝑢
𝑚
𝑢
𝑚
𝑀𝑖 = 𝑀𝑖,𝐿
+ 𝑀𝑖,𝐿
+ 𝑀𝑖,𝐶
+ 𝑀𝑖,𝐶

(1a)

𝑢
𝑚
𝑢
𝑚
𝑀𝑜 = 𝑀𝑜,𝐿
+ 𝑀𝑜,𝐿
+ 𝑀𝑜,𝐶
+ 𝑀𝑜,𝐶

(1b)

In these equations and from this point on, the superscripts u and m represent unbound
species in the aqueous compartment and phospholipid membrane bound species,
respectively; the subscripts, i, and, o, refer to the intra- and extravesicular compartments,
respectively; and L and C refer to the lactone and carboxylate TPT species, respectively.
These mass balance equations can be transformed to concentrations using volume ratios of
the aqueous and membrane volumes of the inner and outer compartments. These are
expressed below in Equations 2a-e using the same annotations for volume as in Scheme 4.2.

𝑎=

𝑉𝑖𝑤
𝑉𝑖𝑇

,𝑏 =

𝑉𝑖𝑚
𝑉𝑖𝑇

,𝑐 =

𝑉𝑜𝑤
𝑉𝑜𝑇

,𝑑 =

𝑛𝑉𝑜𝑚
𝑉𝑜𝑇

, 𝑓𝑣 =

𝑛𝑉𝑖𝑇

(2a-e)

𝑉𝑜𝑇

Combining the mass balance equations with Equations 2a-d produced equations for total
drug concentration within, 𝑇𝑖 , and outside, 𝑇𝑜 , the vesicles as described below.
𝑚
𝑇𝑖 = 𝑎(𝐿𝑢𝑖 + 𝐶𝑖𝑢 ) + 𝑏(𝐿𝑚
𝑖 + 𝐶𝑖 )

(3a)

𝑚
𝑇𝑜 = 𝑐(𝐿𝑢𝑜 + 𝐶𝑜𝑢 ) + 𝑑(𝐿𝑚
𝑜 + 𝐶𝑜 )

(3b)

Total drug release within a liposome suspension may be described by the total rate of
𝑑𝑇

change for both intra- and extravesicular concentrations of TPT ( 𝑑𝑡𝑖 and

𝑑𝑇𝑜
𝑑𝑡

, respectively).

This total rate of change is the sum of the rates of change for both the lactone,
carboxylate,

𝑑𝐶𝑖
𝑑𝑡

&

𝑑𝐶𝑜
𝑑𝑡

𝑑𝐿𝑖
𝑑𝑡

&

𝑑𝐿𝑜
𝑑𝑡

, and

, forms of TPT in the intra- and extravesicular compartments. This is

expressed in Equations 4a and b.
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𝑑𝑇𝑖
𝑑𝑡

𝑑𝑇𝑜
𝑑𝑡

=

𝑑𝐿𝑖

=

𝑑𝐿𝑜

𝑑𝑡

𝑑𝑡

+

𝑑𝐶𝑖

+

𝑑𝐶𝑜

𝑑𝑡

𝑑𝑡

(4a)

(4b)

The driving force governing liposomal drug release is the concentration gradient
between the unbound, intra- and extra-vesicular concentrations of the permeable species.
In the case of TPT, pH-dependent ring-closure may become the rate-limiting step for drug
release under certain conditions. Thus, the rates of change of the intravesicular lactone and
carboxylate concentrations are determined by both diffusive and chemical kinetic
contributions as depicted in Equation 5.
𝑟𝑎𝑡𝑒 = 𝑑𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛 + 𝑖𝑛𝑡𝑒𝑟𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛

(5)

These terms can be explicitly written for the rates of both the lactone and carboxylate
forms of TPT as shown by Equations 6a-d.
𝑑𝐿𝑖
𝑑𝑡

𝑑𝐶𝑖
𝑑𝑡

𝑑𝐿𝑜
𝑑𝑡

𝑑𝐶𝑜
𝑑𝑡

′ ( 𝑢
= −𝑘𝑚,𝐿
𝐿𝑖 − 𝐿𝑢𝑜 ) − 𝑘𝑐𝑙 𝐾0 𝐿𝑖 + 𝑘𝑐𝑙 𝑓𝐶𝑂𝑂𝐻 𝐶𝑖

(6a)

′ ( 𝑢
= −𝑘𝑚,𝐶
𝐶𝑖 − 𝐶𝑜𝑢 ) + 𝑘𝑐𝑙 𝐾0 𝐿𝑖 − 𝑘𝑐𝑙 𝑓𝐶𝑂𝑂𝐻 𝐶𝑖

(6b)

′
= 𝑘𝑚,𝐿
𝑓𝑣 (𝐿𝑢𝑖 − 𝐿𝑢𝑜 ) − 𝑘𝑐𝑙 𝐾0 𝐿𝑜 + 𝑘𝑐𝑙 𝑓𝐶𝑂𝑂𝐻 𝐶𝑜

(6c)

′
= 𝑘𝑚,𝐶
𝑓𝑣 (𝐶𝑖𝑢 − 𝐶𝑜𝑢 ) + 𝑘𝑐𝑙 𝐾0 𝐿𝑜 − 𝑘𝑐𝑙 𝑓𝐶𝑂𝑂𝐻 𝐶𝑜

(6d)

The colors highlighting the various terms in Equations 6a-d correspond to those in
Equation 5. In these equations, the rates of change of intravesicular lactone and carboxylate
(highlighted green) are composed of diffusive (yellow) and chemical kinetic components
(blue) describing interconversion of TPT between its lactone and carboxylate forms. The
diffusive term describes bilayer-limited Fickian diffusion using a pseudo steady-state
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approximation (based on the absence of a lag time in the observed drug release profiles).
The two terms to the right reflect the reversible kinetics of TPT lactone ring opening and
closing. The term 𝑓𝑣 accounts for the ratio of total entrapped volume to total volume as
defined by Equation 2e.
′
′
In the diffusion term, 𝑘𝑚,𝐿
and 𝑘𝑚,𝐶
are effective transport rate constants for the lactone

and carboxylate species, respectively. These constants are pH dependent, as determined by
the various ionization states of the lactone and carboxylate species (Scheme 4.1) and their
permeability coefficients. The superscript, u, indicates that only lactone and carboxylate
species not bound to the membrane contribute to the diffusive driving force governing
release.
The transport rate constants for the lactone and carboxylate forms of TPT are
dependent upon their ionization states and will vary depending upon the pH. These factors
′
′
are accounted for by Equations 7a and b for both the lactone, 𝑘𝑚,𝐿
, and carboxylate, 𝑘𝑚,𝐶
,

respectively:
′
0
0
𝑘𝑚,𝐿
= 𝑓𝐿𝑢𝑝 𝑘𝑚,𝐿
+ 𝑓𝐿𝑢𝑛 𝑘𝑚,𝐿
𝑝
𝑛

(7a)

′
0
0
𝑘𝑚,𝐶
= 𝑓𝐶𝑢𝑛 𝑘𝑚,𝐶
+ 𝑓𝐶𝑢𝑎 𝑘𝑚,𝐶
𝑛
𝑎

(7b)

Lactone transport is a function of the fraction of the protonated species and its transport
0
coefficient, 𝑘𝑚,𝐿
, and the fraction of zwitterionic phenolate and its transport coefficient,
𝑝
0
𝑘𝑚,𝐿
. Similarly, carboxylate transport is governed by the fraction of the zwitterionic form
𝑛
0
0
and 𝑘𝑚,𝐶
, and the anionic phenolate fraction and 𝑘𝑚,𝐶
. The lactone and carboxylate forms
𝑛
𝑎

were assumed to have the same phenol group pKa because of the separation of the A-ring
phenolic –OH from the lactone ring. Therefore,
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𝑓𝐿𝑢𝑝 = 𝑓𝐶𝑢𝑛 =

𝐻+
𝐻 ++𝐾𝑎1

; 𝑓𝐿𝑢𝑛 = 𝑓𝐶𝑢𝑎 =

𝐾𝑎1
𝐻 + +𝐾𝑎1

(8a;b)

Next, the concentration gradient of aqueous, unbound drug must be solved in terms of
total drug encapsulated for both lactone and carboxylate.

This is accomplished by

incorporating the apparent volume-based membrane partition coefficients for the lactone,
𝐾𝐿′ , and the carboxylate, 𝐾𝐶′ , as shown in Equations 9a and b.
1

𝑢
𝑢
𝐿𝑢𝑖 = 𝑓𝑖,𝐿
𝐿𝑖,𝑇 ; 𝑓𝑖,𝐿
= 𝑎+𝑏𝐾′

𝐿

𝑢
𝑢
𝐶𝑖𝑢 = 𝑓𝑖,𝐶
𝐶𝑖,𝑇 ; 𝑓𝑖,𝐶
=

1
𝑎+𝑏𝐾𝐶′

(9a)

(9b)

𝑢
Similar substitutions can be made for the extra-vesicular fraction unbound for lactone, 𝑓𝑜,𝐿
,
𝑢
and carboxylate, 𝑓𝑜,𝐶
, using the ratios for extra-vesicular membrane, c, and aqueous, d,

volume.
As before with permeability, ionization of these species may also affect binding. The
apparent partition coefficients may then be written in terms of the intrinsic partition
coefficients of each ionization state.
𝐾𝐿′ = 𝑓𝐿𝑢𝑝 𝐾𝐿0𝑝 + 𝑓𝐿𝑢𝑛 𝐾𝐿0𝑛

(10a)

𝐾𝐶′ = 𝑓𝐿𝑢𝑝 𝐾𝐶0𝑛 + 𝑓𝐿𝑢𝑛 𝐾𝐶0𝑎

(10b)

By substituting the expressions in Equations 7 and 9 into Equations 6a-d, the differential
equations may be solved in terms of total intra- and extra-vesicular concentrations of
lactone and carboxylate species.
𝑑𝐿𝑖
𝑑𝑡

𝑢 𝑢
0
0
𝑢 𝑢
= −(𝑓𝐿𝑢𝑝 𝑘𝑚,𝐿
+ 𝑓𝐿𝑢𝑛 𝑘𝑚,𝐿
)(𝑓𝑖,𝐿
𝐿𝑖 − 𝑓𝑜,𝐿
𝐿𝑜 ) − 𝑘𝑐𝑙 𝐾0 𝐿𝑖 + 𝑘𝑐𝑙 𝑓𝐶𝑂𝑂𝐻 𝐶𝑖
𝑝
𝑛

70

(11a)

𝑑𝐶𝑖
𝑑𝑡

𝑑𝐿𝑜
𝑑𝑡

𝑑𝐶𝑜
𝑑𝑡

𝑢 𝑢
0
0
𝑢 𝑢
= −(𝑓𝐿𝑢𝑝 𝑘𝑚,𝐶
+ 𝑓𝐿𝑢𝑛 𝑘𝑚,𝐶
)(𝑓𝑖,𝐿
𝐶𝑖 − 𝑓𝑜,𝐿
𝐶𝑜 ) + 𝑘𝑐𝑙 𝐾0 𝐿𝑖 − 𝑘𝑐𝑙 𝑓𝐶𝑂𝑂𝐻 𝐶𝑖
𝑛
𝑎

(11b)

𝑢 𝑢
0
0
𝑢 𝑢
= 𝑓𝑣 (𝑓𝐿𝑢𝑝 𝑘𝑚,𝐿
+ 𝑓𝐿𝑢𝑛 𝑘𝑚,𝐿
)(𝑓𝑖,𝐿
𝐿𝑖 − 𝑓𝑜,𝐿
𝐿𝑜 ) − 𝑘𝑐𝑙 𝐾0 𝐿𝑜 + 𝑘𝑐𝑙 𝑓𝐶𝑂𝑂𝐻 𝐶𝑜
𝑝
𝑛

(11c)

𝑢 𝑢
0
0
𝑢 𝑢
= 𝑓𝑣 (𝑓𝐿𝑢𝑝 𝑘𝑚,𝐶
+ 𝑓𝐿𝑢𝑛 𝑘𝑚,𝐶
)(𝑓𝑖,𝐿
𝐶𝑖 − 𝑓𝑜,𝐿
𝐶𝑜 ) + 𝑘𝑐𝑙 𝐾0 𝐿𝑜 − 𝑘𝑐𝑙 𝑓𝐶𝑂𝑂𝐻 𝐶𝑜
𝑛
𝑎

(11d)

While this provides a valid set of equations to solve, initial conditions must include the
initial fractions of lactone and carboxylate. These were determined from the pH, assuming
initial equilibrium between the two forms. Because the fraction of ring-opened carboxylic
acid is negligible due to the dominance of lactone at low pH for camptothecins,92 an
apparent acid dissociation constant, 𝐾𝑎2 , relating the lactone to carboxylate form can be
described in terms of the ring-opening constant (𝐾0 ) and the ionization constant for the
carboxylic acid (𝐾𝐶𝑂𝑂𝐻 ). This relationship is expressed by Equation 12.
𝐾𝑎2 =

[𝐻 +][𝐶𝑇𝑤 ]
[𝐿𝑤
𝑇]

= 𝐾𝐶𝑂𝑂𝐻 𝐾0

(12)

Using Equation 12, the initial concentrations of lactone and carboxylate were solved as
shown below.
𝐿𝑖 (0) =

𝑇𝑖 𝐻 +(𝑎+𝑏𝐾𝐿′)
+
𝐻 (𝑎+𝑏𝐾𝐿′ )+𝐾𝑎2(𝑎+𝑏𝐾𝐶′ )

(𝑎+𝑏𝐾𝐶′ )

𝑇𝐾

𝑖 𝑎2
𝐶𝑖 (0) = 𝐻 +(𝑎+𝑏𝐾
′ )+𝐾
𝐿

′
𝑎2 (𝑎+𝑏𝐾𝐶 )

𝑇 𝐻 +(𝑐+𝑏𝐾𝐿′ )

𝑜
𝐿𝑜 (0) = 𝐻 +(𝑐+𝑏𝐾
′ )+𝐾

′
𝑎2 (𝑑+𝑏𝐾𝐶 )

𝐿

(𝑑+𝑏𝐾𝐶′ )

𝑇 𝐾

𝑜 𝑎2
𝐶𝑜 (0) = 𝐻 +(𝑐+𝑏𝐾
′ )+𝐾
𝐿
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′
𝑎2 (𝑑+𝑏𝐾𝐶 )

(13a)

(13b)

(13c)

(13d)

Additionally, observed suspension concentrations obtained from HPLC samples after
ultrafiltration, 𝑇𝑖′ , were related to the total intravesicular concentration of entrapped TPT as
only a small fraction of total suspension volume was encapsulated. The ratio of entrapped
to extra-vesicular volume is 𝑓𝑣 .
𝑇𝑖′ = 𝑓𝑣 𝑇𝑖

(14)

To avoid over-estimation of binding from release studies, any extra-vesicular drug at
the beginning of the experiment was incorporated into the initial conditions when solving
the model. Determination of the extra-vesicular concentration (if any), 𝑇𝑜 , at the beginning
of the experiment was done with the following equation:
𝑇𝑜 = 𝑇 − 𝑇𝑖′

(15)

where 𝑇 is the total TPT concentration in suspension before ultrafiltration. The equations
above were then used to fit the release data obtained at pH 3.35 – 7.67. By incorporating
pKa1,kcl, and Ko (constants previously determined in other experiments), all release data
were fit simultaneously to determine the partition coefficients and rate constants of each
TPT species in solution.
Using this mechanistic model to obtain release rate constants for each TPT species from
transport studies also required separate experiments to generate parameters governing the
ionization state of the TPT A-ring phenol and the lactone-carboxylate interconversion
kinetics. These determinations are described in the following sections.
4.2.7.2 Spectrometric determination of the TPT A-ring phenol (pKa1)
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The ionization state of drugs and small molecules has been shown to alter release
kinetics, typically due to the likelihood that the neutral form is more permeable than
charged species.49, 50, 52 In the case of TPT, the phenolic -OH group ortho to the dimethylaminomethyl substituent on the A ring may ionize and alter the charge of TPT as depicted in
Scheme 4.3.

Scheme 4.3. Phenol ionization on the A ring of TPT is governed by the acid
dissociation constant, 𝐾𝑎1 .
The relationship between the phenol and the phenolate depicted in Scheme 4.3 and its
pH dependence is governed by the acid dissociation constant, 𝐾𝑎1 , as expressed in Equation
16.
𝐾𝑎1 =

[𝐻 +][𝑃𝑂−]
[𝑃𝑂𝐻]

(16)

where [𝑃𝑂− ] is the total concentration of TPT species with an ionized phenolate moiety and
[𝑃𝑂𝐻] is the concentration of all TPT species with the unionized phenol moiety.
At any given excitation wavelength, j, the fluorescence intensity in aqueous solution
emitted at wavelength, 𝐼𝑗 , can be described as the sum of the phenol species, 𝐼𝑗,𝑂𝐻 , and
phenolate species, 𝐼𝑗,𝑂− (Equation 17).
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𝐼𝑗 = 𝐼𝑗,𝑂𝐻 + 𝐼𝑗,𝑂−

(17)

These intensities can be related to the concentrations of each species by their respective
specific intensities, 𝜖𝑂𝐻 , and 𝜖𝑂− , and the fractions of the phenol, 𝑓𝑂𝐻 , and phenolate, 𝑓𝑂− ,
forms in solution containing a total concentration, T. Equation 17 can be rewritten in terms
of the fractions of each species present.
𝐼𝑗 = 𝑇[𝑓𝑂𝐻 𝜖𝑗,𝑂𝐻 + 𝑓𝑂− 𝜖𝑗,𝑂− ]

(18)

Here, the fraction of drug in each form may be expressed by mass balance and
rearrangement of Equation 16 as illustrated below in Equations 19a and b.
𝐻+

𝐾

𝑎1
𝑓𝑂𝐻 = 𝐻 + +𝐾 ; 𝑓𝑂− = 𝐻 ++𝐾
𝑎1

𝑎1

(19a; b)

For spectrometric determination of 𝐾𝑎1 , fluorescence emission at 560 nm was fitted to
the above equations at varying pH (3.5 – 7.5) and a constant TPT concentration of 500 nM
to determine 𝐾𝑎1 and 𝜖𝑗,𝑂− at excitation wavelengths of 335, 365, 380, and 410 nm. The
determination of 𝜖𝑗,𝑂𝐻 was accomplished using the fluorescence intensity at pH 3.5 by
assuming 𝐼𝑗,𝑂− was negligible at this pH.
4.2.7.3 TPT lactone-carboxylate interconversion kinetics in solution and in the presence of
liposomes
The lactone E-ring in TPT can undergo reversible, base-catalyzed hydrolysis to form its
ring-opened, carboxylate form via deprotonation of the carboxylic acid intermediate, 𝐶𝐶𝑂𝑂𝐻
(Scheme 4.4). This process is pH-dependent, similar to other camptothecin analogues, with
the lactone form, 𝐿, dominating at low pH. As pH is increased, both ring-opening and
closing rate constants are base-catalyzed; however, ionization of the ring-opened carboxylic
acid to form 𝐶𝐶𝑂𝑂− shifts the equilibrium toward the ring-opened species.92, 148
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Scheme 4.4.

The proposed mechanism for reversible, pH dependent ring

opening of TPT from its lactone, 𝐿, to carboxylate, 𝐶𝐶𝑂𝑂− , form. Because ring
opening proceeds through the carboxylic acid species, 𝐶𝐶𝑂𝑂𝐻 , ring opening
increases as more carboxylate is formed at higher pH, as governed by the acid
dissociation constant for the E-ring carboxylic acid, KCOOH.
Because of its location and the molecule’s rigidity, it is unlikely that the ionization state
of the phenol would have any effect on the lactone-carboxylate interconversion kinetics.
With this assumption, the rate equations for ring opening and closing can be expressed in
terms of total lactone, 𝐿, and carboxylic acid, 𝐶𝐶𝑂𝑂𝐻 , concentrations in solution as shown
below.
𝑑𝐿
𝑑𝑡
𝑑𝐶
𝑑𝑡

= 𝑘𝑐𝑙 [𝑂𝐻− ]𝐶𝐶𝑂𝑂𝐻 − 𝑘𝑜𝑝 [𝑂𝐻− ]𝐿

(20a)

= −𝑘𝑐𝑙 [𝑂𝐻 − ]𝐶𝐶𝑂𝑂𝐻 + 𝑘𝑜𝑝 [𝑂𝐻 − ]𝐿

(20b)

Solving for 𝐶𝐶𝑂𝑂𝐻 in terms of total ring-opened species, 𝐶, is needed. The fraction of
total ring-opened species present as carboxylic acid at a particular pH, 𝑓𝐶𝑂𝑂𝐻 , can be
determined from the pKa of the carboxylic acid (Equation 21).
𝐻+

𝑓𝐶𝑂𝑂𝐻 = 𝐻 ++𝐾

𝐶𝑂𝑂𝐻
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(21)

In previous studies, the 𝑝𝐾𝐶𝑂𝑂𝐻 for TPT, camptothecin, and other analogues has been
assumed to be 3.8 or 4.0.92, 148 Based on those studies and the pKa value of 3.86 for glycolic
acid, a value of 3.9 was assumed for model fitting.
To reduce the correlation between the ring-opening, 𝑘𝑜𝑝 , and ring-closing, 𝑘𝑐𝑙 , rate
constants during model fitting, the equilibrium constant between the ring-opened
carboxylate acid and ring-closed lactone forms, 𝐾0 , was used. As seen in Equation 22b,
𝑘𝑜𝑝 can be rewritten in terms of 𝑘𝑐𝑙 and 𝐾0 .
𝐾0 =

𝐶𝐶𝑂𝑂𝐻
𝐿

=

𝑘𝑜𝑝
𝑘𝑐𝑙

; 𝑘𝑜𝑝 = 𝑘𝑐𝑙 𝐾0

(22a; b)

Substituting Equations S21 and 22b into rate Equations 20a and b,
𝑑𝐿
𝑑𝑡

𝑑𝐶
𝑑𝑡

= 𝑘𝑐𝑙 [𝑂𝐻− ]𝑓𝐶𝑂𝑂𝐻 𝐶 − 𝑘𝑐𝑙 𝐾0 [𝑂𝐻− ]𝐿

(23a)

= −𝑘𝑐𝑙 [𝑂𝐻 − ]𝑓𝐶𝑂𝑂𝐻 𝐶 + 𝑘𝑐𝑙 𝐾0 [𝑂𝐻 − ]𝐿

(23b)

To determine 𝐾0 and 𝑘𝑐𝑙 at the same conditions used for release studies, TPT
interconversion studies were first performed at varying pH (6.33 – 7.67) in the absence of
liposomes. These studies were fit simultaneously to rate Equations 23a and S8b. Studies in
the presence of liposome suspensions (50 mg/mL) prepared in pH 6.33 and pH 7.67 buffers
were also conducted. The lactone and carboxylate concentration versus time profiles were
compared to those obtained at the same pH in the absence of liposomes to evaluate whether
membrane binding had an effect on the interconversion kinetics.
4.2.7.4 Mathematical model for liposomal TPT release assuming equilibrium for lactone ringopening/closing
To evaluate the need for lactone/carboxylate interconversion kinetics in the release
model, the half-life profile of that model was compared to a half-life profile generated by
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fitting TPT release profiles at varying pH to an equilibrium model. To determine the halflife profile for the equilibrium model, 𝑡1/2 may be expressed by Equation 24.
ln(2)

𝑡1/2 = 𝑘

𝑢
𝑚𝑓

=

ln(2)(𝑎+𝑏𝐾 ′ )
𝑘𝑚

(24)

Here, the overall release constant, 𝑘𝑚 , and total fraction of unbound intravesicular drug, 𝑓 𝑢 ,
are considered. Both parameters are a function of pH. In equation 24, 𝑘𝑚 accounts for the
fraction of each permeable species found in solution along with their respective transport
0
0
rate constants, where 𝑘𝑚,𝐿
is the transport rate constant for the protonated lactone, 𝑘𝑚,𝐿
𝑝
𝑛
0
is for the zwitterionic phenolate form of the lactone, and 𝑘𝑚,𝐶
is for the ring-opened
𝑛

carboxylate zwitterion.

𝑘𝑚 =

0
0
0
𝐻 +(𝑓𝐿𝑢𝑝 𝑘𝑚,𝐿
+𝑓𝐿𝑢𝑛 𝑘𝑚,𝐿
)+𝐾𝐴2 𝑓𝐿𝑢𝑝 𝑘𝑚,𝐶
𝑝
𝑛
𝑛

𝐻 ++𝐾𝐴2

(25)

The unbound fraction (𝑓 𝑢 ) in Equation 24 varies with pH as it is a function of the
apparent membrane binding constant, 𝐾’, as illustrated by Equation 25. The binding
constants obtained previously using the mathematical model for liposomal TPT release that
included the kinetics of lactone ring-opening/closing were inserted as constants into
Equation 25.

𝐾′ =

𝑓𝐿𝑢𝑝 (𝐻 + 𝐾𝐿0𝑝 +𝐾𝐴2 𝐾𝐶0𝑛 )
𝐻 ++𝐾𝐴2

(25)

The release profiles were simultaneously fit to the equilibrium model described by
0
0
0
0
Equations S22-24 where the rate constants ( 𝑘𝑚,𝐿
, 𝑘𝑚,𝐿
, 𝑘𝑚,𝐶
, and 𝑘𝑚,𝐶
) and membrane
𝑝
𝑛
𝑛
𝑎

binding constants (𝐾𝐿0𝑝 , 𝐾𝐿0𝑛 , 𝐾𝐶0𝑛 , and 𝐾𝐶0𝑎 ) were fitted using non-linear regression.
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4.2.7.5 Regression Analysis
Data fitting for constants describing the A-ring phenol pKa, ring-opening
interconversion kinetics, and release kinetics was performed using Scientist® non-linear
least squares regression software with a weighting factor of two.

4.3 Results
4.3.1 Validation of analytical methods and liposome characterization
TPT concentrations were analyzed by HPLC with fluorescence detection using excitation
and emission wavelengths of 380 nm and 550 nm, respectively. Peak areas varied linearly
with concentration between 20 and 200 nM for both lactone and carboxylate standards.
Release studies monitored total TPT concentration by converting all drug to its lactone form
by diluting samples with chilled acidified methanol into the concentration range of
standards. Coefficients of variation for response factors of standards were ±1.4% intraday
and ±2.6% interday.

Initial TPT concentrations ranged from 0.2-1.0 µM for these

experiments. Studies monitoring TPT interconversion kinetics were performed with initial
concentrations of 0.4-0.6 µM and coefficients of variation for response factors were ±2.0%
intraday and ±7.1% interday for carboxylate standards and ±1.5% intraday and ±2.1%
interday for lactone standards. Phospholipid content was determined by a previously
validated HPLC method with slight modifications.49, 60 ELSD, necessary due to the lack of
chromophore/fluorophore in the lipid molecules, provided linear log-log plots of the peak
areas versus DSPC concentration between 0.025 – 0.3 mg/mL and a peak retention time of
7.9 minutes, similar to that previously reported.49
To validate the ultrafiltration procedure as a reliable technique to analyze drug release
kinetics, the recovery efficiency of TPT and phospholipid after ultrafiltration was
determined. Sephadex separation of liposomally entrapped TPT from unencapsulated drug
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was used as previously reported147 to determine this recovery value. By analyzing TPT
concentrations in liposomal fractions collected immediately after Sephadex purification, the
percentage of TPT recovered after the ultrafiltration procedure was determined to be 88.0 ±
2.4%; however, this value may be an underestimation if trace amounts of unentrapped TPT
were present after Sephadex separation. To further explore this as a possible source of
error, phospholipid content was also determined in liposome samples after ultrafiltration.
Phospholipid recovery was determined to be 94.0 ± 3.9%. The slightly higher recovery of
phospholipid in comparison to TPT after ultrafiltration of freshly purified drug-loaded
liposomes provides evidence for the presence of a small percentage of unentrapped drug.
Consequently, phospholipid and TPT recovery were compared at the start of a release
experiment to estimate the initial amount of TPT in the extra-vesicular solution. During
these experiments, the initial extra-vesicular TPT was never more than 2.5% of the initial
intra-vesicular TPT. As a final validation, suspensions of liposomes containing no drug were
spiked with TPT and then ultrafiltered. Ultrafiltration of these spiked solutions showed only
trace amounts of TPT present well, below the limit of quantitation (less than 0.3% of initial
TPT). Because passive loading was used to conduct these experiments, encapsulation
efficiency was not determined as it was expected to be low (< 3%) and not germane to the
goals of this study.
Volume parameters (Table 1) used in model fitting were calculated from particle sizes
and phospholipid contents determined during release studies. Particle size was determined
at each pH (8 measurements) for the suspensions before and after the conclusion of release
studies. The average particle size before release studies (with 95 % confidence interval)
was 96 ± 2 nm and 98 ± 3 nm after release studies were finished, indicating no statistically
significant change in particle size during the experiments. Because of the narrow particle
size distribution, average particle size was used to determine the aqueous/total entrapped
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volume ratio (a) and membrane/total entrapped volume ratio (b), parameters that were
necessary for the analysis of the transport data (see Supplementary Data). Extra-vesicular
volume ratios (c and d) analogous to a and b were also required for the determination of
membrane binding constants and subsequently release rate constants because these studies
were not performed under sink conditions. The entrapped/unentrapped volume ratio (𝑓𝑣 )
calculated from the lipid content present in suspension was varied in release studies by
altering the lipid concentration to avoid possible systematic errors in estimation of
membrane binding constants from release profiles. Thus, the lipid content determined for
each release study was used rather than the average of values for all experiments. The
values in Table 1 reflect the parameter ranges explored.50, 135, 149
Table 4.1. Volume parameters used in TPT release studies
Parameter

Average

Range

a

0.855

NA

b

0.145

NA

c

0.9997

0.9995 – 0.9999

d

0.0003

0.0001 – 0.0005

𝑓𝑣

0.0067

0.0024 – 0.0110

Phospholipids undergo acid-catalyzed ester hydrolysis142-144 that could lead to hydrolysisinduced changes in bilayer integrity over longer periods of time. This possibility was
examined by monitoring lipid content in solution using HPLC with an ELSD. No loss of lipid
was detected in release studies at pH 4.01 over 72 hr but >10% lipid loss was found after 48
hr at pH 3.35 (Figure 4.1) which is qualitatively consistent with literature data 150. Previous
literature reports have shown compromised bilayer integrity when 15% or more
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phospholipid has degraded.143 Consequently, only samples taken before 36 hours from the
pH 3.35 release study were used in data fitting.

1.25

Ct/C0

1.00
0.75
0.50
0.25
0.00
0

12

24

36

48

60

72

Time (hours)
Figure 4.1. The fraction of DSPC remaining during release studies conducted at
pH 3.35

and 4.01

. Error bars at pH 4.01 are the 95 % confidence intervals

determined by samples taken from four independent experiments.

4.3.2 Spectrometric determination of the TPT A-ring phenol (pKa1)
Because of the high dependency of bilayer permeability on permeant charge,3, 50, 52, 60, 73
the pKa of the phenolic -OH on the A ring was determined at 37 °C from changes in the TPT
fluorescence excitation spectra with pH as seen in Figure 4.2a. Spectral changes as a
function of pH (Fig. 2b) were used to determine 𝑝𝐾𝑎1 to be 6.56 ± 0.12. This value is similar
to those previously reported at lower temperatures.90, 92, 138, 151

81

4.5E+05
4.0E+05
3.5E+05

I (cps)

3.0E+05

pH

2.5E+05

2.0E+05
1.5E+05
1.0E+05
5.0E+04
0.0E+00
300 325 350 375 400 425 450 475
λ (nm)

A.
4.5E+05
4.0E+05

3.5E+05

I (cps)

3.0E+05
2.5E+05
2.0E+05
1.5E+05
1.0E+05

5.0E+04
0.0E+00
3

4

5

6

7

8

pH

B.

Figure 4.2. A) TPT excitation spectra at varying pH (3.50, 4.50, 5.50, 6.00, 6.27,
6.50, 6.80, 7.10, and 7.50) obtained at an emission wavelength of 560 nm. As pH
is increased, a red shift occurs with maximum excitation shifting from 380 nm to
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410 nm. B) Fluorescence intensities at an emission wavelength of 560 nm and at
excitation wavelengths of 380 (), 365 (), 335 (), and 410 nm () from
TPT solutions at varying pH and fit to Equations S3 & S4 to determine 𝑝𝐾𝑎1. The
lines represent the simultaneous fit of intensities at all wavelengths vs. pH.

4.3.3 TPT lactone-carboxylate interconversion kinetics
The kinetics of interconversion of TPT between its lactone and carboxylate forms was
monitored as a function of pH by following both carboxylate and lactone species (Figure
4.3a). A kinetic model based on a ring opening/closing mechanism previously described in
the literature,92 was able to account for the pH-dependence, resulting in a base-catalyzed
ring-closing rate constant (𝑘𝑐,𝑂𝐻 ) of 7.4 ± 0.3 x 108 mol-1hr-1 and a carboxylic acid/lactone
equilibrium constant (𝐾0 ) of 1.98 ± 0.07 x 10-3. Combining the pKa of the ring-opened
carboxylic acid assumed to be 3.9 (based on values previously assumed for camptothecin
and its analogues and a pKa of 3.86 for the α-hydroxy acid glycolic acid)with 𝐾0 gave an
effective pKa for the ring-opening/ionization reaction (𝑝𝐾𝑎2 ) of 6.60. This value is similar
to that reported for camptothecin and other analogues.92, 148
Interconversion studies conducted in liposomal suspensions at high lipid content
revealed no significant changes in the kinetic parameters or value of 𝐾0 from those obtained
at the same pH in aqueous solutions (Figures 4.3b and c). This supports the negligible effect
of membrane binding on interconversion kinetics and the use of 𝑘𝑐𝑙 and 𝐾0 to describe
inter-conversion kinetics of total intravesicular TPT.
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Figure 4.3. Ring opening/closing kinetics of TPT as a function of pH. A) The
plots display the fractions of total TPT in the lactone form (closed symbols) or
carboxylate form (open symbols) versus time at the same pH of 5.92 ( ,
6.33(

,

), 7.04 ( ,

),

), 7.39 ( , ), or 7.67 ( X , x). The curves of matching
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36

color represent simultaneous fits of the kinetic interconversion model to the
lactone (solid lines) and carboxylate (dashed lines) data. Most interconversion
occurred within the first three hours (left) while equilibrium was achieved for
all studies (right). Interconversion of TPT in liposome suspensions (50

mg/mL) at pH 6.33 (B) and pH 7.67 (C) is also shown. The fractions of total
TPT in the lactone

and carboxylate

form are shown in aqueous solution

while the open symbols represent studies conducted in liposomal suspensions.
Solid and dotted lines indicate the simulated interconversion profiles for both
aqueous and liposome studies simulated by the kinetic parameters previously
determined from aqueous solution studies.
4.3.4 pH Sensitive release of TPT
Transport experiments were performed at varying pH and at a recorded average
temperature of 38.7 ± 0.1 °C during the time period of the studies. The fractions of TPT
retained in DSPC/DSPE-PEG2K liposomes versus time at varying pH are shown in Figure
4.4. The curves displayed in Figure 4.4 represent simultaneous fits to the mechanism-based
mathematical model for TPT release developed in the Supplementary Data using the
equilibria and

chemical kinetic constants

interconversion studies.

determined

from spectrometric and

From these data, transport rate constants and partition

coefficients were obtained for the various ionization states of the lactone and carboxylate
species (see Scheme 4.1). Transport rate constants of 0.51 ± 0.07 hr -1 and 33.9 ± 4.6 hr-1
were found for the cationic lactone species (𝐿𝑝 ) and the zwitterionic lactone (𝐿𝑛 ),
respectively, while the ring-opened carboxylate zwitterion (𝐶𝑛 ) had a rate constant of 5.7 ±
0.5 hr-1 and its anionic form (Ca) was found to be impermeable.
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Figure 4.4. Fraction of TPT retained in DSPC/DSPE-PEG2K liposomes vs. time
at varying pH (right panel displays only the first 6 hrs). Release studies were
conducted at pH 3.35 , 4.10

, 5.10 +, 5.93

, 6.33
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x. The solid curves of the same color represent the simultaneous fit of the
mechanism-based mathematical model developed in this paper to the entire
data set.
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The same analysis also indicated that the zwitterionic lactone (𝐿𝑛 ) and anionic
carboxylate form 𝐶𝑎 exhibited negligible binding to the phospholipid bilayer. Both of these
species have in common a phenolate moiety that evidently disfavors interaction with the
bilayer. This and the similar partition coefficients of 62 ± 6 and 42 ± 6 for the lactone and
carboxylate species in which the phenol is unionized (𝐿𝑝 and 𝐶𝑛 , respectively) suggest that
binding likely occurs with preferential orientation of the TPT A-ring toward the
hydrophobic region of the phospholipid bilayer. Opening of the lactone ring had a negligible
effect on membrane binding.

4.4 Discussion
4.4.1 Effect of TPT ring-opening on pH sensitive release kinetics
The significantly greater permeability of the zwitterionic lactone species (𝐿𝑛 ) than any
of the other TPT species present in the pH range explored (Scheme 4.1) raises the
possibility that, under certain pH conditions, this species might be depleted from the
intravesicular compartment due to its slow regeneration from the ring-opened form.
Simulated profiles of the concentrations of carboxylate and lactone species at pH 6.33
(where the lactone fraction is greater) and pH 7.04 (where the carboxylate fraction is
greater) are shown in Figure 4.5 along with the profile of total drug released in Figure 4.4.
Because interconversion is not instantaneous, the more permeable lactone zwitterion was
depleted at a faster rate than its carboxylate counterpart, resulting in biphasic release
profiles at certain pH values such as within the first 30 min of release at pH 7.04 (Figure
4.5b, see also Figure 4.5b).
The ratio of lactone to carboxylate species, 𝑅, during release is also depicted in Figure
4.5. The profile of 𝑅 initially shows a rapid decrease as the more permeable lactone species
are depleted during the early phase of release.
87

During the later phase of release, R

approaches its initial equilibrium value as the less permeable carboxylate specie continues
to release. Similar trends of 𝑅 are evident for release studies conducted in the neutral pH
range (Figure 4.5c)
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Figure 4.5. Liposomal TPT release profiles at pH 6.33 (A) and 7.04 (B). The
observed fraction of total TPT retained
described within this paper (
lactone (

) and ring-opened (

and the resulting fit to the model

) are shown. The simulated profiles of the
) forms are also displayed to illustrate the

rapid depletion of the lactone. The lactone to carboxylate ratio, R (

), is also

shown to highlight the role of slow carboxylate-> lactone conversion during TPT
release. C) Changes in 𝑹 during liposomal TPT release studies for all pH

studied where interconversion kinetics were not instantaneous (pH 6.33 (
7.04 (

), 7.39 (

), and 7.67 (

),

)) were also simulated. All profiles show

a decrease in 𝑹 as the more permeable lactone is depleted, thus indicating
non-instantaneous interconversion between the two species.
4.4.2 Comparison of kinetic and equilibrium models of lactone ringopening/closing
In previous pH-dependent release studies with the camptothecin analogue AR-67, ringopening kinetics could be assumed to be instantaneous because the high membrane-binding
constant for the lactone form reduced the driving force for release and provided a reservoir
of the lactone species.49, 60, 63 Both of these factors minimized the depletion of lactone. In
contrast, the low membrane-partitioning observed for TPT required such an assumption to
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be tested. To compare the release model that incorporated the kinetics of ring-opening
with one that assumed ring-opening/closing equilibrium, the pH profiles for the release
half-lives (𝑡1/2 ) generated by the two models as a function of pH were compared in Figure
4.6 along with the experimentally-observed half-lives.
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Figure 4.6. (A) Comparison of the experimental pH profile of TPT release halflives ( ) to model fits that account for the kinetics of lactone-carboxylate
interconversion (

) or assume lactone-carboxylate equilibrium (

). The

equilibrium model was unable to account for the steep changes in half-life in the
neutral pH region. The blue section highlights the pH region in which release
was slowed by greater than 25% due to rate-limiting ring-closure. (B) The
biphasic release profile observed at pH 7.04 and the fits of models that either
include interconversion kinetics (
(

) or assuming interconversion equilibrium

).

Because the equilibrium model does not account for interconversion kinetics, it tries to
compensate for the steep change in half-life (resulting from rate-limited ring-closing) seen
at neutral pH (6.8 – 8.0) by overestimating release in the acidic region and underestimating
release at higher pH. Figure 4.6 also demonstrates the inadequate fit of the equilibrium
model to a single release profile. Here, the equilibrium model underestimated the initial
phase of drug release as it could not account for biphasic kinetics. In contrast, the model
incorporating interconversion kinetics is able to account for the rapid initial phase of drug
release that leads to lactone depletion followed by subsequent slower release limited by
intravesicular regeneration of lactone from the carboxylate.

4.4.3 Determination of species permeability coefficients
The apparent permeability coefficient, 𝑃𝑚0 , is related to the apparent transport rate
constant at a given pH and the radius of the particle, 𝑟, as expressed by Equation 26.
𝑟

0
𝑃𝑚0 = 3 𝑘𝑚

(26)

Using the release model that included the kinetics of ring-opening/closing, three TPT
species were determined to contribute to the liposomal transport. From these release rate
constants, permeability coefficients could be calculated for these species.
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Based on the 100 nm liposomes used in these studies, the cationic and zwitterionic
lactone permeability coefficients were 2.4 × 10−10 𝑐𝑚⁄𝑠 and 1.5 × 10−8 𝑐𝑚⁄𝑠 while TPT
carboxylate zwitterion permeability coefficient was 3.0 × 10−9 𝑐𝑚⁄𝑠 . Generally, neutral,
non-ionized species are orders-of-magnitude more permeable than charged species;
however, few zwitterions have been explored.49, 50, 52 The permeability coefficient for the
lactone zwitterion determined from this work is similar to one obtained for the neutral,
unionized lactone species of another camptothecin analogue.49 This is likely due to an
intramolecular interaction between the A-ring phenolate and dimethyl-ammonium
substituents. Because of their close proximity and orientation, the free energy required for
bilayer partitioning of this specie may be lower due to an electrostatic interaction or an
intramolecular hydrogen bond between the heteroatoms. This is supported by the large pKa
shifts observed in aqueous solution for the phenolic –OH (i.e., from 10.0 in phenol to 6.56 in
TPT) and dimethyl-aminomethyl substituent (from 8.93 in benzyldimethylamine to 10.5 in
TPT), respectively. These shifts in pKa are a direct consequence of the stabilization of the
zwitterionic form in Scheme 4.3.

A similar effect has also been reported for other

compounds with this same feature,92, 152 and recent studies of TPT fluorescence lifetimes in
aqueous solution have distinguished intramolecular and bulk solution contributions to
phenol deprotonation.151 These interactions may help explain the small but significant
permeability of the cationic species, 𝐿𝑝 , seen in this study. Partial shielding of the cationic
charge of 𝐿𝑝 may be through hydrogen bonding with the phenol which may be further
stabilized by resonance forms that delocalize the charge throughout TPT’s conjugated ring
structure.
Unlike the lactone zwitterion, the carboxylate form, 𝐶𝑛 , does not offer the possibility of
such intramolecular interactions between adjacent charged residues. Without this feature,

92

the observed permeability may reflect the minor fraction of unionized neutral species, 𝐶0 , as
depicted in Scheme 4.5.

Scheme 4.5.

The equilibrium between TPT’s carboxylate zwitterion and

neutral, unionized form is governed by 𝑲𝟎,𝑪 .
To ascertain whether the observed permeability for the carboxylate could be
attributable to 𝐶0 , the equilibrium constant between 𝐶𝑛 and 𝐶0 , 𝐾0,𝐶 , must be determined.
This may be written in terms of the fraction of the zwitterion, 𝑓𝑧,𝐶 , and non-ionized, 𝑓0,𝐶 ,
species as expressed in Equation 26.
𝑓

𝐶

𝐾0,𝐶 = 𝐶0 = 𝑓0,𝐶 = 𝐾
𝑛

𝑧,𝐶

𝐾𝑎3

𝐶𝑂𝑂𝐻

(26)

Using this ratio, a maximum permeability for 𝐶0 may be determined if one assumes 𝐶0 is the
sole specie contributing to the observed permeability of the carboxylate.

Using this

assumption and a 𝑝𝐾𝑎3 of 10.5 for the dimethyl-amino group,92 the maximum permeability
coefficient is estimated to be 9.3 × 10−3 𝑐𝑚⁄𝑠 for 𝐶0 .
To assess the significance of this permeability coefficient, comparison to the theoretical
maximum permeability, 𝑃𝑚𝑎𝑥 , is needed.

𝑃𝑚𝑎𝑥 can be described by diffusion-limited

transport through the boundary layer of a spherical particle. This is given by Equation 27.
𝑃𝑚𝑎𝑥 =

𝐷𝑇𝑃𝑇
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𝑟

(27)

Here, the diffusivity of TPT, 𝐷𝑇𝑃𝑇 , was determined by the Stokes-Einstein equation for
diffusivity in water at 37 °C and a molecular volume of 366.8 Å3 (ACD labs). Based on this
information, 𝐷𝑇𝑃𝑇 was calculated to be 7.52 × 10−6 𝑐𝑚 2⁄𝑠 and 𝑃𝑚𝑎𝑥 was estimated to be
1.50 𝑐𝑚/𝑠. While the estimated permeability coefficient of 𝐶0 necessary to account for the
experimental data is below 𝑃𝑚𝑎𝑥 , it is still several orders of magnitude higher than that of
TPT’s lactone zwitterion and another neutral, non-ionized camptothecin of similar size.49
This analysis suggests transport of the neutral, unionized ring-opened species is unlikely to
fully account for the transport observed. Other mechanisms that may stabilize the ringopened carboxylate zwitterion as it traverses the bilayer include: long-range intramolecular
substituent effects on membrane partitioning, formation of water bridges through the
bilayer, or ion-pairing within the barrier domain during TPT transport.45, 129, 153-155

4.5 Conclusions
The pH dependent release of TPT from DSPC/m-PEG DSPE liposomes was characterized
and the contribution of the kinetics of the pH-dependent ring-closure reaction to this
process was assessed.

These factors were incorporated into a mechanism-based

mathematical model to describe TPT release. Based on this model, three TPT species were
determined to be permeable to the membrane with the A-ring zwitterion form being the
most permeable species. Within a defined pH region lactone depletion resulted in ringclosure of the ring-opened carboxylate form becoming at least partially rate-determining. A
mathematical model that assumed equilibrium between the lactone and ring-opened
species was inadequate in accounting for the complete profile for the dependence of t 1/2 on
pH and the biphasic release kinetics observed at certain pH values. The mechanism-based
model developed in these studies will provide a basis for understanding the loading and
release kinetics of actively-loaded formulations of TPT.
Copyright © Kyle Daniel Fugit
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CHAPTER FIVE
Insights Into Accelerated Liposomal Release of Topotecan in Plasma
Monitored by a Non-invasive Fluorescence Spectroscopic Method
5.1 Introduction
Many physiological factors (i.e. age, gender, dose regimen, type or location of cancer,
mononuclear phagocyte system25) have been proposed to influence the pharmacokinetics
(PK) and pharmacodynamics (PD) of nanoparticle formulations of anticancer agents.
Unfortunately, the correlation between these factors and nanoparticle efficacy remain
largely unknown.26, 27 In liposomal formulations, bilayer integrity may be compromised by
the particles’ interactions with proteins (e.g. vesicle binding and particle opsonization) 54-57
or osmotic stresses58, 59 while in circulation or at the tumor site. Other factors may also
accelerate release of actively-loaded drug by destabilizing the pH gradient in vivo. 60
Actively-loaded liposomal formulations of anticancer agents are numerous 21, 42, 62, 73, 95, 156
and would share in these susceptibilities.

Reports describing the effects of such

physiological phenomena on release kinetics in vivo have been limited due to the lack of
available in-situ methods to monitor and distinguish entrapped from free drug. Methods to
determine the release kinetics of drug from circulating liposomes and/or at the tumor site
are crucial to optimizing the efficacy of liposomal-based drug delivery systems.
Validation of such a method to quantify release kinetics requires parallel development
of a mathematical model to interpret observed release profiles. The model must distinguish
physicochemical release characteristics intrinsic to the drug/particle system from artifacts
of the release environment (i.e. kinetic or thermodynamic effects attributable to the
particular medium within which release is determined).49, 60, 63, 124-126 With such models, the
in vivo factors that lead to variability in liposomal formulation performance may be
identified and mechanistically understood.
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Topotecan (TPT) is a camptothecin analogue known for its topoisomerase-I inhibitory
activity and regulation of genes associated with angiogenesis. 157 Several preclinical studies
have demonstrated increased anti-tumorigenic efficacy of liposomal formulations of TPT
that have reduced systemic clearance, allowing greater uptake and extended tissue
exposure in murine solid tumors.62, 158, 159 Many of the liposomal formulations of TPT are
actively loaded by establishing an acidic intravesicular compartment relative to the
extravesicular pH of the loading solution.

This process provides high drug loading

efficiencies while ensuring the pharmacologically active lactone form of TPT is delivered to
the tumor. While actively loaded liposomal formulations have often shown prolonged
retention in aqueous buffers,23, 62, 64 the same formulations may exhibit accelerated release
in plasma.23, 62
While the low intravesicular pH persists after active drug loading,

62, 64, 159-161

to the

authors’ knowledge it has never been used to differentiate between entrapped and free TPT
during drug release. Because the fluorescence of TPT is pH-dependent,156, 162 changes in
TPT fluorescence in aqueous liposomal suspensions and in plasma were explored as a
potential means of non-invasively monitoring liposomal release in real-time. Analyses of
fluorescence spectra confirmed that free TPT exhibits a red shift in its excitation spectrum
as pH is increased. Due to this red shift, release of TPT from actively loaded liposomal TPT
(ALLT) formulations could be monitored using fluorescence at higher wavelengths (410430nm) where entrapped drug at low intravesicular pH does not fluoresce.
The initial aim of this study was to validate a fluorescence method to non-invasively
monitor liposomal release of TPT in tissue samples. During the course of comparing
apparent liposomal release profiles in different media including PBS buffer, plasma, and
plasma ultrafiltrate using either the fluorescence method or HPLC it became evident that: a)
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TPT release is dramatically accelerated in human plasma as initially reported by Liu et al.; 62
and b) similar release kinetics were obtained in plasma ultrafiltrates. Recognizing that a
non-filterable plasma component must be responsible for the accelerated release and that
normal human plasma contains low levels of ammonia,163,

164

additional studies were

conducted to probe the concentrations of ammonia in the plasma samples and the effect of
ammonia on TPT release. To mechanistically rationalize differences in release profiles
using different analytical methods and media, mathematical models were developed to
account for the effects of liposome concentration, intravesicular pH, TPT ionization, and
ammonia concentration on release kinetics.

5.2 Materials and Methods
5.2.1 Materials
Powders of 1,2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC, >99% purity) and
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000]
(DSPE-PEG2K, MW = 2806, >99% purity) were purchased from Avanti Polar Lipids
(Alabaster, AL). Topotecan hydrochloride was purchased from AK Scientific (Union City,
CA). Heparinized human plasma samples from three individual donors of different ethnicity
were purchased from Innovative Research (Novi, MI), aliquoted and stored at -20°C.
Benzene sulfonic acid sodium salt (sodium besylate) was purchased from Spectrum
Chemicals (New Brunswick, NJ). Millipore ultrafiltration cartridges (Amicon® Ultra 0.5 mL
centrifugal filter device with 3,000 MWCO Ultracel® membrane), Nuclepore polycarbonate
membranes (0.1 µm), Dowex 50Wx8-200 resin in the H+ form, solvents, and buffer salts
were purchased from Fisher Scientific (Florence, KY). All solvents were HPLC grade.
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5.2.2 Liposome preparation
Large unilamellar liposomes were prepared based on previously reported methods. 49, 50,
60, 118, 124, 125

Briefly, powders of DSPC and DSPE-PEG2K were dissolved in chloroform at a

molar ratio of 95:5, then dried under nitrogen, and finally under vacuum (- 30 in Hg) at 35
°C for 6 hours. After drying, the films were hydrated in either 0.3 M ammonium besylate, 1
mM TPT in 50 mM pH 3.75 formate buffer, or pH 7.4 phosphate buffered saline (PBS)
solutions to produce 30 mg/mL lipid suspensions. These suspensions were vortexed at 60
°C, then extruded through two 100 nm polycarbonate membranes 10 times at 40 psig and
60 °C to yield suspensions of ammonium besylate-loaded liposomes (ABLs), passivelyloaded TPT-containing liposomes, or blank liposomes, respectively.
The ammonium besylate solutions (0.3 M) used for liposome hydration were prepared
in a manner similar to that previously used to make other amino-based salts.21, 42 Solutions
of sodium besylate (0.6 M) were passed through an ion exchange column loaded with
Dowex 50Wx8-200 resin in the H+ form. The eluted solutions were subsequently titrated
with ammonium hydroxide (3.0 M) to the equivalence point and diluted to the desired
concentration.

5.2.3 Active loading of TPT into ammonium besylate liposomes
Previous studies have shown that active-loading of weakly basic drugs results in high
encapsulation efficiency and possibly longer drug retention in vitro and in vivo. 62,

159

Actively- loaded liposomal suspensions of TPT were prepared with the aim of evaluating a
fluorescence method to analyze drug release in vivo or ex vivo.

Active loading was

performed by generating a low intravesicular pH via an ammonia gradient. 62,

73

This

gradient was established when extravesicular ammonium besylate was removed by passing
the suspension through a Sephadex G-25 column similar to previous reports.62 In this case,
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0.4 mL of the ABL suspension was passed through the column equilibrated with 100 mM 2(N-morpholino) ethanesulfonic acid (MES) pH 5.5 buffer and the first 5 mL of eluted
suspension was collected for loading studies. Next, 1.5 mL of the eluted suspension was
added to an equal volume of TPT dissolved in the same pH 5.5 buffer to achieve a total TPT
suspension concentration of 50 or 200 µM and a lipid concentration of 0.92 mg lipid/mL.
Loading occurred over a 72 hour period within a 37 °C incubator.
Actively-loaded liposomal TPT (ALLT) suspensions were prepared for release studies
by removing extravesicular buffer and any remaining unloaded drug by applying 0.5 mL of
ALLT to a Sephadex G-25 column equilibrated with PBS similar to previous reports.60, 63 The
first 2.5 mL fraction eluted from the column was discarded. ALLT eluted in the next 2.5 mL
fraction and was collected for use in release studies monitored by fluorescence or HPLC.

5.2.4 Liposome characterization
Particle size was determined for ALLT and PLLT using dynamic light scattering (DLS)
using a Beckman Delsa™ Nano C Particle Sizer as previously reported. 125, 126 Lipid content
was monitored by HPLC using an evaporative light scattering detector (ELSD). A Waters
Alliance 2695 separations module equipped with an Allsphere (Alltech Associates, Inc.,
Deerfield, IL) silica column (4 x 150 mm, 5 µm) and guard column (20 x 4.0 mm, 5 µm) and
a mobile phase consisting of 80% of solvent A (80% chloroform:19.5% methanol:0.5%(v/v)
NH4OH) and 20% of solvent B (80% methanol:19.5% water:0.5% (v/v) NH4OH) flowing at
1 mL/min was used to quantify DSPC in conjunction with an ELSD (Sedere, Inc.,
Lawrenceville, NJ) operated at 40 psig and 40 °C. Standards of DSPC were dissolved in
mobile phase A (0.05 – 0.3 mg DSPC/mL). Log-log plots of peak area versus concentration
were linear over this concentration range. Samples (100 – 250 µL) were dried at room
temperature under N2, then dissolved in chilled solvent A before analysis.
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5.2.5 Fluorescence method development and validation
5.2.5.1 TPT Excitation Spectra
Samples and standards from validation and release studies were placed in 1 ml quartz
cuvettes (NSG Precision Cells, Inc. Farmingdale, NY) for spectrometric analysis.
Fluorescence excitation spectra (290-500nm) were collected with a FluoroMax-3
spectrofluorometer (Jobin Yvon Inc. Edison, NJ) operating at a constant emission
wavelength of 550 nm, slit width of 1.5 nm, and a 0.5 second integration time. The
temperature of the sample chamber was maintained at 37 °C.
Excitation spectra of free TPT (2.5 µM) and PLLT (2.5 µM total suspension
concentration of TPT after Sephadex removal of unentrapped drug) in pH 3.75 formate
buffer were analyzed to compare the excitation spectra of free and entrapped TPT under
acidic conditions. Excitation spectra were obtained by Dr. Amar Jyoti. These spectra were
compared to excitation spectra of free TPT (2.5 µM) at pH 7.4 and ALLT suspensions in pH
7.4 PBS (2.5 µM suspension TPT, 37 ug lipid/mL) to determine if ALLT spectra were
indicative of an acidic intravesicular environment and whether spectra of entrapped and
unentrapped drug were different.
5.2.5.2 TPT release studies by fluorescence
Release of liposomal TPT in the presence of extravesicular ammonia may be particularly
important, as it is present in physiological fluids and tissues and may have an effect on
intravesicular pH and subsequently on release kinetics. To observe these effects, release
studies of ALLT were conducted at 37 °C in pH 7.4, phosphate buffered saline (PBS) solution
and in PBS containing 60 µM of NH4Cl.
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For release studies monitored by fluorescence, 100 uL aliquots of the liposomal
suspension collected after Sephadex purification were diluted to 1 mL with either PBS,
human plasma (from three individual donors), or plasma ultrafiltrate (obtained from the
donors’ plasma used in release studies) to achieve suspension concentrations of 19.2 µg/mL
lipid and 3.2 µM TPT (as determined by HPLC). Excitation spectra were collected over time
and compared to spectra for TPT standards (0.5-5 µM) in the same sample matrix analyzed
at the same time to quantify the accumulation of free TPT released into the extravesicular
solution.
TPT release was monitored by Dr. Jyoti using the increase of fluorescence intensity at an
excitation wavelength of 410 nm for PBS and plasma ultrafiltrate while intensities at 420
nm were used for human plasma studies. TPT standard calibration curves were constructed
using Equation 14 to adjust for fluctuations in lamp intensity at each sample time, 𝐼0 (𝑡), and
TPT dimerization in solution:137, 138
𝐼 (𝑡) = (𝑖1 𝑇1 + 𝑖2 𝑇2 )𝐼0 (𝑡)

(14)

where T1 and T2 are the solution concentrations of TPT monomer and dimer, respectively,
and i1 and i2 are the corresponding response factors for these species. Using a mass balance
equation for total TPT in solution (𝑇𝑜 = 𝑇1 + 2𝑇2 ), the TPT dimerization constant ( 𝐾2 =
𝑇2 /𝑇1 2 ), and Equation 11, fitted values for 𝑖1 , 𝑖2 , 𝐼0 (𝑡), and 𝐾2 were obtained from these
calibration curves and used to calculate the concentration of extravesicular TPT at each
time point.

5.2.6 TPT release by HPLC
TPT release was monitored by HPLC in suspensions prepared by diluting 0.2 mL of the
suspension collected after Sephadex to 4 mL with pH 7.4 PBS containing either no added
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ammonia or 60 µM NH4Cl. The resulting TPT and lipid suspension concentrations were 240
nM and 6.4 µg/mL, respectively. Aliquots (150 µL) withdrawn at various times were
diluted with chilled methanol (-20 °C) to disrupt the liposomes and quench the
lactone/carboxylate interconversion of TPT. Samples were immediately analyzed by HPLC
to quantify both the lactone and carboxylate forms of TPT. A previously published HPLC
method was employed with slight modifications.125

Briefly, a Waters Alliance 2695

separation system with a Waters Symmetry® C18 column (3.9×150 mm, 5 µm) and guard
column (3.9 x 20 mm) was used to separate lactone and carboxylate TPT using a mobile
phase of 11.5% acetonitrile: 88.5% (v/v) of a 5% (pH = 5.5) triethylamine acetate, 50 mM
tetrabutylammonium hydrogen sulfate (TBAHS) buffer at a flow rate of 1 mL/min. TPT
lactone and carboxylate standards (20-200 nM) were prepared in chilled, acidified
methanol (-20 °C) and 10 mM sodium carbonate buffer (pH 10.1), respectively. Lactone and
carboxylate retention times were 6.1 and 2.7 min, respectively.

A Waters M474

fluorescence detector (operating at excitation and emission wavelengths of 380 and 560
nm, respectively) was used to analyze the fractions of lactone and carboxylate TPT after
separation.

5.2.7 TPT degradation kinetics in the presence/absence of ammonia
Significant TPT degradation would affect the observed concentration of extravesicular
TPT and must be incorporated into models describing liposomal TPT release. TPT (0.5 - 5
µM) degradation was assessed in pH 7.4 PBS with or without 60 µM NH4Cl at 37°C.
Degradation of TPT was measured by Dr. Jyoti in the presence of ammonia due to its
presence in release studies and previous reports indicating that increasing concentrations
of ammonia promote TPT degradation via formation of 9-amino methyl degradants.91
Aliquots (25 - 40µL) of TPT solutions taken over a 5 day period were diluted to a final
volume of 1 mL with acidified methanol (0.001 N HCl) to convert all TPT to its lactone form
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and analyzed by the HPLC method used to monitor release. TPT concentrations versus time
(t) were fit to a first-order kinetic model as shown below in Equation 12 where 𝑘𝑑 is the
first-order degradation rate constant and X is the fraction of initial TPT remaining in
solution.
𝑋 = 𝑒 −𝑘𝑑 𝑡

(12)

5.2.8 Ammonia analyses
Potentiometric measurements of ammonia content in plasma were performed before
and after release studies by Dr. Jyoti using an Orion ammonia electrode in conjunction with
a Thermo Scientific Orion Star A214 pH, ISE, mV, temperature meter. Ammonia standards
were prepared between 0.01-0.3 ppm in Milli-Q H2O.

Immediately before ammonia

analysis, 100 μL of NaOH reagent was added to 10 mL of standards to raise pH and convert
any ammonium to ammonia. Solutions were allowed to equilibrate for 3-5 minutes under
mild stirring and the final voltage was recorded. A Nernst relationship between ammonia
concentrations and electric potential (mV) was observed and used to make a standard curve
for the estimation of total ammonia in solution. Plasma samples (100µL) were analyzed
after ultrafiltration and subjugation to the same dilution and addition of NaOH as standards
to obtain ammonia concentrations within the sample.

5.2.9 General mathematical model for actively-loaded liposomal TPT release
under non-sink conditions
Because of the low intravesicular pH established during the active loading process,
encapsulated TPT exists solely in its lactone form.62,

97, 165

Under physiological pH, TPT

undergoes pH-dependent conversion to its carboxylate counterpart as it is released
(Scheme 5.1A).62,

165

TPT’s ionization state also changes upon release as the unionized

phenol dominates at low intravesicular pH (pKa = 6.56) while the phenolate anion is the
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major species at physiological pH (Scheme 5.1B).92,

125, 138

By applying the appropriate

mathematical model, it is possible to extract the critical release parameters from either the
time-dependent profiles of TPT lactone and carboxylate generated by HPLC or changes in
fluorescence excitation spectra.

Scheme 5.1.

Physicochemical properties of TPT considered in modeling

liposomal release kinetics.

TPT undergoes pH-dependent interconversion

between its lactone and ring-opened carboxylate forms which can be monitored
by HPLC (A). Ionization of the A-ring phenol causes a shift in the fluorescence
excitation spectrum of TPT which occurs only when drug is exposed to a
physiological pH upon liposomal release (B).
A simple kinetic model describing drug release proceeding to equilibrium under nonsink conditions was used to quantify the release profiles obtained by both HPLC and
fluorescence methods. Because previous studies have shown the lactone form of TPT to be
the most permeable, this model assumes the intra- and extravesicular lactone species (Li
𝑑𝑇

and Lo, respectively) govern the rates of change of total intra- and extra-vesicular TPT ( 𝑑𝑡𝑖
and

𝑑𝑇𝑜
𝑑𝑡

, respectively).
104

𝑑𝑇𝑖

= −𝑘𝑚 𝐿𝑖 + 𝑘𝑚 𝐾𝐿𝑜

(1a)

= 𝑘𝑚 𝐿𝑖 − 𝑘𝑚 𝐾𝐿𝑜 − 𝑘𝑑 𝑇𝑜

(1b)

𝑑𝑡

𝑑𝑇𝑜
𝑑𝑡

where 𝑘𝑚 is the rate constant for bidirectional TPT transport, K is the ratio Li /Lo at
equilibrium, and kd is the first-order degradation constant for TPT released into the
extravesicular solution.
Once released, lactone TPT undergoes reversible, pH-dependent lactone hydrolysis to
form its ring-opened, carboxylate counterpart. This process may be assumed to be fast
relative to release and thus in equilibrium. Assuming this pH-dependent equilibrium, an
apparent acid dissociation constant (𝐾𝐴 ′) may be used to solve for the fraction of
𝐻+

extravesicular TPT in the lactone form (𝑓𝐿 = 𝐻 + +𝐾 ′). This expression allows 𝐿𝑜 to be
𝐴

written in terms of 𝑇𝑜 , and 𝐿𝑖 ≅ 𝑇𝑖 due to the low intravesicular pH resulting from active
loading. Using this information, the rate equations can be rewritten as shown below.
𝑑𝑇𝑖
𝑑𝑡

𝑑𝑇𝑜
𝑑𝑡

= −𝑘𝑚 (𝑇𝑖 − 𝑓𝐿 𝐾𝑇𝑜 )

= 𝑘𝑚 (𝑇𝑖 − 𝑓𝐿 𝐾𝑇𝑜 ) − 𝑘𝑑 𝑇𝑜

(2a)

(2b)

𝑇𝑜 was directly monitored by fluorescence while the fractions of total drug remaining in the
suspension in the lactone and carboxylate forms were monitored by HPLC. Ti and To could
be obtained from the total lactone and carboxylate fractions (𝐿(𝑡) and 𝐶(𝑡), respectively)
and the total suspension concentration of TPT measured at each time point, 𝑇(𝑡):
𝐿 𝑇𝑜
𝐿(𝑡) = 𝑇𝑖 +𝑓
𝑇(𝑡)

(3a)

𝐿)𝑇𝑜
𝐶(𝑡) = (1−𝑓
𝑇(𝑡)

(3b)
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Initial conditions were required to accurately solve and fit the above differential
equations to release data. In fluorescence studies, extravesicular drug present at the
beginning of the release study (𝑇𝑜0 ) was directly analyzed by fluorescence; however, the
initial intravesicular drug could not be determined directly from fluorescence. The initial
concentration of intravesicular drug was determined after subtracting 𝑇𝑜0 from the total
initial suspension concentration (𝑇 0 ) obtained by HPLC analysis. These initial conditions
are expressed by the equations below.
𝑇𝑜 (0) = 𝑇𝑜0

(4a)

𝑇𝑖 (0) = 𝑇 0 − 𝑇𝑜0

(4b)

HPLC studies had similar initial conditions. Assuming that any carboxylate in the
suspensions was attributable to extravesicular drug, the initial fraction of carboxylate
present in the release suspension (𝐶0 ) could be related to 𝑇𝑜0 and subsequently be used in
conjunction with the initial fraction of lactone (𝐿0 ) to solve for the initial intra- and extravesicular conditions as shown below.
𝐶

𝑇𝑜 (0) = 𝑇𝑜0 = (1−𝑓0

𝐿)

𝑇𝑖 (0) = 𝐿0 −

𝐶0
(1−𝑓𝐿 )
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(5a)

(5b)

5.3 Results
5.3.1 Differences in fluorescence spectra and quantitation of extravesicular
TPT
Increases in pH result in a red shift in TPT excitation spectra in aqueous solution. 125, 138
Such a shift suggests TPT release from actively-loaded liposomes into a pH 7.4 buffer or
plasma could be distinguished from entrapped drug. This hypothesis was confirmed by
comparing the fluorescence excitation spectra obtained for various aqueous solutions and
liposomal suspensions of TPT. In Figure 5.1, the excitation spectra of TPT under acidic
conditions (either in solution or encapsulated) were nearly identical to the excitation
spectrum obtained for ALLT suspended in pH 7.4 PBS with maximum excitation occurring
at 380 nm. These results are indicative of a low intravesicular pH environment remaining
after the active loading process.21,

42, 62, 64, 73, 95

The red shift observed for free or

extravesicular TPT in PBS at pH 7.4 resulting in maximum excitation at 410 nm is not
altered in the presence of blank liposomes (Figure 5.1). Determination of extravesicular
TPT is possible without significant interference from encapsulated drug because TPT under
these more acidic conditions is not excitable at this higher wavelength.
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Figure 5.1. Illustration of differences in normalized excitation spectra between
free and entrapped TPT at 37 °C. Excitation spectra of free TPT at pH 3.75,
passively-loaded liposomal TPT (PLLT) at the same pH, and actively-loaded
liposomal TPT (ALLT) suspensions in pH 7.4 buffer have identical spectra,
indicating an acidic intraliposomal pH within ALLT.. At pH 7.4, spectra of free
TPT solutions and suspensions of blank liposomes spiked with free TPT (i.e.,
spiked TPT pH 7.4) exhibit a red shift in the excitation spectrum (denoted by the
arrow). The identical spectra of spiked and free TPT indicates that drug binding
to the outer bilayer leaflet or particle scattering have no effect on the spectra of
extravesicular TPT.

All the spectra displayed contained total TPT

concentrations of ~ 2.5 µM. The lipid concentration in liposome suspensions
was ~ 37 µg lipid/mL.
Calibration curves for quantifying extravesicular TPT were constructed from excitation
spectra at varying concentrations (0.2-5 µM) of TPT in pH 7.4 PBS, human plasma, and
plasma ultrafiltrate.

Fluorescence intensity versus TPT concentration was nearly linear
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with slight quenching of fluorescence at higher concentrations (~ 5 µM). This quenching
was due to TPT dimerization and accounted for in the calibration curve (see Methods). 138
Quantitation of intravesicular TPT was not possible due to self-association and collisional
quenching effects at the high intravesicular TPT concentrations (~ 15 mM) present as a
consequence of the active loading process.

5.3.2 TPT degradation in the presence and absence of ammonia
TPT degradation was monitored by HPLC at pH 7.4 and 37 C in PBS and PBS containing
60 M NH4Cl (data not shown). The degradation was first-order and independent of the
presence of ammonia. The rate constant for degradation was determined to be 1.15 ± 0.08 x
10-2 hr-1 (95% CI). This value was incorporated into the models used to fit release data.

5.3.3 Comparison of fluorescence and HPLC methods to monitor release
Release studies were conducted in PBS with or without added ammonia and analyzed
by HPLC and fluorescence methods to validate the use of fluorescence for determining
release. Degradation of topotecan at pH 7.4 limited the time frame for release studies by
fluorescence to ~ 24 h.

However, because longer times were necessary to establish

equilibrium, both HPLC and fluorescence release data in PBS with and without ammonia
were fit simultaneously to determine values for K (Ti /𝑓𝐿 To at equilibrium). The resulting
fits indicated that K decreases with the addition of extravesicular ammonia to the release
media.
While K was assumed to be independent of the method of analysis, separate km values
were determined for each method and condition. The values obtained are shown in Table
5.1, and the resulting fits of the data from both methods are illustrated in Figure 5.2. Half𝑒𝑞

𝑒𝑞

lives to equilibrium, 𝑡1/2 , were also calculated for easier comparison. This 𝑡1/2 is defined by
the equation below.
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𝑒𝑞
𝑡1/2
=𝑘

ln (2)

(6)

𝑚 (1+𝐾𝑓𝐿 )

Both methods show similar trends in km, with faster release in PBS containing 60 µM
NH4Cl than that in PBS alone. In PBS containing 60 µM NH4Cl, the 95% confidence limits of
the km values determined from both methods overlapped. However, in PBS without
ammonia km values differed significantly depending on the monitoring method, with TPT
release monitored by fluorescence being faster than that obtained by HPLC. This was
attributed to the lower concentration of liposomes in the experiments monitored by HPLC
which resulted in more ammonia release. Reduction in the intravesicular concentration of
ammonia lowered the intravesicular pH, thus slowing TPT release.125 A detailed analysis of
the differences in ammonia release and subsequent effects on intravesicular pH is provided
in a later section.
Table 5.1. Release parameters obtained from HPLC and fluorescence methods.b

Constant
𝑘𝑚 (hr -1)
𝐾
𝑒𝑞
𝑡1/2 (hr)

PBS only
HPLC
Fluorescence
0.037 ± 0.004 0.053 ± 0.008
4.1 ± 0.6
10 ± 1
6.9 ± 0.9

PBS w/ 60 µM NH4Cl
HPLC
Fluorescence
0.15 ± 0.02
0.18 ± 0.04
0.5 ± 0.2
4.6 ± 0.6
3.8 ± 0.8

𝑘𝑑 (hr -1)
0.0115
0.0115
b ± 95 % confidence intervals

0.0115
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0.0115

Plasma &
Ultrafiltrate
1.5 ± 0.4
0
0.54 ± 0.2
0.1
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Figure 5.2. Comparison of release profiles obtained by HPLC and fluorescence
methods. A) Changes in the fraction of TPT carboxylate versus time obtained by
HPLC in release studies at 37 °C in pH 7.4 PBS with 60 µM NH4Cl and without
ammonia (

and

, respectively) are shown along with fits of the carboxylate

fraction to the release model (

and

). The open symbols in the inset

reflect the change in the fraction of lactone over the same time frame with
and

reflecting their respective fits to the release model. B) The fraction of

TPT in the extravesicular compartment relative to the initial total suspension
concentration of TPT (To/T0) versus time determined by the fluorescence
method in pH 7.4 PBS in the presence or absence of ammonia (

and

,

respectively). Solid lines (

and

) represent fits to the release model . The

short-dashed

and

) reflect simulated profiles using the

lines (

parameters obtained from release data monitored by HPLC for comparison.
Release rates were accelerated to the same degree in plasma ( ) and plasma
ultrafiltrates ( ).

The long-dashed line (

) is representative of the

simultaneous fits of all six data sets (i.e. plasma and plasma ultrafiltrate from
three separate donors) from which the parameters listed in Table 5.1 were
obtained.

5.3.4 Release experiments in human plasma and plasma ultrafiltrate
Red shifts in excitation spectra were also observed during release studies in plasma.
These shifts were again used to monitor TPT release. This is illustrated in Figure 5.3. Rate
constants for release in plasma were ~30-fold greater than in PBS (Figure 5.2b and Table
5.1) alone. To assess possible contributions of colloidal lipoprotein particles that might
participate in lipid exchange with the lipid bilayer or protein effects such as opsonization, 93,
156, 166-168

plasma samples were ultrafiltered and the ultrafiltrates were then used in release

experiments. TPT release in plasma ultrafiltrates was indistinguishable from the plasma
release profiles (see Figure 5.2b) and the release rate constants in both plasma and plasma
ultrafiltrates were ~10-fold greater than in PBS containing 60 M NH4Cl.

These

observations provided motivation to measure ammonia concentrations in plasma to
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determine whether the accelerated release rates seen in plasma and plasma ultrafiltrates
were related to higher ammonia concentrations in these samples. The ammonia
concentrations, analyzed using an ammonia selective electrode, were 180, 185, and 355 µM
for these three plasma samples (each from a different donor) and their respective
ultrafiltrates. These levels were much higher than those reported in normal human blood
(15-60 µM).

163, 164

These higher levels were likely due to protein degradation during

storage, even under the -20 °C temperatures employed.169

Figure 5.3. Fluorescence excitation spectra of ALLT in plasma over time. The
change in fluorescence at 420 nm was used to monitor extravesicular TPT and
subsequently liposomal release kinetics.
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5.4 Discussion
5.4.1 Differences in liposome concentration led to changes in intravesicular
ammonia, pH, and subsequent release kinetics
While attempts were made to keep the release media consistent between experiments
analyzed by HPLC and fluorescence, the liposome suspension concentrations differed
between the two methods. This was necessary for maintaining TPT concentrations in an
optimal range for quantification by each method. Simulations indicated that this seemingly
minor difference could be important.
A preliminary estimate of the intravesicular pH under the different conditions in these
experiments was obtained by simulating the effects of ammonia transport across the
bilayer. The first-order rate constant for ammonia bilayer transport, 𝑘𝑚,𝑛 , is related to the
𝑚
permeability coefficient for ammonia transport, 𝑃𝑁𝐻
, and liposome diameter d:50
3

k m,n 

m
6 PNH
3

d

(7)

The differential equations that govern ammonia transport are then:
𝑑𝑁𝑖
𝑑𝑡

𝑑𝑁𝑜
𝑑𝑡

= −𝑘𝑚,𝑛 (𝑁𝐻3,𝑖 − 𝑁𝐻3,𝑜 )

(8a)

= 𝑓𝑣 𝑘𝑚,𝑛 (𝑁𝐻3,𝑖 − 𝑁𝐻3,𝑜 )

(8b)

Because the free base form of ammonia is the permeable species, 170 the rates of change in
the total concentration of ammonia in the intra- and extra-vesicular compartments (Ni and
No respectively) are dependent on the concentration gradient between neutral ammonia in
the intra- and extra-vesicular compartments (NH3,i and NH3,o respectively), the rate constant
for neutral ammonia transport (𝑘𝑚,𝑛 ), and the ratio of liposomally-entrapped to
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unentrapped volume (fv). The latter quantity, fv, can be calculated from the particle size and
lipid content in the liposome suspension with knowledge of the lipid surface density. 50
NH3,I and NH3,o may be written in terms of Ni and No by solving for the fractions of neutral
ammonia in the intra- and extra-vesicular phases (𝑓𝑖𝑁 and 𝑓𝑜𝑁 ):
𝑓𝑖𝑁 =

𝑓𝑜𝑁 =

𝐾𝐴𝑁

(9a)

𝐾𝐴𝑁

(9b)

𝐻𝑖++𝐾𝐴𝑁

𝐻𝑜++𝐾𝐴𝑁

These fractions are dependent on the acid dissociation constant for ammonia, 𝐾𝐴𝑁 , and
the acidity or hydrogen ion concentrations in the intra-or extra-vesicular compartments
(𝐻𝑖+ and 𝐻𝑜+ , respectively). Using these fractions, equations 8a and b can be rewritten to
yield:
𝑑𝑁𝑖
𝑑𝑡

𝑑𝑁𝑜
𝑑𝑡

= −𝑘𝑚,𝑛 (𝑓𝑖𝑁 𝑁𝑖 − 𝑓𝑜𝑁 𝑁𝑜 )

(10a)

= 𝑓𝑣 𝑘𝑚,𝑛 (𝑓𝑖𝑁 𝑁𝑖 − 𝑓𝑜𝑁 𝑁𝑜 )

(10b)

The pH in the intravesicular compartment decreases as ammonia release causes
deprotonation of ammonium to replenish the released ammonia. This process governs the
acidity of the intravesicular compartment by satisfying the charge balance equation:
+
𝐻𝑖+ = 𝐵− + 𝑂𝐻𝑖− − (𝑁𝐻4,𝑖
+ 𝑇𝑃𝑇𝐻𝑖+ )

(11)

where B- is the ammonium salt counterion (besylate) concentration and 𝑇𝑃𝑇𝐻𝑖+ is the
+
concentration of the cationic form of topotecan. The ammonium (𝑁𝐻4,𝑖
) and 𝑇𝑃𝑇𝐻𝑖+

concentrations can be expressed in terms of total intravesicular concentration of ammonia
(Ni) and topotecan (Ti) while 𝑂𝐻𝑖− can be rewritten in terms of 𝐻𝑖+ and the ion product of
water, Kw.
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𝐻𝑖+ = 𝐵− +

𝐾𝑤
⁄𝐻 + − [(1 − 𝑓𝑖𝑁 )𝑁𝑖 + 𝑓𝑖𝑇 𝑇𝑖 ]
𝑖

(12)

At low pH, the fraction of intravesicular TPT in its protonated form, 𝑓𝑖𝑇 , is a function of 𝐻𝑖+
and the TPT phenol acid dissociation constant, KA1:
𝑓𝑖𝑇 =

𝐻𝑖+
+
𝐻𝑖 +𝐾𝐴1

(13)

Simulations were performed using these equations and the values in Table 5.2 to
calculate 𝐻𝑖+ concentration versus time when the extravesicular solution initially contained
either no ammonia (Figure 5.4A) or 60 µM of NH4Cl (Figure 5.4B) using the lipid
concentrations measured in this study. From these simulations, it is apparent that the
entrapped volume can have a significant impact on intravesicular pH depending on the
concentration of extravesicular ammonia present. In solutions that initially contained no
buffer, the higher lipid concentration (i.e. large entrapped volume) allows more ammonia
release while the intravesicular ammonia is depleted to a lesser extent. Because of the
resulting higher intravesicular ammonia concentration, the increase in 𝐻𝑖+ is less for the
liposome suspensions used in the fluorescence method. TPT release is pH-dependent and
slower as 𝐻𝑖+ increases.125 The higher rate of TPT release determined by the fluorescence
method compared to that observed by HPLC is consistent with this difference in 𝐻𝑖+ .
This effect, however, is not apparent in the release studies conducted in PBS solutions
which initially had ammonia present. At 60 µM NH4Cl, the extravesicular concentration of
ammonia is sufficiently high and the volume entrapped low enough that the extravesicular
concentration essentially remained constant. This normalized the ammonia concentration
gradient to be the same and independent of the entrapped volume (Figure 5.5b). This
results in nearly identical 𝐻𝑖+ profiles for both methods and subsequently the same release
kinetics for both methods.
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For these simulations, the initial 𝐻𝑖+ was calculated assuming a 1:1 exchange between
ammonia and TPT during the active loading process (i.e. 𝑁𝑜 (0) = 0.3 − 𝑇𝑖 ). While this can
only be a rough estimation of the initial 𝐻𝑖+ , simulations at a higher or lower initial 𝐻𝑖+ (102.5 and 10-5.5 or pH of 2.5 and 5.5, respectively) also resulted in similar trends in the
terminal 𝐻𝑖+ simulated in Figure 5.4.
Table 5.2. Parameters used to simulate 𝐻𝑖+ profiles at different lipid concentrations
Parameters
Values
km,n
2.88 × 104 𝑠 −1 c
KA1
2.8 × 10−7 d
KAN
9.40 × 10−10 e
Kw
2.12 × 10−14 e
Ho
3.98 × 10−8 𝑀
Ti
1.45 × 10−2 𝑀
Bi
0.3 𝑀
fv – HPLC conditions
1.66 × 10−5 f
(6.4 µg lipid/mL)
fv – Fluorescence conditions
5.19 × 10−5 f
(19.2 µg lipid/mL)
c Calculated from a previously reported ammonia permeability coefficient of
𝑚
𝑃𝑁𝐻
= 48 × 10−3 𝑐𝑚⁄𝑠 171
3
d Obtained from a previous study125
e Values adjusted to reflect conditions at 37 °C and 0.3 I
f
Calculated based on particle size, lipid content, and lipid surface density
calculations previously reported50, 135
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Figure 5.4. The simulated profiles of [𝐻𝑖+ ] and [𝑁𝑜 ] versus time in pH 7.4 PBS
release media that initially contained no extravesicular ammonia (A) or 60 µM
NH4Cl (B). [𝐻𝑖+ ] simulations shown are at the lipid concentrations at which
release studies by HPLC (

) and fluorescence methods (

) were conducted.

The dotted lines of corresponding color reflect the total extravesicular ammonia
present over this time period for HPLC and fluorescence methods, respectively.

5.4.2

Effects of ammonia concentration in physiological samples and

implications on liposomal TPT release
Initial simulations of intravesicular pH showed that the presence of extravesicular
ammonia in the release media partially dissipated the pH gradient. Such an effect may also
be possible in the release studies in plasma and plasma ultrafiltrates as relatively high levels
of ammonia were detected in these samples. This was explored further in simulations of the
intravesicular pH after accounting for the extravesicular ammonia present in the various
release media studied (buffer, plasma, or plasma ultrafiltrate). These simulations, shown in
Figure 5.5, indicate a negative correlation between the release half-life and the
intravesicular pH.

This relationship provides further evidence that the presence of

extravesicular ammonia raises intravesicular pH, given the pH-sensitive release of
liposomal TPT previously reported.125
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Figure 5.5.

The relationship between TPT release half-life and simulated

intravesicular pH. Release studies performed in PBS ( ), plasma ( ), and
ultrafiltrate obtained from plasma (

) are shown. In some instances, the

plasma ultrafiltrate data are difficult to observe due to overlap with data points
from plasma studies. The resulting trend line along with its R 2 are shown to
illustrate the negative correlation between TPT retention and intravesicular pH.
While further studies are necessary to fully understand the effect of ammonia transport
on

actively-loaded

liposomal

precipitation/complexation

systems

(e.g.

in

formulations

with

drug

within the intravesicular environment), the potential

implications are considerable.

Many liposomal drug loading strategies rely on the

generation of a pH gradient using ammonia,62,

73

an ionophore,64,

permeable amine (e.g. di- or tri-methylamine).21,

42

96, 97

or another highly

In all of these strategies, the pH

gradients generated to stabilize drug encapsulation are susceptible to the influx of ammonia
or other highly permeable basic species present in physiological tissue or fluid. The
intravesicular pH in these formulations should be calculable using an equation based on a
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charge balance similar to Equation 11 with appropriate modifications to account for
precipitation, self-association, etc. Under in vivo conditions, the much larger volume of
physiological fluids, in comparison with the entrapped volume of administered liposomes,
would also provide constant extravesicular ammonia levels, similar in manner to the
conditions studied within this chapter.
While it is likely that ammonia is the primary basic-permeable species present in
physiological fluids and tissues, other low molecular weight amines (e.g. di- and trimethylamine) are also present at levels which vary from patient to patient. 172-174 Other
effects have been suggested to account for variability of liposomal release kinetics in plasma
such as destabilization of the bilayer due to protein interactions. 32, 55, 57, 166, 167, 175 However,
these theories could not explain the effects seen here as release kinetics obtained in plasma
would have been significantly different from release kinetics obtained in studies performed
in an ultrafiltrate of the same plasma (which was not the case).
Lastly, the storage conditions and history of the plasma may also have a considerable
effect on release rates from actively loaded liposomes. Previous reports on the production
of ammonia under a wide variety of conditions typically encountered during the processing
and storage of plasma are considerable. 169,

173

Furthermore, these studies indicate that

ammonia production is significant at room temperature and even when samples have been
frozen. This may account for the higher ammonia levels in these plasma studies than those
reported in the literature for fresh plasma and blood samples.163, 164 Such an issue could
lead to overestimations of drug release in vivo. Characterization of the ammonia content
and possibly other protein degradants in release studies performed in plasma should be
considered. Furthermore, ammonia generation during release studies may also affect
release kinetics. In the present study, ammonia levels in plasma after a 48 hour release
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experiment were considerably higher (approximately two-fold) than the initial ammonia
levels. This is yet another scenario that could lead to possible overestimation of drug
release based on characterization studies in plasma, as renal excretion of ammonia would
typically prevent such high levels in patients. In contrast, however, patients suffering from
hyperammonemia could present much higher ammonia concentrations (~1 mM).176,
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This condition may be quite relevant in cancer patients with diminished liver function,178
either as a result of the cancer’s pathophysiology, a side effect of a previous treatment,178-181
or a preexisting condition (e.g. cirrhosis).178 In such cases, further acceleration in liposomal
drug release may be seen.

5.4.3 Adaptation of method for other nanoparticles and drugs
In the field of nanotechnology-based drug delivery systems, analytical methods to
quantify in vivo drug release from nanoparticles are needed to develop in vitro-in vivo
release rate correlations and to ultimately relate anti-tumor efficacy to drug exposure.
Described herein is a fluorescence technique to non-invasively distinguish free TPT from
liposomally entrapped drug in tissue (human plasma). The release profiles generated were
analyzed using mathematical models to probe the effects of critical experimental variables
affecting release rates. The combination of a non-invasive method to analyze liposomal
drug release and mechanism-based mathematical modeling to interpret release profiles
represents a powerful new approach for understanding actively-loaded liposomal drug
release that may ultimately contribute to improved liposomal drug therapy.
For these studies, fluorescence spectroscopy is used; however, the general validation
scheme could be applied to other spectroscopic techniques depending on the spectrometric
properties of the particular drug and/or nanoparticle. While qualitative comparisons of
spectrometric data are initially made to distinguish free from entrapped drug, quantitative
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analysis and validation of release kinetics requires a mathematical model describing release
kinetics.

5.5 Conclusion
Reliable methods to monitor drug release in physiological fluids and tissues could improve
predictions of in vivo performance of liposomal drug delivery systems. To this end, a noninvasive method was developed to monitor liposomal release kinetics of TPT. This method
utilizes the pH-dependent shift in the excitation spectra of TPT to distinguish between drug
entrapped at the low intravesicular pH in actively-loaded liposomal formulations from
released drug. Release kinetics obtained by fluorescence were consistent with results using
an HPLC method to monitor release.
Accelerated liposomal TPT release kinetics were observed in human plasma. Additional
experiments in plasma that was ultrafiltered to remove protein and lipid components that
have previously been theorized to alter release kinetics indicated similar accelerated
release rates. When release studies were performed in PBS buffer at pH 7.4, the addition of
ammonia to the buffer was also found to dramatically increase release rates. Analyses of
ammonia concentrations in the plasma samples employed in release studies were therefore
undertaken. Model-based simulations were used to estimate the intravesicular pH in the
presence or absence of extravesicular ammonia. The intravesicular pH increased with
increasing concentrations of extravesicular ammonia. A significant correlation was found
between TPT release rates and intravesicular pH simulated based on the extravesicular
ammonia present in the plasma, plasma ultrafiltrates, or PBS buffer in which release studies
were conducted.

These findings may account for the accelerated release rates typically

experienced in physiological fluids and potentially some of the preclinical variability
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observed from ALLTs23 and likely present for other actively-loaded, weakly basic drugs (e.g.
doxorubicin, irinotecan, and vincristine).21, 73, 95, 96, 112, 182
Because extensive processing of sample is not required to analyze drug release, the noninvasive fluorescence method developed in this work has potential applications for
analyzing release kinetics in real-time for physiological samples. One such application may
include analysis of free and entrapped drug in blood samples taken for PK studies. This
would allow for both particle clearance and liposomal release kinetics of drug in systemic
circulation to be analyzed simultaneously. Currently, adaptation of this method is under
investigation using two-photon fluorescence for intratumoral imaging of release kinetics in
mouse xenografts equipped with a dorsal window. This method may also be adaptable to
other molecules that exhibit pH dependent fluorescence spectra.

Copyright © Kyle Daniel Fugit
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CHAPTER SIX
Mechanistic Evaluation of Self-association, Ion-pairing, Ammonia, and
Precipitation Effects on Active Loading and Release of Liposomal
Topotecan
6.1 Introduction
Nanoparticle formulations of anticancer agents are studied intensively for drug delivery
applications due to their unique ability to passively or actively target their payloads of
anticancer agents to the tumor site. Such targeting has the potential to lower systemic
toxicity while increasing intratumoral concentrations of the pharmaceutical agent of
interest.6,

7, 42

Liposomes constitute a class of nanoparticles that has shown additional

benefits in chemotherapy delivery due to their slow systemic clearance allowing greater
accumulation of the particles (and consequently, the drug) at the tumor site.30, 111, 183, 184
Many of the well-studied liposomal formulations incorporate a weakly basic anticancer
agent due to their ability to achieve high drug-to-lipid ratios21, 42, 62, 73, 94, 95 . This result is
beneficial for a variety of reasons including: increased API solubility, smaller infusion
volume for patients, higher encapsulation efficiency (i.e. high drug loading) resulting in less
waste of valuable API, and altered exposure profiles of said API due to liposomal release
kinetics.

While high loading efficiency is desirable, understanding its effect on in vivo

performance (i.e. release kinetics) has yet to be adequately characterized.
Mechanistic modeling constitutes a means to provide such understanding by
distinguishing physicochemical release characteristics intrinsic to the drug/particles
system from artifacts of the release environment (i.e. kinetic or thermodynamic effects
attributable to the particular medium that release is studied within).49, 60, 63, 124, 126, 130 With
mechanistic models, optimization of drug release profiles may be achieved by rationally
selecting the proper drug loading conditions (e.g. drug suspension concentration, pH,
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temperature, counter-ions in solution, etc.). A model capable of providing predictable
release rates under a variety of in vitro conditions could be adapted to incorporate
physiological variables which affect release in vivo.

Such modeling would allow a

formulator to reasonably predict in vivo formulation performance from in vitro release
studies and reduce the need for costly preclinical testing.
One of the anticancer agents extensively researched as an actively-loaded liposomal
formulation is the anticancer agent topotecan (TPT). TPT is a camptothecin analogue
known for its topoisomerase-I inhibitory activity185 and has demonstrated increased antitumorigenic efficacy as a liposomal formulation.62, 158, 159 Many liposomal TPT formulations
utilize active loading of the anticancer agent via the establishment of a pH gradient.
Generating an acidic intravesicular environment relative to the extravesicular loading
solution preserves the active lactone form of the drug while achieving high drug loading
efficiencies.

Furthermore, this active loading strategy has been shown to result in

prolonged retention in release studies conducted in aqueous solution. 62,

64

Unfortunately,

these same formulations have shown accelerated release in plasma.62 Understanding what
underlying

mechanisms

lead

to

these

differences,

whether

physiological

or

physicochemical, requires rigorous studies of the active loading process of liposomal TPT.
Understanding the kinetic and thermodynamic factors that drive loading will not only allow
for optimization of the active loading process, but also help decipher the subsequent release
of TPT from these formulations.
This study develops and evaluates several models to describe active loading of TPT
based on physicochemical properties of the drug and the liposomal environment. All of
these models accounted for the generation of low intravesicular pH in addition to other
factors, including TPT self-association and/or ion-pairing transport across the bilayer. The
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validity of these models was assessed by fitting experimentally observed uptake profiles of
TPT undergoing active loading into liposomes containing ammonium besylate
[NH4C6H6SO3] or sulfate [(NH4)2SO4].

A loading model which incorporated ion-paired

transport of cationic TPT with chloride and TPT dimerization was found to describe drug
loading best. Further validation of this model was performed by assessing the model’s
ability to predict TPT release under varying chloride conditions. Lastly, the influence of
chloride on TPT loading at higher temperature was also demonstrated experimentally,
showing much higher encapsulation efficiencies and slower release than formulations
loaded at lower temperatures. These effects were rationalized by the development of a
mechanistic release model which suggests the prolonged release from these hightemperature-loaded liposomes was due to the precipitation of intravesicular TPTHCl. These
findings suggest that tunable drug release of liposomal TPT could be achieved through
manipulation of chloride during active loading. This work also provides a general approach
for mechanistically characterizing active loading and release kinetics of liposomal
formulations.

6.2 Materials and methods
6.2.1 Materials
Powders of 1,2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC, >99% purity) and
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000]
(m-PEG DSPE, MW = 2806, >99% purity) were purchased from Avanti Polar Lipids
(Alabaster, AL). Topotecan hydrochloride was purchased from AK Scientific (Union City,
CA). Benzene sulfonic acid sodium salt (sodium besylate) was purchased from Spectrum
Chemicals. Millipore ultrafiltration cartridges (Amicon® Ultra 0.5 mL centrifugal filter
device with 30,000 MWCO Ultracel® membrane), Nuclepore polycarbonate membranes
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(0.1 µm), Dowex 50Wx8-200 resin in the H+ form, solvents, and buffer salts were purchased
from Fisher Scientific (Florence, KY). All solvents were HPLC grade.

6.2.2 Liposome preparation and characterization
Large unilamellar liposomes were prepared based on previously reported methods. 49, 50,
60, 118, 124, 130

Briefly, powders of DSPC and DSPE-PEG2K were dissolved in chloroform at a

ratio of 95:5 mol:mol, then dried under nitrogen, then under vacuum (- 30 in Hg) at 35 °C
for 6 hours. After drying, the films were hydrated with ammonium besylate solutions (0.3
M), 0.3 M (NH4)2SO4, or a solution of 50 uM TPT in pH 4.1 50 mM sodium formate (adjusted
to an ionic strength of 0.3 with NaCl) to make 30 mg/mL lipid suspensions.

These

suspensions were vortexed at 60 °C, then extruded through 2, 100 nm polycarbonate
membranes 10 times at 40 psig and 60 °C to yield ammonium besylate or sulfate-containing
liposomes (ABLs and ASLs respectively) for active loading and passively-loaded TPT
liposomes (PLLT), for separate release studies. Liposome particle size was determined with
dynamic light scattering (DLS) as reported previously,126, 130 yielding diameters (with 95%
CI of 6 independent readings) of 100 ± 4 and 103 ± 2 nm before active loading and release
studies, respectively.

Lipid content was also determined (see HPLC analyses) for

calculations of entrapped volume and TPT loading efficiency.
The ammonium besylate solutions used for ABL hydration were prepared by
passing solutions of sodium besylate (0.6 M) through an ion exchange column made of
Dowex 50Wx8-200 resin in the H+ form. The eluted solutions were subsequently titrated
with ammonium hydroxide (3.0 M) to the equivalence point and diluted to the desired
concentration as previously reported for several other amino-based salts.21, 42
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6.2.3 Active loading of TPT
Previous studies have shown that active loading of weakly basic drugs results in high
encapsulation efficiency and possibly longer drug retention in vitro and in vivo. Active
loading was performed by generating low intravesicular pH via an ammonia gradient. 62, 73
Establishing an ammonia (or another small-MW amine) gradient is typically accomplished
via removal of extravesicular ammonia upon elution of the suspension through a size
exclusion column.21, 42, 62, 73, 95 In this study, 0.4 mL of the ABL or ASL suspension was passed
through

a

Sephadex

G-25

column

equilibrated

with

100

mM

2-(N-

morpholino)ethanesulfonic acid (MES) pH 5.5 buffer containing 0.25 M NaCl to maintain an
isotonic state between the intra-and extra-vesicular solutions. The first 5 mL of eluted
suspension was collected for loading studies.
Next, 1.5 mL of the eluted suspension was added to an equal volume of TPT dissolved in
the same pH 5.5 buffer to achieve a total TPT suspension concentration of 60, 130, or 180
µM and lipid concentration of 0.92 mg lipid/mL. Loading either occurred over a 72 hour
period within a 37 °C incubator or over 30 min in a 60 °C oven as previously reported.62
Loading kinetics was monitored at 37 °C by isolating intravesicular TPT with a previously
validated ultrafiltration method.126,
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After ultrafiltration, the obtained suspensions of

intravesicular TPT were dissolved in chilled (-20 °C) acidified (0.001 N HCl) methanol to
convert all drug to its lactone form for monitoring of loading with HPLC (see HPLC
analyses). The levels of released ammonia were also monitored during loading studies.
This was achieved by ultrafiltering 0.4 mL of the liposome suspension and analyzing
ammonia levels in the ultrafiltrate with an ammonia selective ion probe (see ammonia
analyses section).
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6.2.4 Release of passively-loaded TPT
Passively-loaded liposomal release was used to assess transport of cationic TPT via ionpairing with chloride. This was examined by performing TPT release studies where the
cationic form of TPT was dominant (pH 4.1) and by examining three different chloride
conditions including: 1) an excessive amount of chloride present in both the intra- and
extravesicular compartments, 2) only chloride from the TPTHCl salt present in the
intravesicular compartment and no chloride present in the extravesicular compartment and
3) only Cl from the TPTHCl salt present in the intravesicular compartment with a large
concentration of chloride in the extravesicular compartment.

These conditions were

achieved using passively-loaded liposomes made in solutions of 50 µM TPTHCl in pH 4.1 50
mM sodium formate buffer with either 0.25 M NaCl or 0.167 M Na2SO4 to achieve isotonic
conditions. Release was monitored after removal of extravesicular TPT by passing 0.35 mL
of the liposomal suspensions through a Sephadex column. For liposomes made with 0.25 M
NaCl solutions, the same buffer was used in the Sephadex column. For liposomes made in
the presence of sulfate, the suspensions were passed through columns equilibrated with
either the same formate buffer or the buffer with 0.25 M NaCl. After 1.5 mL of buffer had
been passed through the column, liposomal TPT was eluted in the next 3.5 mL and collected
to achieve a final suspension concentration of 135 nM TPT and 0.9 mg lipid/mL. At various
time points, 150 uL aliquots of the suspension were collected. Release was monitored by
isolating intravesicular TPT using ultrafiltration. After ultrafiltration, intravesicular TPT
was dissolved in chilled acidified methanol and analyzed by HPLC.
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6.2.5 Release of actively-loaded TPT in the presence of extravesicular
ammonia
Release of liposomal TPT in the presence of extravesicular ammonia may be particularly
important, as it is present in physiological fluids and tissues and may have an effect on
intravesicular pH and subsequently alter release kinetics (as already illustrated in Chapter
5). To observe this effect, release studies of actively loaded TPT in ABLs and ASLs were
conducted at 37 °C in pH 7.4, phosphate buffered saline (PBS) solution and in PBS which
also contained 12 or 60 µM of NH4Cl. Removal of extravesicular buffer and any unloaded
drug from the loading phase was accomplished by applying 0.5 mL of actively-loaded
liposome suspensions to a Sephadex G-25 column equilibrated with PBS similar to previous
reports.60, 63 The first 2.5 mL fraction eluted from the column was discarded and the next
2.5 mL fraction was collected and used in release studies. Release studies were performed
by diluting 0.2 mL of the actively-loaded liposomal suspension of TPT obtained from
Sephadex to a final volume of 4 mL using PBS with NH4Cl to achieve final concentrations of
0, 12, or 60 µM. The resulting TPT suspension concentrations ranged between 240 and 600
nM and had a lipid concentration of 6.4 µg/mL. Over time, 150 µL aliquots were withdrawn
from the suspension and diluted with chilled methanol (-20 °C) to disrupt the liposomes
and quench the lactone/carboxylate ratio of TPT. These samples were immediately injected
and analyzed by HPLC to monitor release.

6.2.6 Isolation of intravesicular TPT by ultrafiltration
A previously validated ultrafiltration method was used to separate extravesicular from
entrapped TPT126,
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for passively-loaded release studies and active-loading at 37 °C.

Briefly, an Amicon® Ultra 0.5 mL centrifugal filter device with 30,000 MWCO Ultracel®
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membrane containing sample was centrifuged at 14,000 rpm for 10 minutes in an
Eppendorf 5417R maintained at 4 °C.
For the analysis of intravesicular TPT, samples were diluted to 0.45 mL with chilled (4
°C) buffer identical to that of the extravesicular solution to quench loading or release before
centrifugation.

After centrifugation, the resulting concentrate (25 µL) containing the

liposome suspension was recovered by inverting the cartridge and centrifuging at 2000 rpm
for another 2 minutes. Recovered concentrate was resuspended in another 400 µL of
chilled buffer and the process was repeated.

The final concentrate was dissolved in

acidified methanol and diluted within the calibration range for HPLC analysis of TPT.
Extravesicular ammonia released during loading at 37 °C was also separated with this
method with some modification. Here, liposomal suspensions (0.45 mL) were centrifuged
through the same ultrafiltration cartridges; however, only one cycle of centrifugation (with
the same conditions used to isolate intravesicular TPT) was used. After centrifugation, 0.35
mL of the ultrafiltrate was recovered and used for ammonia analysis.

6.2.7 HPLC analyses
Both the lactone and carboxylate forms of TPT were monitored with HPLC using a
previous method with slight modifications.130 Briefly, a Waters Alliance 2695 separation
system running mobile phase (11.5% acetonitrile: 88.5% (v/v) of 5% (pH = 5.5)
triethylamine acetate, 50 mM tetrabutylammonium hydrogen sulfate (TBAHS) buffer) at a
flow rate of 1 mL/min used a Waters Symmetry® C18 column (3.9×150 mm, 5 µm) and
guard column (3.9 x 20 mm) to separate lactone and carboxylate TPT in samples. A Waters
fluorescence detector (M474) (operating at excitation and emission wavelengths of 380 and
560 nm, respectively) was used to analyze the fractions of lactone and carboxylate TPT after
separation. Standards containing TPT in its lactone and carboxylate forms were prepared
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in chilled, acidified methanol (-20 °C) and 10 mM sodium carbonate buffer (pH 10.1),
respectively. Standards ranged from 20-200 nM. Lactone and carboxylate retention times
were 6.1 and 2.7 min, respectively.
Lipid content was also monitored by HPLC using an evaporative light scattering
detector (ELSD). Using the same separations module as mentioned above, an Allsphere
(Alltech Associates, Inc., Deerfield, IL) silica column (4 x 150 mm, 5 µm) and guard column
(20 x 4.0 mm, 5 µm) with a mobile phase consisting of 80% of solvent A (80%
chloroform:19.5% methanol:0.5%(v/v) NH4OH)

and 20% of solvent B (80%

methanol:19.5% water:0.5% (v/v) NH 4OH) at a flow rate of 1 mL/min were used to
quantify DSPC using an ELSD (Sedere, Inc., Lawrenceville, NJ) operated at 40 psig and 40 °C.
Logarithms of peak areas of DSPC standards in mobile phase A (0.05 – 0.3 mg DSPC/mL)
were linear with respect to the logarithm of concentration. Samples (100 – 250 µL) were
dried at room temperature under N2, then dissolved in chilled solvent A before analysis.

6.2.8 Ammonia analyses
Potentiometric measurements of ammonia released during loading at 37 °C employed
an Orion ammonia ion selective electrode in conjunction with a Thermo Scientific Orion Star
A214 pH, ISE, mV, temperature meter. Ammonia standards were prepared between 0.010.3 ppm in Milli-Q H2O. Immediately before the ammonia analyses, NaOH reagent was
added to 10 mL of ammonia standards or samples diluted in Milli-Q H2O (10 – 15 mL total
volume) at a ratio of 0.01:1 (v/v) to raise pH and convert any ammonium to ammonia.
Solutions were allowed to equilibrate for 3-5 minutes under mild stirring and the final
voltage was recorded. A Nernst relationship between ammonia concentration and electric
potential (mV) was observed and used to make a standard curve for estimation of ammonia
concentration in these samples. Blank solutions of MES buffer diluted with Milli-Q H2O in
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the same manner as ammonia samples were found to have no effect on the baseline voltage
and therefore no corrections were necessary.

6.2.9 Loading and release models of liposomal TPT
Models describing the pH-dependent release kinetics of ionizable drugs from liposomes
exist;49, 60, 124, 127, 128, 130 however, only a few have been experimentally tested 49, 60, 124, 130 and
even fewer have been tested under conditions in which a pH gradient was established via
transport of another small, highly permeable acid/base entrapped within the intravesicular
compartment.60, 124 To our knowledge, this is the first mechanistic model used to examine
active loading of a weakly basic drug.

Furthermore, this model also explores the

incorporation of drug self-association, ion-pairing, and precipitation to characterize the
active loading process and subsequent release from these actively-loaded formulations. An
illustration of these factors and others already shown to affect the release of liposomal
TPT130 can be found in Scheme 6.1.
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Scheme 6.1. A mechanistic illustration of the equilibria and kinetic processes
that govern active loading of TPT in the presence of pH and chloride gradients.
Intravesicular pH (i.e. negative logarithm of the proton concentration, 𝐻𝑖+ ) is
lowered as ammonia permeates the lipid bilayer.

This is governed by

ammonia’s release rate constant, 𝑘𝑚𝑛 , and the concentration gradient between
intra- and extravesicular ammonia (𝑁𝐻3,𝑖 and 𝑁𝐻3,𝑜 , respectively). Similar
release rate constants governing the transport of the zwitterionic lactone
(𝐿𝑧1,𝑖 and 𝐿𝑧1,𝑜 ) and carboxylate (𝐶𝑜𝑧,𝑤 ) forms of TPT as well as its ion-pair with
chloride (𝐿𝐶𝑙𝑖 and 𝐿𝐶𝑙𝑜 ) are represented by 𝑘𝑚𝑧 , 𝑘𝑚𝑐 , and 𝑘𝑚𝑝 , respectively.
Equilibria governing dimerization of TPT (𝐾2 ), partitioning of cationic lactone
and zwitterionic carboxylate TPT to the bilayer/solution interface (𝐾𝑝 and 𝐾𝑐 ,,
respectively), and the ionization state of TPT lactone and carboxylate (𝐾𝐴1 ) are
shown along with the rate constants governing ring-opening and closing of TPT
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(𝑘𝑜𝑝 and 𝑘𝑐𝑙 ,.

respectively). The inset at the bottom depicts the ion-pair

transport of TPT-Cl across the bilayer which is dependent on the association
constant of the ion-pair (Kip) in addition to kmp. A TPTHCl salt may also form in
the intravesicular compartment (TCli) during or after the loading process as
governed by the salt’s solubility product, Ksp.
6.2.9.1 TPT rate equations governing loading kinetics
The rate equations governing transport of TPT may contain multiple terms to account
for the permeable species in the intra- and extravesicular compartments (from this point
on, the subscript “i” and “o” will refer to chemical species in the intra- and extra-vesicular
compartments respectively.) This is expressed by Equations 1a and b.
𝑑𝑇𝑖
𝑑𝑡
𝑑𝑇𝑜
𝑑𝑡

=

=
𝑑 𝐿𝑧𝑜
𝑑𝑡

𝑑𝐿𝑧𝑖
𝑑𝑡

+

+

𝑑𝐿𝐶𝑙𝑖

𝑑𝐿𝐶𝑙𝑜
𝑑𝑡

(1a)

𝑑𝑡

+

𝑑𝐶𝑜
𝑑𝑡

(1b)

Here, the rates of change of total intra- and extra-vesicular TPT (Ti and To, respectively)
are a sum of the transport rates of the lactone forms (Li and L,o, respectively), the TPT-Cl
ion-pair (𝐿𝐶𝑙𝑖 and𝐿𝐶𝑙𝑜 , respectively), and extravesicular carboxylate (Co). Intravesicular
carboxylate may be ignored as the intravesicular pH is sufficiently low that essentially no
carboxylate exists inside the liposome as shown in CH. 5.92, 130
The rates governing transport may be described by pseudo steady-state Fickian
diffusion through a membrane49, 50, 60, 124, 130 of each drug species (or complex) permeable to
the bilayer. These terms are incorporated into the rate equations governing intravesicular
transport of TPT below.
𝑑𝑇𝑖
𝑑𝑡

= −𝑘𝑚𝑧 (𝐿𝑧1,𝑖 − 𝐿𝑧1,𝑜 ) − 𝑘𝑚𝑝 (𝐿𝐶𝑙𝑖 − 𝐿𝐶𝑙0 ) + 𝑘𝑚𝑐 𝐶𝑜𝑧,𝑤

(2)

The concentration gradient governing Fickian diffusion across the membrane is
between the monomeric forms of the lactone zwitterion (𝐿𝑧1,𝑖 and 𝐿𝑧1,𝑜 ).
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Because

intravesicular carboxylate is negligible at low pH, only unbound extravesicular carboxylate
zwitterion (𝐶𝑜𝑧,𝑤 ) contributes to transport. In previous studies, such transport was also
assumed for L+1. However, those studies were performed in dilute concentrations of TPT
and high chloride concentrations in both the intra- and extra-vesicular compartments. Such
conditions are not present during active loading. Because several gradients now exist in
active loading (e.g., pH, TPT, chloride, and ammonia), a more complex process may become
apparent.
This complexity regarding the transport of L+1 was hypothesized to proceed through
ion-pairing of the cationic lactone form of TPT with chloride since it is the smallest and
most abundant anion present in the extravesicular (i.e. loading) solution. Transport across
the bilayer is governed by the release rate constant kmp, and the concentration gradient of
the TPT-Cl ion pair formed in the intra- and extra-vesicular compartments (𝐿𝐶𝑙𝑖 and 𝐿𝐶𝑙𝑜 ,
respectively).
The rate equation governing the extravesicular compartment is similar to that for the
intravesicular compartment and shown below.
𝑑𝑇𝑜
𝑑𝑡

𝑢 ]
= 𝑓𝑣 [𝑘𝑚𝑧 (𝐿𝑧1,𝑖 − 𝐿𝑧1,𝑜 ) + 𝑘𝑚𝑝 (𝐿𝐶𝑙𝑖 − 𝐿𝐶𝑙0 ) − 𝑘𝑚𝑐 𝐶𝑛,𝑜

(3)

Here, the ratio of entrapped volume to extravesicular volume (𝑓𝑣 = 𝑉𝑉𝑜𝑖 ) is used to maintain
mass balance between the intra-and extra-vesicular compartments. The calculation of 𝑓𝑣 is
possible with the aid of lipid surface area densities, particle size, and the concentration of
lipid as previously defined elsewhere.50, 126, 130, 135
Accounting for chloride transport is also necessary due to ion-pairing. This is achieved
with rate equations governing intra- and extra-vesicular chloride (𝐶𝑙 𝑇,𝑖 and 𝐶𝑙 𝑇,𝑜 ,
respectively) as shown below.
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𝑑𝐶𝑙𝑇,𝑖
𝑑𝑡
𝑑𝐶𝑙𝑇,𝑜
𝑑𝑡

= −𝑘𝑚𝑝 (𝐿𝐶𝑙𝑖 − 𝐿𝐶𝑙0 )

(4a)

= 𝑓𝑣 𝑘𝑚𝑝 (𝐿𝐶𝑙𝑖 − 𝐿𝐶𝑙0 )

(4b)

Initial conditions are required to solve this system of differential equations. These
initial conditions are shown by the equations below for loading studies.
𝑇𝑖 (0) = 𝐶𝑙 𝑇,𝑖 (0) = 0
𝐶𝑙 𝑇,𝑜 (0) = 0.25𝑀
𝑇𝑖𝑏 (0) = 𝐿𝑆

(5a &b)
(5c)
(5d)

Here, LS is the concentration of TPT in the loading suspension which was varied to examine
self-association and its effect on loading efficiency.
Derivation of the concentrations of monomeric species of TPT in terms of Ti and To are
required to model drug transport during the active loading process. These derivations will
be described in the subsequent sections for the different loading models examined.
6.2.9.2 Generation of pH gradient
The release of neutral ammonia from the intravesicular compartment generates a low
intravesicular pH (pHi).170 This is governed by the rate equations below.
𝑑𝑁𝑖
𝑑𝑡
𝑑𝑁𝑜
𝑑𝑡

= −𝑘𝑚𝑛 (𝑁𝐻3,𝑖 − 𝑁𝐻3,𝑜 )

(6a)

= 𝑓𝑣 𝑘𝑚𝑛 (𝑁𝐻3,𝑖 − 𝑁𝐻3,𝑜 )

(6b)

The rates of change in the total concentration of ammonia in the intra- and extra-vesicular
compartments (Ni and No respectively) are dependent on the concentration gradient
between neutral ammonia in the intra- and extra-vesicular compartments (NH3,i and NH3,o,,
respectively), the rate constant for neutral ammonia transport (𝑘𝑚𝑛 ), and fv. NH3,i and NH3,o
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may be written in terms of Ni and No by solving for the fractions of neutral ammonia in the
intra- and extra-vesicular compartments (𝑓𝑖𝑁 and 𝑓𝑜𝑁 ):
𝑓𝑖𝑁 =
𝑓𝑜𝑁 =

𝐾𝐴𝑁

(7a)

𝐾𝐴𝑁

(7b)

𝐻𝑖++𝐾𝐴𝑁

𝐻𝑜++𝐾𝐴𝑁

These fractions are dependent on the acid dissociation constant for ammonia, 𝐾𝐴𝑁 , and the
acidity or hydrogen ion concentrations in the intra-or extra-vesicular compartments (𝐻𝑖+
and 𝐻𝑜+ , respectively). Using these fractions, Equations 6a and b can be rewritten to yield:
𝑑𝑁𝑖
𝑑𝑡
𝑑𝑁𝑜
𝑑𝑡

= −𝑘𝑚,𝑛 (𝑓𝑖𝑁 𝑁𝑖 − 𝑓𝑜𝑁 𝑁𝑜 )

(8a)

= 𝑓𝑣 𝑘𝑚,𝑛 (𝑓𝑖𝑁 𝑁𝑖 − 𝑓𝑜𝑁 𝑁𝑜 )

(8b)

The pH in the intravesicular compartment decreases as ammonia release causes
deprotonation of ammonium to replenish the released ammonia. This process governs the
acidity of the intravesicular compartment by satisfying the overall charge balance expressed
by the following equation:
𝐾

+
𝐻𝑖+ = 𝐻𝑤+ + 𝐶𝑙𝑖− + 𝐵𝑖− − 𝑁𝐻4,𝑖
− 𝐿+𝑛
𝑖
𝑖

(9)

The dissociation of water, 𝐾𝑤 , is included along with free chloride, 𝐶𝑙𝑖−, and besylate, 𝐵𝑖− , in
+
the intravesicular compartment. The concentration of intravesicular ammonium, 𝑁𝐻4,𝑖
,

may be rewritten in terms of 𝑁𝑖 as shown below.
+
𝑁𝐻4,𝑖
= (1 − 𝑓𝑖𝑁 )𝑁𝑖

Solving for total cationic TPT, 𝐿+𝑛
𝑖 , will be discussed in the next section.
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(10)

6.2.9.3 Loading Model #1: TPT dimerization and ion-pairing
TPT has been shown to self-associate in solution to form dimers137, 138 The equilibrium
expression for TPT dimerization may be expressed with the constant 𝐾2 and the expression
below relating the unbound lactone monomer, 𝐿𝑤
1 , and dimer, 𝐿2 , species.
𝐿

𝐾2 = (𝐿𝑤2)2
1

(11)

Only the lactone form of TPT is considered to self-associate as previous studies have
suggested the carboxylate conformation does not lend itself to stacking.137
With this information, the total concentration of TPT in both the intra-and extravesicular compartments (𝑇𝑖 and 𝑇𝑜 , respectively) may be rewritten in terms of the various
species present in solution.

These overall mass balances are written in terms of

concentration using corrections for the differences in volumes of the various compartments.
𝑇𝑖 = 𝑎(𝐿𝑤
1,𝑖 + 2𝐿2,𝑖 )
𝑢
𝑚
𝑇𝑜 = 𝑐(𝐿𝑤
1,𝑜 + 2𝐿2,𝑜 + 𝐶𝑜 ) + 𝑑𝐶𝑜

(12a)
(12b)

These corrections relate aqueous to total volumes of the intra- and extravesicular
compartments (a and c, respectively) and the membrane volume of the outer bilayer leaflet
to total extra-vesicular volume (d) as defined in previous studies of liposomal transport of
TPT.126, 130
Previous studies also indicated the lactone zwitterion of TPT does not bind to the
bilayer while its cationic form does;126,

130

however, the high intravesicular TPT

concentrations achieved during active loading (>1 mM) and the small surface area-tovolume ratio of the membrane in the external compartment make binding of the cationic
species negligible in both compartments. This is supported by previous studies which show
only the monomeric species binds, and the cationic species follows the Gouy Chapman
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theory of diminished binding as the charge on the membrane increases.126,
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These

assumptions make intravesicular TPT only a function of the monomer and dimer forms of
lactone TPT.
136, 186
Using Equation 11, Equation 12a can be rewritten solely in terms of 𝐿𝑤
1,𝑖 and 𝑇𝑖 ,

resulting in the equations below.
2

(13a)

−1+ √1+8𝐾2 𝑇𝑖 /𝑎
4𝐾2

(13b)

𝑤
𝑇𝑖 = 𝑎(𝐿𝑤
1,𝑖 + 2𝐿1,𝑖 )

𝐿𝑤
1,𝑖 =

At the extravesicular pH at which loading studies were conducted, extravesicular
carboxylate TPT in solution, 𝐶𝑜𝑢 , and bound to the membrane, 𝐶𝑜𝑚 , must be considered. This
𝑤
makes solving for 𝐿𝑤
1,𝑜 more complex. Eqn. 12b can be rewritten in terms of 𝐿1,𝑜 and takes

on the general form of a quadratic equation which is illustrated below:
𝐿𝑤
1,𝑜 =

−𝛽+√𝛽 2−4𝛼𝛾
2𝛼

′ )
′
where 𝛽 = 𝑐 (𝐻𝑜+ + 𝐾𝐴2
+ 𝑑𝐾𝐶′ 𝐾𝐴2
, 𝛼 = 2𝑐𝐻𝑜+ 𝐾2 , and 𝛾 = 𝐻𝑜+ 𝑇𝑜 .

(14)
In these terms, the

carboxylate species may be rewritten in terms of 𝐿𝑤
1,𝑜 using the apparent acid dissociation
′
constant for the equilibrium between the lactone and carboxylate forms, 𝐾𝐴2
and the

apparent binding coefficient for carboxylate, 𝐾𝐶′ , in addition to other constants already
defined. The value of 𝐾𝐶′ is pH dependent and may be determined using the intrinsic
binding constant of the zwitterionic carboxylate, 𝐾𝑐 , and the dissociation constant of TPT’s
phenol, 𝐾𝐴1 . These conditions are incorporated into the following equation based on the
equilibria scheme described for TPT in Chapter 4.130
𝐾𝐶′ =

′
𝐻𝑜+𝐾𝐴2
𝐾𝑐
2
+
+
′
𝐻𝑜 +𝐻𝑜 𝐾𝐴1 +𝐾𝐴1 𝐾𝐴2
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(15)

While total monomer may now be expressed in terms of total drug in both
compartments, the determination of each permeable species is still required. This may be
accomplished using the mass balances below for the aqueous monomeric species in both
intra- and extra-vesicular compartments.
+1,𝑤
𝑧
𝐿𝑤
+ 𝐿𝐶𝑙𝑖
1,𝑖 = 𝐿1,𝑖 + 𝐿1,𝑖

(16a)

+1,𝑤
𝑧
𝐿𝑤
1,𝑜 = 𝐿1,𝑜 + 𝐿1,𝑜 + 𝐿𝐶𝑙𝑜

(16b)

Since 𝐿𝐶𝑙𝑖 and 𝐿𝐶𝑙𝑜 also contain chloride, a mass balance for chloride must be considered
for each compartment.
𝐶𝑙 𝑇,𝑖 = 𝐶𝑙𝑖− + 𝐿𝐶𝑙𝑖

(17a)

𝐶𝑙 𝑇,𝑜 = 𝐶𝑙𝑜− + 𝐿𝐶𝑙𝑜

(17b)

It is easiest to first solve for 𝐿+1,𝑤
by combining equations 16a_and 17a in addition to
1,𝑖
the expressions governing the equilibrium constants KIP and KA1. The resulting equation is
shown below.

𝐿𝑤
1,𝑖 =

𝐾𝐴1 +1,𝑤
𝐿
𝐻 + 1,𝑖
𝑖

+ 𝐿+1,𝑤
+
1,𝑖

+1,𝑤

𝐾𝐼𝑃 𝐶𝑙𝑇,𝑖𝐿1,𝑖

1+𝐾𝐼𝑃 𝐿+1,𝑤
1,𝑖

(18)

This equation is quadratic in nature and takes on the general form below when solved for
𝐿+1,𝑤
1,𝑖 :

𝐿+1,𝑤
1,𝑖

=

−𝐵𝑖 +√𝐵𝑖2 −4𝐴𝑖 𝐶𝑖
2𝐴𝑖

(19)

+
+ 𝑤
where 𝐵𝑖 = 𝐾𝐴1 + 𝐻𝑖+ (1 + 𝐾𝐼𝑃 𝐶𝑙 𝑇,𝑖 − 𝐾𝐼𝑃 𝐿𝑤
1,𝑖 ), 𝐴𝑖 = 𝐾𝐼𝑃 (𝐻𝑖 + 𝐾𝐴1 ), and 𝐶𝑖 = −𝐻𝑖 𝐿1,𝑖 .

A

𝑤
+
similar expression for 𝐿+1,𝑤
1,𝑜 may be written where 𝐵𝑜 = 𝐾𝐴1 + 𝐻𝑜 (1 + 𝐾𝐼𝑃 𝐶𝑙 𝑇,𝑜 − 𝐾𝐼𝑃 𝐿1,𝑜 ),

𝐴𝑜 = 𝐾𝐼𝑃 (𝐻𝑜+ + 𝐾𝐴1 ), and 𝐶𝑜 = −𝐻𝑜+ 𝐿𝑤
1,𝑜 .
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𝑧
𝑧
With 𝐿+1,𝑤
and 𝐿+1,𝑤
1,𝑜 solved, solutions for 𝐿1,𝑖 , 𝐿1,𝑜 , 𝐿𝐶𝑙𝑖 , and 𝐿𝐶𝑙𝑜 are straightforward
1,𝑖

and shown below.
𝐿𝑧1,𝑖 =

𝐾𝐴1 +1,𝑤
𝐿
𝐻 + 1,𝑖

(20a)

𝑖

+1,𝑤

𝐿𝐶𝑙𝑖 =

𝐾𝐼𝑃 𝐶𝑙𝑇,𝑖𝐿1,𝑖

1+𝐾𝐼𝑃 𝐿+1,𝑤
1,𝑖

(20b)

𝑤
+
Similar equations for 𝐿+1,𝑤
and 𝐿𝑧1,𝑖 use 𝐻𝑖+ and 𝐿𝑤
1,𝑖 instead of 𝐻𝑜 and 𝐿1,𝑜 .
1,𝑖

𝐾𝐴1 𝑤
𝐿
𝐻𝑜+ 1,𝑜

𝐿𝑧1,𝑜 =
𝐿𝐶𝑙𝑜 =

(21a)
+1,𝑤

𝐾𝐼𝑃 𝐶𝑙𝑇,𝑜𝐿1,𝑜

1+𝐾𝐼𝑃 𝐿+1,𝑤
1,𝑜

(21b)

And the solution for 𝐶𝑜𝑧,𝑤 is simply the following expression.
𝐶𝑜𝑧,𝑤 =

′
𝐾𝐴2
+
𝐻𝑜 +𝐾𝐴1

𝐿𝑤
1,𝑜

(21c)

Equations 20a-b and 21a-c can be substituted back into Equations 13 and 14,
respectively, so the transport equations governing loading and release of TPT may be
written in terms of 𝑇𝑖 and 𝑇𝑜 , respectively, and of 𝐶𝑙 𝑇,𝑖 and 𝐶𝑙 𝑇,𝑜 , respectively. These
equations are also used for the transport equations governing chloride.
The following equation was used to express the total concentration of intravesicular
cationic TPT, 𝐿+𝑛
𝑖 , for the calculation of intravesicular pH during the loading process
𝐿+𝑛
𝑖 =

𝐻𝑖+(𝑇𝑖 −𝐿𝐶𝑙𝑖 )
𝑎(𝐻𝑖++𝐾𝐴1 )

(22)

while 𝐶𝑙𝑖− was simply calculated with the rearrangement of Eqn. 17a (shown below).
𝐶𝑙𝑖− = 𝐶𝑙 𝑇,𝑖 − 𝐿𝐶𝑙𝑖
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(23)

6.2.9.4 Loading Model #2: Ion-pairing without dimerization
Without dimerization, 𝑎𝐿𝑤
1,𝑖 = 𝑇𝑖 and the subsequent equations solving for the different
intravesicular species of TPT (Eqns. 18-19b) may be used for this model. The equations
governing the extravesicular compartment require more explanation as 𝑇𝑜 is now expressed
by the following equation.
𝑢
𝑚
𝑇𝑜 = 𝑐 (𝐿𝑤
𝑜 + 𝐶𝑜 ) + 𝑑𝐶𝑜

(24)

′
′
𝑤
Now 𝐿𝑤
𝑜 may be expressed using 𝐾𝐴2 and 𝐾𝐶 yielding the following equation for 𝐿𝑜 in terms

of 𝑇𝑜 .
𝐿𝑤
𝑜 =

𝐻𝑜+𝑇𝑜
+
′ +𝑏𝐾 ′ 𝐾 ′
𝑎𝐻𝑜 +𝑎𝐾𝐴2
𝐴2 𝐶

(25)

𝑤
+
+
From this point, Eqns. 19 (substituting 𝐿𝑤
𝑜 and 𝐻𝑜 for 𝐿𝑖 and 𝐻𝑖 , respectively) and 20a-c
𝑧,𝑤
𝑧
𝑧
can be used to determine the concentrations of 𝐿+1,𝑤
1,𝑜 , 𝐿1,𝑜 , 𝐿1,𝑜 , and 𝐶𝑜 , respectively.

Lastly, the calculation of intravesicular pH can be made assuming 𝐿+1,𝑤
= 𝐿+𝑛
𝑖 .
1,𝑖
6.2.9.5 Loading Model #3: Dimerization with no ion-pairing
The rate equations governing TPT transport are the same if one substitutes 𝐿+1,𝑤
and
1,𝑖
𝐿+1,𝑤
1,𝑜 for 𝐿𝐶𝑙𝑖 and 𝐿𝐶𝑙𝑜 , respectively, and neglects the transport equations for Cl. Solving for
𝑧,𝑤
the monomeric species is the same as Equations 13 and 14 so solving for 𝐿+1,𝑤
1,𝑖 , and 𝐿1,𝑖

becomes straightforward, resulting in the equations below.
𝐻+

𝑖
𝐿+1,𝑤
= 𝐻 ++𝐾
1,𝑖
𝑖

𝐴1

𝐾

𝐿𝑤
1,𝑖

𝐴1
𝑤
𝐿𝑧,𝑤
1,𝑖 = 𝐻 ++𝐾 𝐿1,𝑖
𝑖

𝐴1

(26a)
(26b)

𝑧,𝑤
+
The equations for 𝐿+1,𝑤
1,𝑜 , and 𝐿1,𝑜 are the same as 24 a & b aside from using 𝐻𝑜 instead of

𝐻𝑖+ .
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6.2.9.6 Equations describing PLLT release
The equations describing TPT transport and model #1 were used to simulate the
release of PLLT. This is achieved by setting 𝐻𝑖+ = 𝐻𝑜+ = 10−4.1 and setting the initial
conditions to reflect the concentrations of TPT and chloride present in the solution used to
hydrate these passively-loaded liposomes. For all PLLT studies, the initial conditions for
TPT were the same and shown below.
𝑇𝑖 (0) = 50 µ𝑀

(27a)

𝑇𝑜 (0) = 0

(27b)

The initial conditions for chloride, however, were varied. In two release studies, 𝐶𝑙𝑖− (0) =
𝑇𝑖 (0) since its HCl salt was used to make the solutions. In one of these studies, the
extravesicular solution contained no chloride (𝐶𝑙𝑖− (0) = 0) while the other suspension did
have chloride (𝐶𝑙𝑖− (0) = 0.25𝑀) present. The other PLLT suspension contained Cl on both
sides. Its initial conditions were 𝐶𝑙𝑜− (0) = 𝐶𝑙𝑖− (0) = 0.25𝑀. The rate equations governing
ammonia transport were unnecessary since it was not present in any of the buffers used in
PLLT studies.
6.2.9.7 Equations describing release of liposomal TPT loaded at 37 °C
Equilibrium between the lactone and carboxylate forms of TPT was assumed in loading
studies as ring-opening/closing kinetics for TPT and other camptothecins have been shown
to be acid-catalyzed at the pH of the loading solution.92

Because the intravesicular

compartment retains its low pH, carboxylate is still negligible and Equations 2a and b may
be used to describe intravesicular transport of TPT. However, this interconversion has
previously been shown to have an effect on liposomal TPT release at physiological pH
(7.4).130 This effect requires the differential equation governing extravesicular TPT (Eqn. 3)
to be modified as shown below.
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𝑑𝐿𝑜
𝑑𝑡

𝑢
= 𝑓𝑣 [𝑘𝑚𝑧 (𝐿𝑧1,𝑖 − 𝐿𝑧1,𝑜 ) + 𝑘𝑚𝑝 (𝐿𝐶𝑙𝑖 − 𝐿𝐶𝑙0 ) − 𝑘𝑚𝑐 𝐶𝑛,𝑜
] − 𝑘𝑜𝑝 𝑂𝐻𝑜− 𝐿𝑜 + 𝑘𝑐𝑙 𝑂𝐻𝑜− 𝑓𝐶𝑂𝑂𝐻 𝐶𝑜 (28)

This equation now reflects the interconversion kinetics previously reported with rate
constants governing base-catalyzed ring-opening and closing kinetics (𝑘𝑜𝑝 and 𝑘𝑐𝑙 ,
respectively).92, 130 Since the carboxylic acid form of TPT is the only ring-opened species
involved in ring-closing,92 the term 𝑓𝐶𝑂𝑂𝐻 is introduced to account for this fraction of ringopened TPT.130
𝐻+

𝑓𝐶𝑂𝑂𝐻 = 𝐻 ++𝐾𝑜
𝑜

𝐶𝑂𝑂𝐻

(29)

The ionization of the carboxylic acid to form carboxylate TPT is pH-sensitive and governed
by 𝐾𝐶𝑂𝑂𝐻 .
One should notice that Equation 28 only governs the rate of change of Lo due to noninstantaneous interconversion. A differential equation governing 𝐶𝑜 is required.
𝑑𝐶𝑜
𝑑𝑡

= −𝑓𝑣 𝑘𝑚𝑐 𝐶𝑜𝑧,𝑤 + 𝑘𝑜𝑝 𝑂𝐻𝑜− 𝐿𝑜 − 𝑘𝑐𝑙 𝑂𝐻𝑜− 𝑓𝐶𝑂𝑂𝐻 𝐶𝑜

(30)

The permeable, zwitterionic form of carboxylate TPT unbound to the membrane, 𝐶𝑜𝑧,𝑤 , may
be defined in terms of 𝐶𝑜 . This is shown in the equation below.
𝐻𝑜+ 𝐶𝑜

𝐶𝑜𝑧,𝑤 = (𝐻 ++𝐾
𝑜

𝐴1 )(𝑐+𝑑𝐾𝐶 )

(31)

In loading studies, the permeability of chloride alone was not considered since its influx
into the liposome through this pathway would be much slower than through the ion pair.
During release studies however, the influx of chloride from the extravesicular solution 187-189
would alter the amount of drug released as it would continue to provide more chloride for
transport of 𝐿𝐶𝑙𝑖 . Accounting for this effect requires a release rate constant for chloride,
kmCl, and modification of the transport equations governing chloride. These equations are
shown below.
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𝑑𝐶𝑙𝑇,𝑖
𝑑𝑡
𝑑𝐶𝑙𝑇,𝑜
𝑑𝑡

= −𝑘𝑚𝑝 (𝐿𝐶𝑙𝑖 − 𝐿𝐶𝑙0 ) − 𝑘𝑚𝐶𝑙 (𝐶𝑙𝑖− − 𝐶𝑙0− )

(32a)

= 𝑓𝑣 [𝑘𝑚𝑝 (𝐿𝐶𝑙𝑖 − 𝐿𝐶𝑙0 ) + 𝑘𝑚𝐶𝑙 (𝐶𝑙𝑖− − 𝐶𝑙0− )]

(32b)

The concentration gradient is between the anionic forms of intra- and extra-vesicular
chloride (𝐶𝑙𝑖− and 𝐶𝑙0−, respectively). These concentrations may be expressed in terms of
𝐶𝑙 𝑇,𝑖 and 𝐶𝑙 𝑇,𝑜 using the ion-pairing constant and the equations below.
𝐶𝑙𝑇,𝑖

𝐶𝑙𝑖− = 1+𝐾

(33a)

+1,𝑤
𝐼𝑃 𝐿1,𝑖

𝐶𝑙𝑇,𝑜

𝐶𝑙𝑜− = 1+𝐾

(33b)

+1,𝑤
𝐼𝑃 𝐿1,𝑜

While the equations above imply that chloride permeability soley involves the chloride
anion, the identity of this permeable species is a point of contention. Cl- permeability has
been argued to behave as an ion-pair, typically suggested to be the HCl pair since protons
are much smaller than any other cations in solution. This assumption would indicate Cl flux to be pH-dependent as a pKa exists for the HCl pair and its dissociated ions, and a pHdependence in Cl- permeability has been observed.187,

190

However, a pH-independent

pathway has also been observed.187, 190 This pH-independent pathway suggests Cl- to be the
permeable species and is supported by molecular dynamics simulations (arguing several
different transport mechanisms) which illustrate anion transport.153, 188, 191, 192 Because a
mechanistic evaluation of Cl- was beyond the scope of this study, Cl- co-transport was
assumed. Under this assumption, Cl- transport was pH-independent and proton conduction
across the bilayer was assumed to be fast enough to maintain electroneutrality and prevent
the generation of an electrical potential across the membrane. While proton transport
equations are not used, they are implicitly expressed mathematically by assuming charge is
conserved within the intravesicular compartment.

This was previously expressed

mathematically by Equation 9 and in the subsequent calculation of intravesicular pH.
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Finally, the concentrations obtained from this release model must be transformed to
illustrate the fraction of lactone and carboxylate TPT (L(t) and C(t), respectively) in solution
at each time point. This is shown by the following equations.
𝑓 𝐿 +𝐿𝑜

𝐿(𝑡) = 𝑓 𝐿𝑣 +𝐿𝑖

𝑜 +𝐶𝑜

𝑣 𝑖

𝐶

𝐶 (𝑡) = 𝑓 𝐿 +𝐿𝑜
𝑣 𝑖

𝑜 +𝐶𝑜

(34a)
(34b)

The initial conditions for the various differential equations for the transport of each
permeable molecule are shown in Table 6.4 while those of the extravesicular compartment
were determined based on the concentrations calculated at the end of loading studies.
6.2.9.8 Equations describing release of liposomal TPT loaded at 60 °C
At 60 °C, DSPC bilayers are in a more permeable liquid crystalline state as opposed to
their rigid gel phase below 54 °C.135, 193 Under these conditions, the permeabilities of both
the zwitterion and ion-paired form of TPT may be much faster and increased to different
extents, resulting in altered Cl: TPT ratios. Further alteration of this ratio may be due to the
the relative change in chloride permeability as well. These effects may ultimately lead to
much higher Cl: TPT ratios and possibly supersaturate the intravesicular compartment at
this higher temperature, resulting in precipitate formation upon cooling.
The formation of precipitate in the intravesicular aqueous compartment is governed by
an apparent solubility product, K’sp, as illustrated by the following equation:
′
𝐾𝑠𝑝
= 𝑇𝑖(𝑎𝑞) 𝐶𝑙𝑖(𝑎𝑞)

(35)

where 𝑇𝑖(𝑎𝑞) and 𝐶𝑙𝑖(𝑎𝑞) are the concentrations of TPT and chloride still solubilized in
solution. Only these soluble species may be considered in the equation used to calculate pH.
Furthermore, these species along with the precipitate, 𝑇𝐶𝑙𝑖(𝑠), must be incorporated into the
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rate equations governing drug and chloride transport.

Equations 1a and 4a may be

modified to reflect these stipulations as shown below.
𝑑𝑇𝑖
𝑑𝑡
𝑑𝐶𝑙𝑇,𝑖
𝑑𝑡

=
=

𝑑 𝐿𝑧1,𝑖
𝑑𝑡

+

𝑑𝐿𝐶𝑙𝑖
𝑑𝑡

𝑑𝐿𝐶𝑙𝑖

+

𝑑𝑡

+

𝑑𝐶𝑙𝑖−
𝑑𝑡

𝑑𝑇𝐶𝑙𝑖(𝑠)

+

𝑑𝑡
𝑑𝑇𝐶𝑙𝑖(𝑠)
𝑑𝑡

=
=

𝑑𝑇𝑖(𝑎𝑞)
𝑑𝑡

+

𝑑𝐶𝑙𝑖(𝑎𝑞)
𝑑𝑡

𝑑𝑇𝐶𝑙𝑖(𝑠)

+

𝑑𝑡
𝑑𝑇𝐶𝑙𝑖(𝑠)
𝑑𝑡

(36a)
(36b)

Since both TPT and chloride leave in a 1:1 ratio via transport of their ion pair, the rate of
precipitate dissolution is simply equal to that of the rate of ion-pair transport as shown by
the following equation.
′
If: 𝐾𝑠𝑝
≥ 𝑇𝑖(𝑎𝑞) 𝐶𝑙𝑖(𝑎𝑞)

𝑑𝑇𝐶𝑙𝑖(𝑠)
𝑑𝑡

=

𝑑𝐿𝐶𝑙𝑖
𝑑𝑡

= 𝑘𝑚𝑝 (𝐿𝐶𝑙𝑖 − 𝐿𝐶𝑙0 )

(37a)

′
When 𝐾𝑠𝑝
< 𝑇𝑖(𝑎𝑞) 𝐶𝑙𝑖(𝑎𝑞) , changes in the amount of 𝑇𝐶𝑙𝑖(𝑠) will be governed by the flux of

free chloride as illustrated by the expression below.
′
If: 𝐾𝑠𝑝
< 𝑇𝑖(𝑎𝑞) 𝐶𝑙𝑖(𝑎𝑞)

𝑑𝑇𝐶𝑙𝑖(𝑠)
𝑑𝑡

= −𝑘𝑚𝐶𝑙 (𝐶𝑙𝑖− − 𝐶𝑙0− )

(37b)

With these rate equations, the rate equations already derived for the extravesicular
compartment during ALLT release, and the expressions already derived for the various
aqueous TPT and chloride species, these differential equations may be modeled once the
initial conditions (i.e. how much drug and chloride are in the aqueous and solid phases) are
determined for the intravesicular compartment. For this calculation, the mass balances for
TPT and total chloride in the intravesicular compartment, MTPT and MCl respectively, are
necessary and shown below.
𝑀𝑇𝑃𝑇 = 𝑀𝑇𝑃𝑇(𝑎𝑞) + 𝑀𝑇𝐶𝑙(𝑠)

(38a)

𝑀𝐶𝑙 = 𝑀𝐶𝑙(𝑎𝑞) + 𝑀𝑇𝐶𝑙(𝑠)

(38b)
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Assuming the intravesicular volume remains constant, the masses for the aqueous species
of TPT and Cl may be rewritten in terms of the concentrations used in the rate equations
(Eqns. 36a and b) as illustrated by the following equations.
𝑇𝑖 = 𝑇𝑖(𝑎𝑞) + 𝑇𝐶𝑙𝑖(𝑠)

(39a)

𝐶𝑙 𝑇,𝑖 = 𝐶𝑙𝑖(𝑎𝑞) + 𝑇𝐶𝑙𝑖(𝑠)

(39b)

This system of equations may be used along with the equation for K’sp to solve for 𝑇𝐶𝑙𝑖(𝑠) in
terms of the initial amount of total intravesicular TPT and Cl, 𝑇𝑖 (0) and 𝐶𝑙 𝑇,𝑖 (0) respectively.
The resulting solution is expressed below as the initial condition for 𝑇𝐶𝑙𝑖(𝑠)

𝑇𝐶𝑙𝑖(𝑠) (0) =

′
𝑇𝑖 (0) + 𝐶𝑙 𝑇,𝑖 (0) − √[𝑇𝑖 (0) + 𝐶𝑙 𝑇,𝑖 (0)]2 − 4(𝑇𝑖 (0)𝐶𝑙 𝑇,𝑖 (0) − 𝐾𝑠𝑝
)

2

(40a)

while the initial conditions for 𝑇𝑖(𝑎𝑞) and 𝐶𝑙𝑖(𝑎𝑞) simply become the following expressions.
𝑇𝑖(𝑎𝑞) (0) = 𝑇𝑖 (0) − 𝑇𝐶𝑙𝑖(𝑠) (0)

(40b)

𝐶𝑙𝑖(𝑎𝑞) (0) = 𝐶𝑙 𝑇,𝑖 (0) − 𝑇𝐶𝑙𝑖(𝑠) (0)

(40c)

HPLC analysis of carboxylate and lactone forms of TPT can again be used to monitor release
by modifying the Eqns. 34a and b to the form below.
𝑓𝑣 [𝑇𝑖(𝑎𝑞) +𝑇𝐶𝑙𝑖(𝑠) ]+𝐿𝑜

𝐿(𝑡) = 𝑓 [𝑇
𝑣

𝑖(𝑎𝑞) +𝑇𝐶𝑙𝑖(𝑠) ]+𝐿𝑜 +𝐶𝑜

𝐶𝑜

𝐶 (𝑡) = 𝑓 [𝑇
𝑣

𝑖(𝑎𝑞) +𝑇𝐶𝑙𝑖(𝑠) ]+𝐿𝑜 +𝐶𝑜

(41a)
(41b)

′
This model was used to determine both 𝐾𝑠𝑝
and 𝐶𝑙 𝑇,𝑖 (0) from the release profiles obtained

after active loading of TPT into liposomes at 60 °C.
All data fitting to the models described above was performed with MicroMath®
Scientist® non-linear regression software in conjunction with the values supplied in Tables
6.1 and 6.2 for the various parameters used in these models.
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Table 6.1. Parameters used to model release and loading kinetics of liposomal TPT that are
independent of the experiment
Parameters

Values

kmn

2.88 × 104 𝑠 −1 a

kmz

43 ℎ𝑟 −1 b

kmc

5.6 ℎ𝑟 −1 b

Kc

42 b

K’A1

2.8 × 10−7 b

KAN

9.40 × 10−10 c

Kw

2.12 × 10−14 c

Bi

0.3 𝑀

a

0.15 d

b

0.85 d

Calculated from a previously reported ammonia permeability coefficient of
𝑚
𝑃𝑁𝐻
= 48 × 10−3 𝑐𝑚⁄𝑠 171
3
b Obtained from a previous study125
c Values adjusted to reflect conditions at 37 °C and 0.3 I
d Calculated based on particle size, lipid content, and lipid surface density calculations
previously reported50, 135
a

Table 6.2. Parameters used to model release and loading kinetics of liposomal TPT that are
experiment-specific*
Param-

Values
Active Loading #1

PLLT

ALLT release (6.4

(19.2 µg lipid/mL)

(19.2 µg lipid/mL)

µg lipid/mL)

K’A2

2.66 × 10−7 b

2.66 × 10−7 b

N/A

kcl

N/A

N/A

7.4 x 108 mol-1hr-1b

kop

N/A

N/A

1.4 x 106 mol-1hr-1b

fv

2.40 × 10−3 d

2.40 × 10−3 d

1.66 × 10−5 d

c

0.9997 d

0.9997 d

0.9999 d

d

3.44 × 10−4 d

3.44 × 10−4 d

2.58 × 10−6 d

𝐻𝑜+

3.16 × 10−6 𝑀

7.94 × 10−5 𝑀

3.98 × 10−8 𝑀

eters

* Superscripts same as those used in Table 6.1.
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6.3 Results
6.3.1 Active loading of TPT at 37 °C
Multiple loading models were explored and the estimated values for the fitted
parameters are shown for each model in Table 6.3. The values for the parameters are quite
revealing. The model selection criterion (MSC) generated by the non-linear regression
software provides an indication of the goodness-of-fit for each model to the data obtained
from fitting the profiles of TPT during active loading at 37 °C. The MSC for model #3 is
drastically lower than the other models as it does not account for ion-pairing effects. This
result suggests the importance of ion-pairing transport during active loading of TPT. The
differences between the MSC for model #1 and #2 are less drastic; however, closer
examination of the fitted parameters in Table 6.3 provides further evidence of the validity of
model #1. The confidence limits for these parameters are far better for model #1, which is
in agreement upon comparison of the fitted models to the loading data illustrated by
Figures 6.1a and b. Furthermore, the value of kmp is nearly identical to the value of kmz. This
is reasonable considering the ion-pair is likely not much larger than the TPT zwitterion (i.e.
similar diffusivity through the bilayer). This value is much more reasonable than the kmp
obtained from model # 2 which is 70 fold higher than that of the zwitterion rate constant.
Figure 6.1c shows the predicted profile of ammonia release from model #1 has a similar
trend as that experimentally observed for each of the loading conditions studied. While the
trends are similar, it does appear that ammonia release is over- and under-predicted at the
loading conditions using 180 and 60 µM of TPT in the extravesicular solution, respectively.
This is likely due to a couple of factors. The first is using an average ratio of entrapped
volume to extravesicular volume (𝑓𝑣 ) to calculate uptake rather than an individual 𝑓𝑣 for
each suspension. The average 𝑓𝑣 was 4.6 % lower and 2.6 % higher than the actual values
determined from uptake in the 180 and 60 µM TPT loading solutions, respectively. The
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respective over and under-estimations of 𝑓𝑣 would consequently lead to under- and overestimations in the amount of ammonia released similar to that shown in Figure 6.1c. With
this consideration and the high sensitivity of the ammonia probe’s response to different
buffers and ions in solution (attempts were made to keep the solution composition of
ammonia standards as similar as possible to the samples), the differences in observed and
predicted ammonia release appear to correlate well.

Using the ammonia release in

conjunction with the chloride and TPT loaded into the intravesicular compartment, the
profile of intravesicular pH was also calculated and is illustrated by Figure 6.1d. This drop
in intravesicular pH agrees with that expected during the active loading process.
Table 6.3. Values of release parameters and goodness-of-fit for the various loading models
developeda
Loading
Model

𝐾2 (M

-1 b
)

𝐾𝐼𝑃

𝑘𝑚𝑝 (hr )

Model Selection
Criterion (MSC)

-1

Model #1

6700

0.9 ± 0.7

49 ± 7

5.2

Model #2

NA

0.1 ± 2

3400 ± 2000

2.9

Model #3

6700

NA

0.65c

0.8

± 95% confidence intervals
Previously determined in another study.126
c Based on a previously reported value of 0.51 hr -1 which assumed kmp referred to
transport of the cation without a counterion. This value was altered to reflect the
fraction of monomer being 0.78 in that study.130
a
b
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Figure 6.1. Loading profiles at 37 °C with TPT loading concentrations of 60,
130, and 180 µM in the extravesicular compartment with lines indicating
simulated profiles obtained from the fit of loading models #1 (A) and #2 (B). A
comparison of the fit of these two models to the studied loading conditions
shows TPT dimerization and ion-pairing affects loading kinetics. Profiles of
ammonia

released

during

the

loading

process

were

also

observed

experimentally and shown along with the profiles of ammonia release predicted
by model #1 (C). Using the amount of ammonia released and TPT and Cl loaded
based on loading model #1, the intravesicular pH during the time course of the
loading experiments could be calculated (D) and shows the initial drop in pHi is
rapid and slowly increases during uptake as illustrated in the legend.
It should also be noted that during the course of fitting models considering ion-pairing,
the dissociation constant of TPT’s phenol, KA!, was allowed to change during regression in
accordance with KIP. This consideration was made due to the high levels of chloride present
in previous studies would result in the measurement of an effective dissociation constant,
K’A1, for TPT if ion-pairing was present in those solutions.130 The effect of ion-pairing on K’A1
is illustrated with the equation below.
𝐻 +𝐿𝑧

1
′
𝐾𝐴1
= 𝐿++𝐿𝐶𝑙

(42)

1

The value for KA! can be used to calculate KA! to be used during regression of the loading
studies. This is done using the following equation.
𝐾′

𝐾𝐴1 = 1+𝐾𝐴1𝐶𝑙
𝐼𝑃

𝑇

(43)

The equation above assumes TPT dimerization is negligible and that very little chloride is
consumed to form the ion-pair (𝐶𝑙 𝑇 ≅ 𝐶𝑙 − ) as solutions used to spectrometrically
determined K’A1 contained 500 nM TPT and 225 mM chloride.130 With this correction and
KIP determined with loading model #1, KA1 was determined to be 3.3 x 10-7.
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6.3.2 PLLT release studies
PLLT release studies were conducted at 37 °C in pH 4.1 buffer containing 50 uM
TPTHCl. The concentration of intra- and extra-vesicular Cl was altered and the resulting
release profiles of TPT are shown below in Figure 6.2. The release studies in which no
excess Cl was added to the intravesicular buffer agreed well with the profile predicted by
the parameters obtained from loading studies. The release profile of TPT in the presence of
excess Cl (0.25 M) in the intravesicular compartment is over 4 times faster than that of
these other release profiles. This supports the hypothesis of bilayer transport via the TPTCl ion pair.

1
0.9

TPT(t)/TPT (0)

0.8

0.7
0.6
0.5
0.4
0.3

0.2
0.1
0
0

12

24

36

48
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Time (hr)
Figure 6.2. Comparison of release profile of PLLT in the presence or absence of
chloride at 37 °C. Release when chloride was not added to intravesicular buffer
and either none ( ) or 0.25 M Cl was added to the extravesicular buffer (
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) are

shown. The profiles predicted based on the fitted values obtained from loading
studies were the same and are both represented by (

). Release when ClT was

0.25 M in both intra- and extra-vesicular compartments was also observed ( )
and compared with the profiles predicted by the loading model under these
chloride conditions (

) and when Cli,T was fitted to be 1.1 mM (

).

While TPT release is faster in the presence of 0.25 M Cl, one may also notice that the
release profile predicted by the values obtained from loading experiments would suggest
much faster release in the presence of that much Cl. Part of this discrepancy may be due to
the method employed to monitor release as the fastest release half-life monitored before
with this method was ~0.5 hrs.130 The ionic strengths of the two intravesicular solutions
used in these release studies, while different (0.3 vs. 0.55), are sufficiently high that
differences in chloride activity would be minimal and therefore an unlikely factor in the
discrepancy between predicted and observed release kinetics. Previous reports of chloride
binding to other gel phosphatidylcholine bilayers would reduce the driving force for ionpair formation and release.194 Ion-pairing of chloride with sodium in the aqueous phase or
at the interface of the bilayer solution could also hinder ion-pair transport of TPT.
A more likely explanation for the slower release at these high Cl concentrations may be
related to the differences in PEG density between the intra- and extra-vesicular
compartments. The higher PEG density within the aqueous core may create an aqueous
two-phase system.

Such systems are routinely used for milder separations of more

hydrophobic solutes by their partitioning into the PEG phase.195 Partitioning of TPT into
this PEG phase would reduce ion-pair transport in two ways: 1) the amount of TPT available
to ion-pair with Cl in the aq. salt phase near the bilayer would be reduced and subsequently
lower the effective driving force for ion-pair transport,196 and 2) the rate of TPT transfer
from the PEG-phase to the aq. salt phase may become partially rate-limiting to bilayer
transport due to the increased viscosity (i.e. reduced TPT diffusivity) of the PEG-phase.195
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This effect would only be present within the intravesicular compartment since the PEG
density near the bilayer would be much higher due to curvature effects inherent to the
spherical shape of liposomes. Furthermore, NaCl was never present in the intravesicular
compartments of liposomal formulations used in active loading studies.

Since drug

partitioning and liquid viscosity are highly dependent upon the concentration and type of
salt(s) present in the PEG-salt system,195, 196 it is plausible that the ammonium salts and the
lower, model-calculated intravesicular Cl concentrations of the actively-loaded systems
would likely not suffer the same effects during release studies.

6.3.3 ALLT release studies
6.3.3.1 Effect of chloride permeability on ALLT release
After loading at 37 °C, ALLT release was monitored in pH 7.4 PBS at 37 °C with the
changes in the lactone and carboxylate fractions of TPT in solution. Simulations of these
release profiles were made using the fitted values obtained from loading experiments. The
initial conditions used in these studies were obtained from the final concentrations of total
intravesicular chloride, ammonia, and TPT calculated from the loading model and are found
below in Table 6.4. Initial simulations did not predict the extent of release seen in the later
phase of release of these ALLT formulations. This was likely due to the slight but significant
permeability of chloride that was not a factor during loading. With this rationale, these
ALLT release profiles were used to fit a chloride release rate constant, kmCl, and resulted in
the fit shown in Figures 6.4a and b. Based on this fit, kmCl was estimated to be 3.8 ± 0.4 x 10-4
hr-1. Based on the 100 nm diameter of these liposomal formulations, the permeability of the
−

chloride anion, 𝑃𝑚𝐶𝑙 , can be estimated by the following equation.
−

𝑑

𝑃𝑚𝐶𝑙 = 𝑘𝑚𝐶𝑙
6
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(44)

The resulting permeability coefficient for chloride is 1.8 ± 0.2 x 10-13 cm/s. This value is
lower than other values reported for chloride permeability through phosphatidylcholine
(PC) liposomes and is expected due to the greater rigidity of DSPC bilayers over the PC
bilayers studied by Toyoshima and Thompson.187 In those studies, PC liposomes were a
mixture of DSPC and shorter saturated fatty acids that tend to provide less resistance to
transport and higher permeabilities.50, 53, 187
Table 6.4 Initial conditions used for modeling ALLT release
Ammonium Besylate ALLT
Loading Temp

37 °C

Loading TPT

60 µM

𝑇𝑖 (0) (mM)a

13.7

23.4

𝐶𝑙 𝑇,𝑖 (0) (mM)

5.52b

𝑁𝑖 (0) (mM)b

263

(NH4)2SO4 ALLT

60 °C

130 µM 180 µM

60 °C

60 µM

180 µM

130 µM

29.5

24.6

61.2

42.6

7.09b

9.12b

68 ± 8c

250± 60c

140 ± 60c

257

253

255

220

453

𝐶𝑙 𝑇,𝑜 (0) (mM)

0.13

𝑁𝑜 (0) (µM)

0, 12, or 60

Values calculated based on initial amount of TPT observed in release study and entrapped
volume (𝐿𝑖 (0) = 𝑇𝑇𝑜𝑡𝑎𝑙 (0)⁄𝑓𝑣 )
a

b
c

Value obtained from loading model simulation of final experimental loading time point.
Fitted value from release profile with 95% CI.
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Figure 6.3. Release at 37 °C in PBS of ALLT formulations loaded at 37 °C.
Release was monitored by the changes in the fractions of lactone (A) and
carboxylate (B) TPT (L(t) and C(t), respectively) for TPT actively loaded into
ABLs (loaded with TPT suspension concentrations of 60, 130, and 180 µM TPT
as designated in the legend). The lines through the data points represent the fits
of the profiles to the ALLT release model accounting for chloride permeability.
Simulations of the interconversion of pure lactone TPT spiked in the pH 7.4
buffer is also shown to emphasize the retardation in ring-opening due to
liposomal release kinetics while ALLT loaded in the presence of a 180 µM TPT
was simulated assuming no Cl permeability to illustrate its effect on release.
The intravesicular pH was also calculated to reiterate the low intravesicular pH
maintained during these release studies (C).
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6.3.3.2 Effect of ammonia transport on ALLT release
Preliminary simulations from Chapter 5 indicated the concentration of extravesicular
ammonia in release media could alter the intravesicular pH and subsequently accelerate
release with higher ammonia concentrations. In Figure 6.3c, the intravesicular pH remains
low as ammonia is continuously released because no ammonia was present in the PBS
buffer.

The profiles in Figure 6.4, however, show the effect of ammonia influx on

intravesicular pH and subsequently release kinetics. As more NH 4Cl is added to the pH 7.4
PBS release media, the rate and extent of release also increases. Simultaneous fitting of
release profiles in PBS with varying concentrations of NH 4Cl were conducted for ALLT
suspensions using 60 uM TPT in the loading solution (Figures 6.4a and b). Fitting these
profiles identified a shift in the pKA for intravesicular ammonia which was estimated to be
1.49 ± 0.05. The change in intravesicular pH due to ammonia influx can be calculated and
shows the considerable increase in pH resulting in accelerated release (Figure 6.4c). This
change in the pKA allows prediction of the release kinetics in the presence of 60 µM NH 4Cl
for the other ALLT formulations studied (Figures 6.4d & e).
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Figure 6.4. The effect of ammonia transport on ALLT release at pH 7.4 (PBS)
and 37 °C. After active loading in a 60 µM TPT suspension using ABLs, TPT
release was monitored in PBS with the NH4Cl concentrations displayed in the
legend. The changes in L(t) and C(t) are used to monitor release and shown in
(A) and (B) respectively while intravesicular pH is shown to illustrate the effect
of ammonia influx (C). The shift in ammonia pK A fit to these release profiles is
shown by the plotted lines. This shift in pK A was able to predict the release
profiles in 60 µM NH4Cl for the ALLT formulations listed in the legends of (D)
and (E). Because ammonia may evaporate over time from solutions, the release
kinetics of can slow over time as shown in (F) and (G). The loss of ammonia
from the PBS buffer over time reduces the influx of ammonia and lessens the
increase of intravesicular pH (H).
Another factor which may impact release profiles is the evaporation of ammonia during
release studies. Even through rubber stoppers were used to seal the suspension vials
during release studies, the gaseous form of ammonia may fill the air space in the vial and
possibly diffuse through the rubber stopper, and be released when the vials are open for
sampling. This appears to have some effect on the release profile of ALLT in the presence of
PBS with 12 µM NH4Cl (Figure 6.4a & b). The model expects more TPT to be released than
that observed at later time points. Ammonia evaporation could cause such an effect as it
would effectively lower the intravesicular pH as extravesicular ammonia is depleted.
Further evidence of ammonia evaporation from the PBS with 12 µM NH4Cl is illustrated by
the release profiles in Figure 6.4g and h. Release studies were repeated in the same buffer 7
and 10 days after it was initially made, clearly showing slower release the longer the buffer
has aged. Fitting of the initial extravesicular ammonia concentration for these release
profiles estimated these concentrations to be 8.6 ± 1 and 1.9 ± 0.6 µM NH4Cl in the buffer
after 7 and 10 days of aging respectively, further supporting the likelihood of ammonia
evaporation altering release kinetics.
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6.3.3.3 Effect of loading at high temperature (60 °C) on ALLT release
Loading for 30 minutes at 60 °C achieved higher TPT loading efficiencies than loading
for 72 hrs at 37 °C (see Figure 6.5). This is expected due to the bilayer existing in its more
permeable liquid crystalline phase rather than its more rigid gel phase. 135 The ALLT’s made
with the 60 µM TPT loading solution had the highest encapsulation efficiency, which was
similar to previous reports of TPT loading with (NH4)2SO4 liposomes.62
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Comparison of the loading efficiencies of TPT at different

temperatures and suspension conditions. Experimental values were calculated
based on the quotient of the initial TPT suspension concentration and ratio of
volume entrapped ( 𝐿𝑖 (0) = 𝑇𝑇𝑜𝑡𝑎𝑙 (0)⁄𝑓 , determined by HPLC) compared to that if
𝑣

the entire amount of TPT in the loading suspension had been entrapped in the
intravesicular volume.
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Modeling release used the initial conditions in Table 6.4. Initially, release studies for
these formulations were conducted in PBS without any NH 4Cl; however, no significant
release was observed (> 96% still lactone after 72 hours). Release was then studied in PBS
containing 60 µM NH4Cl to increase release, resulting in the profiles of lactone and
carboxylate TPT in Figure 6.6a and b respectively. As expected, the intravesicular pH is
raised due to the influx of ammonia (Figure 6.6c) to increase release. The simulation in
Figure 6.6d of the precipitate dissolution occurring during release from these formulations
reveals the unique profile of release seen due to the high loading temperatures. Initially,
′
𝑇𝑖(𝑎𝑞) 𝐶𝑙𝑖(𝑎𝑞) ≤ 𝐾𝑠𝑝
and dissolution of precipitate occurs. Meanwhile, the influx of chloride is

occurring in the ALLT formulations loaded using solutions of 60 and 130 µM TPT and
liposomes with aqueous cores containing NH4C6H6SO3 and (NH4)2SO4 respectively. The
initial concentration of 𝐶𝑙𝑖(𝑎𝑞) in the formulations was calculated to be 45 and 96 mM,
respectively. These concentrations are lower than that of the extravesicular compartment
(ClT,o of 0.13 M) which remains relatively constant during release studies due to the small
′
fraction of encapsulated volume. As precipitate is dissolved and 𝑇𝑖(𝑎𝑞) 𝐶𝑙𝑖(𝑎𝑞) > 𝐾𝑠𝑝
is

satisfied, release is halted by this chloride influx. In the case of the ALLT formulation loaded
with a loading solution of 180 µM TPT and liposomes containing NH4C6H6SO3, 𝐶𝑙𝑖(𝑎𝑞) is
initially 190 mM, higher than ClT,o, so TPT release continues to release due to efflux of
′
chloride after 𝑇𝑖(𝑎𝑞) 𝐶𝑙𝑖(𝑎𝑞) > 𝐾𝑠𝑝
.

The K’sp determined for each release profile required correction for the fraction of total
aqueous intravesicular TPT in the monomeric (f1), cationic (f+) state. This correction can be
calculated using the equation below.

′
𝐾𝑠𝑝 = 𝑓1 𝑓 + 𝐾𝑠𝑝
=

𝐻𝑖+ (−1+√1+8𝐾2𝑇𝑖(𝑎𝑞))
4𝐾2𝑇𝑖(𝑎𝑞) (𝐻𝑖++𝐾𝐴1 )
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′
𝐾𝑠𝑝

(45)

−1
The importance of this correction is illustrated by Figure 6.6e. A plot of 𝑇𝑖(𝑎𝑞) against 𝐶𝑙𝑖(𝑎𝑞)
−1
is not linear while linearity is quite apparent when 𝑓1 𝑓 + 𝑇𝑖(𝑎𝑞) is plotted against 𝐶𝑙𝑖(𝑎𝑞)
. This
−1
linearity is expected as the slope should be 𝐾𝑠𝑝
. Using these corrections, the average Ksp

was determined to be 1.39 ± 0.08 x 10-5. Figure 6.6e also demonstrates that the Ksp is
independent of the ammonium salt, NH4C6H6SO3 or (NH4)2SO4, used to achieve active
loading. This provides further evidence supporting the hypothesis that the precipitate
formed is the chloride salt rather than a besylate or sulfate salt of TPT.
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Figure 6.6 The effect of high temperature loading (60 °C) on ALLT release in pH
7.4 PBS at 37 °C. The fractions of lactone (A) and carboxylate (B) TPT were
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monitored from ALLT formulations loaded using different concentrations of TPT
and liposomes containing the ammonium salts described in the legend. The
lines represent the profile obtained after fitting the release model which
accounts for the formation of TPT precipitate within the liposomes. The effect of
ammonia influx on intravesicular pH is shown (C) to illustrate that the initial
phase of release is a result of this increased pH while the dissolution of drug
′
precipitate is shown (D) to illustrate the point at which 𝑇𝑖(𝑎𝑞) 𝐶𝑙𝑖(𝑎𝑞) > 𝐾𝑠𝑝
is

reached and TPT release is greatly reduced as it becomes governed by the flux of
chloride.

′
Because a 𝐾𝑠𝑝
was fit for each release profile, corrections for

dimerization and pH were required (E).

Without these corrections, the

−1
relationship between 𝑇𝑖(𝑎𝑞) and 𝐶𝑙𝑖(𝑎𝑞)
(filled-in symbols) exhibits poor

linearity. These corrections were incorporated by plotting 𝑓1 𝑓 + 𝑇𝑖(𝑎𝑞) against
−1
𝐶𝑙𝑖(𝑎𝑞)
(empty symbols). The trend is linear even though the data represent

liposomal formulations containing besylate (circles) and sulfate (triangles)
anions within the aqueous core.

6.4 Discussion
6.4.1 Effect of TPT ion-pairing, dimerization, and intravesicular pH on active
loading and subsequent release kinetics
The significance of ion-pairing and dimerization become apparent upon simulation of
the variables these factors significantly influence. These factors are shown in Figure 6.7. In
𝑑 𝐿𝑧

6.7a, the uptake rates corresponding to those of the zwitterion ( 𝑑𝑡𝑖 = 𝑟𝑧,𝑖 ) and ion-pair
𝑑𝐿𝐶𝑙𝑖

(

𝑑𝑡

= 𝑟𝑖𝑝,𝑖 ) clearly illustrate biphasic uptake as the ion-pair is rapidly taken up in the

initial phase of release until enough chloride accumulates within the intravesicular
compartment. At this point, the influx of zwitterionic TPT dominates uptake and provides
enough additional TPT to stimulate efflux of the ion pair from the intravesicular
compartment, further slowing uptake at later times.
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Dimerization affects loading in drastically different ways between the intra-and extravesicular compartments. Both of these effects are illustrated by Figure 6.7b. Focusing on
the extravesicular compartment first, the fraction of the initial amount of lactone TPT still
0
present in the loading solution (i.e. 𝑓𝑇,𝑜
= 𝐿𝑜 ⁄𝐿𝑜 (0)) decreases faster than the fraction of
0
initial monomer (𝑓1,𝑜
= 𝐿1,𝑜 ⁄𝐿1,𝑜 (0) still present in the loading solution. This illustrates the

ability of TPT dimerization to prolong the faster uptake phase. Dimerization also affects the
intravesicular compartment by greatly reducing the effective concentration of the
permeable species within the intravesicular compartment. This is represented with the
fraction of intravesicular TPT in the monomeric form (i.e. 𝑓1,𝑖 = 𝑇1 ⁄𝑇𝑖 )
0.0014
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Figure 6.7 The effects of ion pairing and dimerization on TPT active loading at
37 °C. (A) The uptake rates of TPT as its zwitterion, rz,i, and ion-pair, rip,I, forms
are shown to illustrate each species’ contribution to the uptake profiles
observed during active loading at the concentrations of TPT used in the loading
solution (see legend). (B) Dimerization prolongs the initial phase of rapid uptake
0
as the change in monomer concentration over time (represented by 𝑓1,𝑜
) is

slowed relative to the change in total TPT concentration in the loading solution
0
(illustrated here with the profile of 𝑓𝑇,𝑜
). Meanwhile, the fraction of total

intravesicular drug in the monomeric form, f1,i, is shown to be greatly reduced in
the inset at the top right.
Similar effects are present for ALLT release and are shown in Figure 6.8. In Figure 6.8a,
the rate of ion-pair release is shown to be far greater than the rates of zwitterion release or
chloride influx when there is no extravesicular ammonia initially present in the buffer.
Under these conditions, zwitterion permeablity is negligible and release is greatly slowed
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after the concentration of ion-pair is depleted over 90%. This is illustrated by Figure 6.8b.
At the same time, however, total intravesicular TPT is only depleted by ~ 50 %.
Upon the additon of ammonia to the extravesicular release media, the influx of ammonia
and subsequently the increase in intravesicular pH (see Figure 6.4c) has a dramatic effect
on the rate of zwitterion release.

This is illustrated by Figure 6.8c.

For the ABL

formulations loaded in the presence of a 60 µM solution of TPT, rz,i increases over 1000-fold
after the addition of 60 µM NH4Cl. With the zwitterion dominating release under these
conditions, release proceeds to completion at this higher intravesicular pH (see Figure
6.8b). Figure 6.8c also shows this effect is independent of the concentration range of TPT
studied here.
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Figure 6.8 The effects of ion-pairing, dimerization, and pH on ALLT release at
37 °C. (A) Simulated rates of TPT release attributed to its zwitterionic, rz,i, and
ion-paired, rip,i, forms are shown to illistrate the ion-pair is the dominant species
governing release when the extravesicular buffer does not contain NH4Cl. (B)
The slow terminal phase of release seen under the conditions in A is the result of
ion-pair depletion well before that of total TPT. This is illustrated for the ALLT
loaded in the presence of 60 µM TPT by normalizing with respect to the intial
amount of ion-pair and total TPT in the intravesicular compartment (LCli(0) and
Ti(0), respectively). (C) The release rates due to increases in intravesicular pH
are shown for ALLT loaded in the presence of 60 µM TPT, illustrating rz,i
increases dramatically and drives release to completion as ammonia
concentrations are increased in the extravesicular buffer. The inset shows
similar rates (i.e. much greater) of zwitterion release in PBS with 60 µM NH 4Cl
for all the loading conditions employed. The legends in A and the insets refer to
the concentration of TPT used during acive loading while the legends for B and C
refer to the amount of NH4Cl added to the extravesicular buffer.

6.4.2 Significance of loading temperature and precipitate identity
Due to the rapid uptake of TPT at 60 °C, direct experimental observations of the loading
kinetics of TPT could not be achieved. Furthermore, assuming the increases in the species’
permeabilities would be proportional would not be appropriate since the temperature
dependence of their water partition coefficients are unknown and the mechanism of
transport for ion-pairs and small anions is highly debated.44,

153, 188, 189

Even so, several

inferences can be made upon comparison of the values estimated by the loading and release
models used during data regression. Figure 6.9a illustrates such a comparison with the
Cl:TPT ratios estimated from these models to be present at the end of loading at 37° and 60
°C. While more TPT is present than Cl after loading at 37 °C, the opposite is the case based
on the precipitation model used to fit the release profiles of the high temperature-loaded
ALLTs. Furthermore, extrapolations from the 37 °C loading model would predict a decrease
rather than an increase in the Cl:TPT ratio based on the amount of entrapped TPT observed
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after loading at 60 °C (see Figure 6.9b). This suggests that the relative changes in species’
permeability are not proportional (i.e. have different activation energies). Based on these
ratios being >1:1 and the observation that the initial chloride concentrations reported in
Table 6.4 are ≤ that of the loading solution (𝐶𝑙 𝑇,𝑜 = 0.25 𝑀), it is also likely that chloride
transport is greatly dependent upon Cl- as well as the ion pair. This conclusion is based on
the observation that the maximum Cl:TPT ratio achievable by ion-pair transport would be 1
while the total amount of intravesicular Cl loaded would be ≥ 𝐶𝑙 𝑇,𝑜 if Cl- permeability was
the main driving force behind Cl transport.
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Figure 6.9. Changes in the intravesicular Cl:TPT ratio provide insight on the
mechanism of TPT uptake at 60 °C. (A) Three different ratios of intravesicular
Cl:TPT are shown for three ALLT formulations with varying combinations of
TPT loading concentrations and ammonium salts. The three Cl:TPT ratios for
each formulation are estimated based on the 37 °C loading model after 72 hrs of
uptake, the 37 °C loading model after 300 hrs of uptake to achieve the
intravesicular concentrations observed from loading at 60 C°, and the release
model which accounts for TPTHCl precipitate. (B) The uptake profile of
intravesicular Cl simulated by the 37 °C loading model for the three TPT loading
concentrations studied (see legend). The vertical line indicates the point at
which this model achieves the same intravesicular TPT concentration as that
determined after loading for 30 min at 60 °C.
In addition to these possible changes to the mechanism of uptake at higher temperature,
these higher intravesicular chloride concentrations are biased due to the model assuming
the Ksp governs precipitation of TPTHCl rather than anion of the ammonium salt used for
loading. This assumption is necessary because of the unique condition of ion-pair transport
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across the bilayer. The transport of both drug and the counterion of its precipitated salt,
chloride, is necessary to account for the burst phase of release observed with ALLT
formulations loaded at 60 °C. This effect is better illustrated by comparing simulations of
release profiles when another anion forms the TPT salt.
Under these conditions, the transport equations governing the extravesicular
compartment (Eqns. 28, 30 and 32) and intravesicular TPT in the presence of precipitate
(Eqn. 36a) do not change while intravesicular chloride transport reverts back to Eqn. 32a.
In the case of a monovalent anion (benzene sulfonate for the purpose of these simulations),
the rate of precipitate dissolution follows the following condition:
′
If: 𝐾𝑠𝑝
≤ 𝑇𝑖(𝑎𝑞) 𝐵𝑖(𝑎𝑞)

𝑑𝑇𝐵𝑖(𝑠)
𝑑𝑡

=−

𝑑𝑇𝑖(𝑎𝑞)
𝑑𝑡

(46)

where 𝐵𝑖(𝑎𝑞) and 𝑇𝐵𝑖(𝑠) are the concentrations of benzene sulfonate in the intravesicular
′
solution and the TPT salt respectively. In the instance where 𝐾𝑠𝑝
> 𝑇𝑖(𝑎𝑞) 𝐵𝑖(𝑎𝑞) , there

should be no precipitate left, 𝑇𝐵𝑖(𝑠) = 0, and intravesicular TPT transport follows Eqn. 28.
With a rate equation for 𝑇𝐵𝑖(𝑠) , 𝐵𝑖(𝑎𝑞) can simply be expressed with the following mass
balance.
𝐵𝑖(𝑎𝑞) = 𝐵𝑇 − 𝑇𝐵𝑖(𝑠)

(47)

where BT is the total concentration of benzene sulfonate. The pH equation (Eqn. 9) may be
satisfied by substituting 𝐵𝑖(𝑎𝑞) for 𝐵𝑖− . Lastly, the initial conditions to define the amount of
precipitate and soluble drug and counterion must be solved. This can be performed with
Eqns. 40a and b by substituting 𝐵𝑇 (0.3 M) for 𝐶𝑙 𝑇,𝑖 (0). Using these equations, release in the
presence of TPT-besylate salt was simulated at varying fractions of total drug precipitated
(𝑓𝑠 = 𝑇𝐵𝑖(𝑠) (0)⁄𝑇𝑖 (0)) and compared to the observed release profile and fit to the
precipitate model which assumes TPTHCl is the salt. This is illustrated in Figure 6.10.
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These simulations show very different release profiles than those observed experimentally
due to the presence of intravesicular Cl in both ammonium sulfate and besylate ALLTs. This
proposed mechanism of ion-paired TPT-Cl loading and precipitation at high temperatures
may also explain the presence of TPT salts within liposomal TPT formulations containing
various intravesicular solutions. This effect was illustrated in a study by Abraham et. al
which showed intravesicular precipitates formed after TPT loading in liposomes containing
(NH4)2SO4, Mn SO4, citrate, and MnCl2.64.
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Figure 6.10 The identity of TPT salt affects release. (A) The change in lactone
was simulated for ALLTs loaded using a 180 µM solution of TPT.

The

simulations assumed TPT was precipitaed as a besylate salt and the resulting
changes in L(t) are shown at varying fractions of TPT initially precipitated, fs
(see legend), while the inset shows the data and fitted model which assumes a
TPTHCl salt. The points at fs=0 are data from the ALLT formulation loaded at 37
°C (using 180 µM TPT), and the dotted line indicates the profile generated from
the code used to simulate this precipitation model. B) The simulations in A were
normalized to fraction retained to illustrate the release profiles more clearly.
The solid line shown in the resulting simulation uses the TPTHCl precipitate
model used for the inset of A.

The simulations for the TPT-besylate

precipitation model used the initial conditions for ALLTs loaded at 37 °C and 60
µM NH4Cl in the release media. Varying these initial conditions resulted in
accelerated or slowed release profiles but showed the same trends as a function
of precipitate present.
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6.4.3 Implications of loading conditions on optimizing release kinetics
The effect of chloride on loading and release of TPT is considerable based on the results
of this study. These effects could be exploited for controlling release kinetics by simply
altering the amount of chloride contained in the loading solution. This would be especially
advantageous at high loading temperatures where intravesicular TPTHCl precipitate is
formed.

Further studies are needed to use this chloride effect as an advantage in

formulation development. The current findings were only able to indicate that ion-pairing
and 𝐶𝑙 − permeabilities both contribute to TPT active loading at higher temperature since
direct measurement of their respective permeabilities was not possible under these
conditions. Without these permeabilities, predicting how much chloride would need to be
added to the loading solution is not possible. Even so, the potential to alter the relative ratio
of fast-to-slow release phases of TPT in these liposomal formulations is worth further
exploration as a tunable drug release system.

6.5 Conclusions
The results of this study provide a mechanistic understanding of the factors governing
the active loading process for liposomal TPT.

The loading model developed herein

combined with experimental observations reveals TPT transport across the lipid bilayer is
achieved in part by ion-pairing with chloride and affected by the drug’s dimerization in
solution. To the author’s knowledge, this is the first report demonstrating significant
bilayer transport of a large cationic molecule due to ion-pairing. Furthermore, subsequent
release studies conducted with these liposomes of actively-loaded TPT were used to
develop a mechanistic release model which incorporated the effect of drug precipitation on
liposomal release kinetics.

Mathematical modeling also identified the TPTHCl as the

precipitated salt rather than the other anions present in the intravesicular core of the
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liposome. The mechanistic underpinnings identified here for active loading of TPT and its
subsequent release will be useful in future studies which aim to optimize the TPT loading
process to provide tunable drug release kinetics via manipulations of the chloride-to-TPT
ratio. The mathematical principles and mechanistic methodology used here should also be
applicable to developing loading and release models for other liposomal formulations of
pharmaceutical agents.

Copyright © Kyle Daniel Fugit
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CHAPTER SEVEN
Mechanistic Modeling Provides Insights on Doxorubicin Release,
Partitioning, and Conjugation Stability in Polymeric Micelles
7.1 Introduction
Nanoparticles such as dendrimers, liposomes, and polymeric micelles have been heavily
explored as drug carriers for the treatment of various human diseases including infection
and cancer.2-4 These nanoparticulate systems are attractive for pharmaceutical applications
for two main reasons: 1) their ability to entrap and release drug payloads in a manner
capable of altering drug pharmacokinetics via increased drug solubility or modulated drug
release from the particle3, 5 and 2) their unique size and multitudes of surface chemistry
may potentially aid in reducing systemic toxicity through passive and active targeting
respectively.3-5, 10-13 While many types of nanoformulations have been developed to take
advantage of these properties, few have had clinical success. Part of this low success rate
may be attributable to differences in release rates observed during in vitro characterization
studies and those which occur in vivo.
There have been many methods used to characterize drug release kinetics from
nanoparticles;115-117 however, stringent validation of these in vitro methods is necessary as
many environmental effects in vitro may alter observed drug release kinetics. Part of this
validation requires mechanistic models which deconvolute these environmental effects
from the intrinsic release parameters governing drug release.118, 197 With models capable of
mechanistically describing nanoparticle drug release, incorporation of in vivo conditions
would be possible and ultimately lead to accurate in vitro/in vivo correlations. Such
correlations would reduce much of the costs incurred during preclinical development due
to extensive animal testing and unguided formulation optimization. To this end,
considerable efforts have been made to establish mechanistic drug release models for
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liposomal formulations;118, 130 however, similar models have yet to be developed for other
nanoparticles. The construction of such models for other nanoparticles will require the
unique physicochemical properties of the drug, particle, and those of the drug-particle
system to be considered.
One of these systems which has received considerable attention is polymeric nanoassemblies.5, 65 These self-assembled nanoparticles are unique structures which provide a
plethora of characteristics that may be exploited for altering drug release (e.g. particle size,
charge, hydrophobicity, and conjugation sites for drug). While these may be advantageous
to altering drug release kinetics, they may also result in a complicated drug release
mechanism. For example, block copolymer micelles are generally composed of a hydrophilic
shell and a hydrophobic core. Drug payloads can partition into the core of the micelle
typically due to the drug’s affinity for the particle’s hydrophobic or highly-charged core.5, 65,
66

Over time, drug is released from these polymeric micelles due to a combination of kinetic

factors (i.e. drug diffusion and/or stability of drug-polymer linkage) and thermodynamic
factors (i.e. complexation/absorption to the micelle core, CMC) intrinsic to the
drug/polymer system and independent of the release environment.
Further complexity is added when nanoparticles are engineered to respond to external
stimuli such as heat, electromagnetic waves, enzymatic activity, or pH. 5, 63, 65, 71-79 Chemically
conjugating drugs to the block copolymers is another way to alter drug release kinetics and
adds another dimension to the mechanism of drug release. In several instances, these drugconjugated micelles exhibit a biphasic drug release pattern (i.e. burst drug release followed
by an extremely slow drug release phase) that varies depending on the pH of release
medium.80-83
In this study, a mathematical was developed to describe hydrazone-conjugated
doxorubicin (DOX) release from block copolymer micelles. The block copolymers were
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composed of 12 kDa poly(ethylene-glycol) (PEG) and 16 hydrophobic repeating units and
conjugated with DOX using a hydrazone linkage. Because hydrazone bonds have been
shown to be pH-sensitive (i.e. responsive to lysosomal pH),80, 81, 198 multiple drug release
studies were performed at pH 5.0 and pH 7.4. Spacer insertion prior to the hydrazone
moiety was previously shown to alter drug release.

80, 82, 83, 102, 199-201

As such, block

copolymer micelles with glycine (GLY) or methyl 4-aminobenzoate (ABZ) spacers and
another formulation without a spacer (HYD) were studied to assess how spacer
modification mechanistically altered DOX release.

Dynamic dialysis was used as the

primary method to monitor release. The dynamic dialysis setting provided an additional
physical barrier (i.e. dialysis membrane) to the removal of released, unconjugated DOX from
the micellar solution. The kinetics of drug transport across the dialysis membrane were
incorporated to isolate its effects on observed drug release profiles and generate intrinsic
kinetic release rate constants for drug release from the block copolymer micelles. Initial
modeling indicated instability of the hydrazone bond during prolonged storage and was
confirmed with subsequent experiments.

Additionally, a non-sink release method

previously developed to determine both release kinetics and drug partitioning 197 was
adapted to determine the extent of free DOX partitioning into the HYD micelle formulations
and validate the mechanistic model. Using this mechanistic model, release parameters were
generated to identify the factors governing the pH-sensitive release of DOX observed by
these micelle formulations. This approach and the subsequent findings from this study will
provide useful guidance to drug release analysis for future polymeric micelle drug carriers.

189

7.2 Materials and methods
7.2.1 Materials
L-aspartic

acid

diisopropylcarbodiimide

β-benzyl
(DIC),

ester,

anhydrous

hydrazine,

4-(dimethylamino)

pyridine

benzene,
(DMAP),

N,N’N-

Hydroxysuccinimide (NHS), N,N-dimethylformamide, anhydrous N,Ndimethylformamide
(DMF), anhydrous dimethylsulfoxide (DMSO), ethanolamine, anhydrous ethyl ether,
anhydrous hexane, anhydrous tetrahydrofuran (THF), triphosgene, acetate buffer solution,
phosphate buffer solution, methyl 4-aminobenzoate, O-Benzotriazole-N,N,N’,N’-tetramethyluronium-hexafluoro-phosphate (HBTU), sodium hydroxide (NaOH) were purchased from
Sigma-Aldrich (USA). Glycine-OMe is from Novabiochem (SUI). α-Methoxy-ω-amino
poly(ethylene glycol) (PEG-NH2, MW=12,266) was purchased from NOF Corporation
(Japan). Doxorubicn hydrochloride was purchased from LC Laboratories (USA). Slide-ALyzer® dialysis cassettes with 10,000 MWCO, Sephadex LH-20 gels, potassium biphthalate
sodium hydroxide buffer solution, potassium phosphate monobasic buffer solution, and 96well plates were purchased from Fisher Scientific (USA).

Amicon-Ultra centrifugal

ultrafiltration devices with MWCO 10,000 were purchased from Millipore (USA).

7.2.2 Preparation and characterization of polymeric micelles
Block copolymers of PEG-polyasparte (PEG-pAsp) were synthesized by Dr. Ponta using
a method previously reported.83 The synthesis involved the following steps: preparation of
β-Benzyl-L-aspartate N-carboxy anhydride monomer (BLA-NCA), block copolymer
synthesis of PEG-poly(16 β-benzyl-L-aspartate BLA) (PEG-pBLA), formation of PEG-polyaspartate [PEG-p(Asp)] with hydrazide [PEG-p(Asp-Hyd)] or with a glycine (Gly) or methyl
4-aminobenzoate (Abz) spacer between the aspartate and hydrazide (PEG-p(Asp-Gly-Hyd)
and PEG-p(Asp-Abz-Hyd) respectively) followed by DOX conjugation via a hydrazone bond.
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7.2.2.1 BLA-NCA monomer synthesis
BLA-NCA was prepared by adding triphosgene (2.88 g, 9.7 mmol) to β-benzyl –Laspartaten (5.0 g, 22.4 mmol) in dry THF (100 mL). The reaction proceeded at 45°C under a
N2 atmosphere. Once the solution became clear, anhydrous hexane was slowly added until
NCA crystals appeared, then rapidly disappeared. Crystallization of BLA-NCA was achieved
after storage in −20°C.
7.2.2.2 PEG-pBLA synthesis
These BLA-NCA crystals were used for synthesis of PEG-pBLA block copolymers via
ring-opening polymerization of BLA-NCA. Using the terminal primary amine of PEG-NH2 as
the initiator, block copolymers containing 16 BLAs per PEG molecule were synthesized by
dissolving BLA-NCA (183 μmol) monomers and PEG (7.67 μmol) in separate flasks to
achieve 50 mg material/mL anhydrous DMSO under a N2 atmosphere. Polymerization was
performed at 45°C for 2 days after the dissolved monomers were added to the PEG solution.
Purification of the resulting block copolymers were was achieved by ether precipitation
then freeze drying from benzene. From this purified PEG-pBLA, three types of PEG-pAsp
block copolymers were synthesized with or without an additional spacer between the
polymer aspartate side chain and the DOX-hydrazone linkage.
7.2.2.3 PEG-p(Asp-Hyd) functionalization
Freeze-dried PEG-p(BLA) (56.42 μmol) was dissolved in dry DMF, and anhydrous
hydrazine (9034 μmol) was added to the solution. PEG-p(Asp-Hyd) was produced after
anhydrous hyrdrazine (9034 µmol) was added to the PEG-pBLA solution and allowed to
react for one hour at 40°C under a N2 atmosphere and constant stirring. The block
copolymers were collected by ether precipitation and subsequent freeze drying.

191

7.2.2.4 Synthesis of PEG-p(Asp-Gly-Hyd) and PEG-p(Asp-Abz-Hyd) block copolymers
Purified PEG-pBLA was subjected to 01. N NaOH to deprotect its side chains and
subsequently yielded PEG-p(Asp) block copolymers. Spacer modification was performed by
dissolving freeze dried PEG-p(Asp) (12 μmol) in THF and reacting the block copolymer with
glycine methyl ester (GlyOMe) (400 μmol) and methyl 4-aminobenzoate (AbzOMe) (450
μmol) using HBTU at 40°C overnight. Precipitates were removed through filtration at the
end of the reaction. Ether precipitation followed by dialysis in a deionized water: methanol
(50:50) solution was used to remove any unreacted GlyOMe and AbzOMe from the sidechain modified block copolymers. Hydrazide (Hyd) functionalization of PEG-p(Asp-GlyOME)
and PEG-p(Asp-AbzOMe) was by removal of the methy esters and amide formation. This
was performed by adding excess hydrazine with respect to number of repeating units (490
μmol, and 515 μmol for the GlyOMe and AbzOMe modified block copolymers, respectively)
to PEG-p(Asp-GlyOMe) (6.5 μmol) and PEG-p(Asp-AbzOMe) (6.8 μmol) in DMF and reacting
at 40°C for 1 h to obtain PEG-p(Asp-Gly-Hyd) and PEG-p(Asp-Abz-Hyd) block copolymers,
respectively.

The block copolymers were purified and recovered by repeated ether

precipitation and freeze drying.
7.2.2.5 DOX conjugation via hydrazone bond
DOX was conjugated to each of the three block copolymers via a hydrozone linkage
between the aspartate side change and the 13 position ketone on DOX. The reaction
between DOX and PEG-p(Asp-Hyd) (750 mg, 53 μmol), PEG-p(Asp-Gly-Hyd) (899 mg, 59
μmol), or PEG-p(Asp-Abz-Hyd) (824 mg, 50 μmol) occurred in DMSO over two days under
gentle shaking at 40°C to produce PEG-p(Asp-Hyd-DOX), PEG-p(Asp-Gly-Hyd-DOX), or PEGp(Asp-Abz-Hyd-DOX) respectively. Physically-entrapped DOX and DMSO were initially
removed by ether precipitation. The block copolymers were then dissolved in methanol
and eluted through a Sephadex LH-20 column for further purification. After elution, the
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block copolymers were dissolved in deionized water and filtered using a 0.22 μm filter. The
final product was obtained after freeze-drying and stored as solids at -20°C.
7.2.2.6 Block copolymer micelle characterization
Once purified, PEG-p(Asp-Hyd-DOX), PEG-p(Asp-Gly-Hyd-DOX), and PEG-p(Asp-AbzHyd-DOX) block copolymers were added to DI water to form HYD, GLY, and ABZ micelles
respectively. Characterization of the block copolymer synthesis is reported elsewhere. 83, 202
For the purpose of these release studies, micelle particle size and ζ-potential were
determined using Zetasizer Nano-ZS (Malvern, UK). Block copolymers were suspended in
DI water to a concentration of 2.0 mg copolymer/mL in triplicate for both analyses (six
samples total). Particle size analysis was based on the average diameter obtained from
number distribution analysis.
DOX loading for the three micelle formulations and subsequent DOX release was
determined from DOX absorption spectra by Dr. Ponta.83,

202

Briefly, standards of DOX

varying in concentration between 0.98 and 250 µM were analyzed by a SpectraMax M5
(Molecular Devices, USA) equipped with variable spectrum filters. Absorbance was found
to be linear at 485 nm over this concentration range. Spectra of DOX conjugated to micelles
was found not to differ from free DOX in solution.202 This allowed DOX concentrations to be
calculated in micelle suspensions during drug release studies from free DOX standards.

7.2.3 Drug release studies
All drug release studies were performed by Dr. Ponta using the particles he developed
above. Release studies were performed at both pH 5.0 and 7.4 using Potassium biphthalate
sodium hydroxide (pH 5.0, 0.01 M ionic strength) and potassium phosphate monobasic
buffer solution (pH 7.4, 0.02 M ionic strength) buffers respectively for all three copolymer
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formulations of micelles. All release conditions were conducted in triplicate for all three
micelle formulations.
7.2.3.1 DOX release monitored by dynamic dialysis: sink conditions
Micelle suspensions of 0.1, 0.5, and 1 mg copolymer/mL were used to fill 3 mL dialysis
cassettes (10,000 MWCO). These cassettes were then dialyzed against reservoirs of the
same buffers used to suspend the micelles at a reservoir: cassette ratio of 5,000:9 (v:v). The
reservoirs were continuously stirred throughout the duration of release studies. During
dialysis, release was monitored over a 72 hour period by withdrawing 0.1 mL samples from
within the dialysis cassettes and analyzing the concentration of DOX using the colorimetric
method already described.
Additional dialysis studies were also conducted to examine DOX transport across the
dialysis membrane along with partitioning of free DOX into the micelle particles. For these
determination of DOX transport across the dialysis membrane, free DOX (0.12 mg/mL)
solutions were put into to dialysis cassettes and dialyzed under the same conditions used
above for DOX-loaded micelle suspensions. Lastly, 0.5 mg copolymer/mL suspensions of
HYD, GLY, and ABZ micelles which had already undergone release for 72 hours were spiked
with free DOX (0.1 mg/mL, 0.17 – 0.25 mg total DOX/mL) and thoroughly mixed. These
suspensions were dialyzed against the same reservoir conditions used in micelle release
studies to observe if partitioning of unconjugated, free DOX into the micelle had any effect
on observed DOX transport across the dialysis membrane.
7.2.3.2 DOX release monitored by ultrafiltration: non-sink conditions
Non-sink studies were performed based on an ultrafiltration method previously
developed in Chapter 3 for use in liposomal release studies. The method was modified by
Dr. Ponta for use with HYD, GLY, and ABZ micelles. Briefly, micelle suspensions (3 mL, 0.5
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mg copolymer/mL) were transferred to scintillation vials and placed in a 37 °C incubator
and gently shaken. At various time points, aliquots (250 µL) of the micelle suspension was
withdrawn and diluted with methanol to 500 µL.

The samples were transferred to an

Amicon® Ultra 0.5 mL centrifugal filter cartridge with 10,000 MWCO Ultracel® membrane.
Ultrafiltration was achieved by centrifugation of these cartridges at 14,000 rpm for 10 min.
After centrifugation, the remaining supernatant was recovered and diluted to 500 µL with
methanol and the process was repeated twice more. Validation of free DOX removal was
performed by ultrafiltration of DOX solutions and by comparison of DOX concentration in
copolymer suspensions spiked with free DOX before and after ultrafiltration.

7.2.4 Determination of unconjugated drug produced during storage
Because of the elapsed time between release studies (approx. 15 months), degradation
of the hydrazone bond may be significant and should be accounted for during modeling.
Two techniques were used to validate the % of unconjugated DOX generated during storage
that was estimated by the mathematical model. Ultrafiltration using the same procedure
described in the non-sink release section was performed on micelle suspensions
immediately after reconstitution. The amount of DOX present in the sample before and
after ultrafiltration was analyzed to calculate the % of DOX conjugated in the suspension.
Secondly, micelle suspensions were passed through a Sephadex LH-20 column and the drug
loading in the eluted volume pertaining to the MW of the copolymer was compared to drug
load before Sephadex calculate the % of DOX conjugated.

7.2.5 Model Development
Several models have been developed for liposomal nanoparticles in which release is
governed mainly by drug permeability through their phospholipid membrane. 50, 60, 63, 124, 127,
128, 130

Other models describing drug release from novel pharmaceutical formulations have
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been developed and to incorporate effects such as Fickian diffusion, particle/drug
dissolution, and polymer degradation/swelling;203, 204 however, these models have not been
applied to nanoparticle formulations. To our knowledge, no such model has been developed
for a micelle formulation in which the drug has been conjugated to the copolymer scaffold of
the micelle. Such a mechanistic model is developed here in collaboration with Dr. Ponta.
The model incorporates two-phase release kinetics attributable to hydrazone bond
hydrolysis of conjugated DOX as well as partitioning of unconjugated DOX into the micelle.
These properties are illustrated by Scheme 7.1. For these studies, dynamic dialysis and
ultrafiltration studies were used to probe and confirm DOX partitioning was a factor in
release studies. The math for both types of release studies are described in the following
sections.

Scheme 7.1.

An illustrated schematic of the mathematical model used to

describe DOX release from the three different micelle formulations studied.
Here, the hydrophilic PEG shell (blue) surrounds the polyaspartate core. In the
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core, two populations of conjugated DOX are shown.

These populations

correspond to fast (𝐶1𝑚 , green) and slow (𝐶2𝑚 , yellow) hydrolysis of the
hydrazone bond and their hydrolysis is governed by rate constants k1 and k2
respectively.

After hydrolysis, unconjugated DOX may stay partitioned in the

micelle nanoenvironment (𝑈 𝑚 ) or reside in the aqueous phase (𝑈 𝑤 ). This
equilibrium is governed by the partition coefficient Kp. In dynamic dialysis
studies, DOX transport though the dialysis membrane is governed by the rate
constant kd and concentration of 𝑈 𝑤 .
Drug release profiles for all three types of micelles and both pH conditions studied were
fit using Micromath Scientist non-linear regression software using a weight factor or two.
7.2.5.1 Release studies monitored by ultrafiltration: non-sink conditions
In release studies monitored by ultrafiltration, the various species of DOX within the
sample vial may be expressed by the mass balance below.
𝑢
𝑀𝑇 = 𝑀1𝑐 + 𝑀2𝑐 + 𝑀𝑚
+ 𝑀𝑤𝑢

(1)

𝑢
Here, 𝑀𝑇 , 𝑀1𝑐 , 𝑀2𝑐 , 𝑀𝑚
, and 𝑀𝑤𝑢 , refer to the total amount of DOX in solution, conjugated DOX

which undergoes fast hydrazone hydrolysis, conjugated DOX which undergoes slow
hydrazone hydrolysis, and unconjugated DOX partitioned into the micelle and aqueous
phases respectively. These terms may be rewritten as the concentrations of total DOX (𝐷𝑇 ),
conjugated DOX undergoing fast hydrolysis kinetics (𝐶1𝑚 ), conjugated DOX undergoing slow
hydrolysis kinetics (𝐶2𝑚 ), and unconjugated DOX in micelle (𝑈 𝑚 ) and aqueous (𝑈 𝑤 ) phases
can be related as described by equation 2.
𝐷𝑇 = 𝑏𝐶1𝑚 + 𝑏𝐶2𝑚 + 𝑏𝑈 𝑚 + 𝑎𝑈 𝑤

(2)

Here, the volume fractions of aqueous and micellar phases (a and b respectively) are used to
relate the total volume of the solution, 𝑉𝑇 , to the volume of aqueous and micelle phases (𝑉 𝑤
and 𝑉 𝑚 respectively). This is expressed by equations 3a and b.
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𝑎=

𝑉𝑤
𝑉𝑇

;𝑏 =

𝑉𝑚

(3a & b)

𝑉𝑇

In these studies, the density of the micelles was not known and assumed to be similar to
that of water which allowed the weight fraction of micelle to be used for volume
calculations. The values used for the different concentration of micelle solutions studied are
found below in Table 7.1.
Table 7.1. Volume parameters used for mathematical modeling of DOX release from block
copolymer micelles
Micelle Concentration

a

b

1.0 mg copolymer/mL

0.9990

0.0010

0.5 mg copolymer/mL

0.9995

0.0005

0.1 mg copolymer/mL

0.9999

0.0001

The differential equations which incorporate two-phase hydrazone hydrolysis kinetics
and govern DOX release are shown below.
𝑑𝐶1𝑚

= −𝑘1 𝐶1𝑚

(4a)

= −𝑘2 𝐶2𝑚

(4b)

= 𝑏(𝑘1 𝐶1𝑚 + 𝑘2 𝐶2𝑚 )

(4c)

𝑑𝑡
𝑑𝐶2𝑚
𝑑𝑡
𝑑𝑈
𝑑𝑡

This system of differential equations may only be solved by defining the initial conditions
for each equation. These conditions must incorporate the initial fraction of total DOX
conjugated to the copolymer (fc), the initial fraction of conjugated DOX in the fast hydrolysis
phase (f) in relation to the total concentration of DOX initially present in solution (𝐶𝑇,0 ).
With these parameters, the initial conditions for equations 4a-c can be expressed.
𝐶1𝑚 (0) = 𝑓𝑐 𝑓𝑏𝐶𝑇,0
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(5a)

𝐶2𝑚 (0) = 𝑓𝑐 (1−𝑓)
𝐶𝑇,0
𝑏

(5b)

𝑈(0) = (1 − 𝑓𝑐 )𝐶𝑇,0

(5c)

Lastly, the concentration profile of DOX obtained by ultrafiltration (𝐷𝑢 ) must defined. This
was done by assuming 𝐷𝑢 was composed of both conjugated DOX and DOX partitioned into
the membrane. This is expressed by equation 6.
𝐷𝑢 = 𝑏(𝐶1𝑚 + 𝐶2𝑚 + 𝑈 𝑚 )

(6)

Solving for Um in terms of U is required to fit 𝐷𝑢 . This may be performed by first defining a
DOX partition coefficient as shown below.
𝐾𝑝 =

𝑈𝑚

(7)

𝑈𝑤

Using this equilibrium expression and the mass balance relating 𝑈 𝑚 and 𝑈 𝑤 to the
concentration of total unconjugated DOX, 𝑈 𝑇 (see equation 8),
𝑈 𝑇 = 𝑎𝑈 𝑤 + 𝑏𝑈 𝑚

(8)

𝑈 𝑚 can be solved in terms of U as illustrated by the following equation.
𝐾 𝑈

𝑝
𝑈 𝑚 = 𝑎+𝑏𝐾

(9)

𝑝

Upon substitution into equation 6, the final equation for 𝐷𝑢 is the result and shown below
by equation 10.
𝐾 𝑈

𝑝
𝐷𝑢 = 𝑏(𝐶1𝑚 + 𝐶2𝑚 + 𝑎+𝑏𝐾
)
𝑝

(10)

7.2.5.2 Release studies monitored by dynamic dialysis: sink conditions
Typically, dynamic dialysis is believed to maintain a “sink” for drug release if an
adequately large reservoir volume is used to maintain the driving force for release and
depletion of released drug from the compartment within the dialysis cassette. However, the
rate of drug transport across the membrane may alter observed release kinetics if initial
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drug release from the nanoparticle formulation is faster, similar,49, 118, 197 or if a significant
fraction of released drug binds to the dialysis membrane or the nanoparticle itself. 49, 118
If one considers the compartment within the dialysis cassette in a context similar to that
already defined in the ultrafiltration studies, the same differential equations governing 𝐶1𝑚
and 𝐶2𝑚 and the mass balances developed there (Equations 1 – 4b) may be used. However,
the differential equation governing unconjugated drug (Equation 4c) must be rewritten to
include DOX diffusion through the dialysis membrane and accumulation in the reservoir
compartment. These events are expressed by equations 11a and b with the parts in red
indicating the features unique to dynamic dialysis.
𝑑𝑈
𝑑𝑡

= 𝑏(𝑘1 𝐶1𝑚 + 𝑘2 𝐶2𝑚 ) − 𝑘𝑑 (𝑎𝑈 𝑤 − 𝑅)
𝑑𝑅
𝑑𝑡

= 𝑘𝑑 𝑓𝑅 (𝑎𝑈 𝑤 − 𝑅)

(11a)
(11b)

Here, R accounts for DOX concentration in the reservoir compartment and fR is the volume
ratio of dialysis tube to reservoir (9/5000). With such a large reservoir volume relative to
the dialysis cassette volume (𝑓𝑅 → 0), the reservoir concentration can be assumed to be
negligible (𝑅 ≅ 0), 𝑑𝑅
may be ignored, and equation 11a may be simplified to the following
𝑑𝑡
equation:
𝑑𝑈
𝑑𝑡

= 𝑏(𝑘1 𝐶1𝑚 + 𝑘2 𝐶2𝑚 ) − 𝑎𝑘𝑑 𝑈 𝑤

(12)

Based on this equation, removal of unconjugated DOX from the dialysis cassette is
dependent upon a rate constant for DOX transport across the dialysis membrane, 𝑘𝑑 , and
the concentration of unconjugated drug in the aqueous phase, 𝑈 𝑤 . Using Equations 7 and 8,
Uw may be rewritten in terms of U and substituted back into equation 12. This is shown by
equations 13a and b.
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𝑈

𝑈 𝑤 = 𝑎+𝑏𝐾

(13a)

𝑝

𝑑𝑈
𝑑𝑡

𝑎𝑈

= 𝑏(𝑘1 𝐶1𝑚 + 𝑘2 𝐶2𝑚 ) − 𝑘𝑑 𝑎+𝑏𝐾

𝑝

(13b)

The initial conditions for this system of differential equations are identical to those used in
the ultrafiltration equations (5a-c).
As a control, spike experiments were also conducted to monitor the effect DOX
partitioning had on the disappearance of unconjugated DOX. This was accomplished by
dialyzing the micelle solution for 72 hours in release medium to minimize the amount of
conjugated DOX before spiking with free DOX. The differential equations are the same for
these experiments as those used for release studies utilizing conjugated DOX (Equations 3a,
3b, and 13b).

The initial conditions for spike experiments, however, required the

concentration of conjugated DOX left after 72 hours of dialysis to be accounted for in the
initial conditions. These corrections are reflected in Equations 14a-c where the terms in
blue indicate the parameters unique to the spike experiments.
𝐶1𝑚 (0) = 𝑓𝑐 𝑓𝑏𝐶𝑇,0 𝑒 −72𝑘1

(14a)

𝐶2𝑚 (0) = 𝑓𝑐 (1−𝑓)
𝐶𝑇,0 𝑒 −72𝑘2
𝑏

(14b)

𝑈(0) = 𝐶𝑆𝑇,0

(14c)

In addition to the terms present in the initial conditions already introduced by Equations
5a-c (𝑓𝑐 , f, and CT,0), the time the micelle solutions were already dialyzed against release
medium used a monoexponential decay for both the fast and slow compartments (with rate
constants k1 and k2 respectively). Because the solution was spiked with DOX solution, the
concentration of this unconjugated DOX, 𝐶𝑆𝑇,0 , was used in equation 14c.
Lastly, dialysis of DOX solutions was also conducted to accurately estimate the rate of
unconjugated DOX transport across the dialysis membrane. Since no micelle material is
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present in these studies, the release of total DOX concentration, 𝐷𝑇 , may be expressed by
equation 15a and its initial conditions are simply the initial concentration of dissolved DOX
in solution (Equation 15b).
𝑑𝐷𝑇

= −𝑘𝑑 𝐷𝑇

(15a)

𝐷𝑇 (0) = 𝐶𝑇,0

(15b)

𝑑𝑡

7.3 Results
7.3.1 Micelle characterization
Characterization of the DOX-conjugated copolymers was reported elsewhere by Dr.
Ponta.202 Upon addition to aqueous solution, these copolymers formed micelles with drug
loading of 26 ± 1.6, 17 ± 1.5, and 26 ± 1.1% by weight while the particle size obtained from
dynamic light scattering resulted in hydrodynamic diameters of 117 ± 37, 54 ± 12, and 58 ±
11 nm for the HYD, ABZ, and GLY micelles respectively. Measurements of ζ-potential were
also taken and found to be 13 ± 0.2, -4.0 ± 0.6, and 0.5 ± 1.5 mV for the HYD, ABZ, and GLY
micelles respectively. Values reported here are averages of triplicate measurements along
with the resulting standard deviation.

7.3.2 Validation of free DOX removal for methods used to monitor release
Both release methods employed in this study have unique conditions which may affect
analysis of release kinetics from observed release profiles.118, 130, 197 In the case of dynamic
dialysis, significant drug binding or absorption may dominate the kinetics observed during
release studies and skew the determination of rate constants and other parameters intrinsic
to the nanoparticle/drug system.118 To assess this factor, free DOX solutions (pH 5.0 and
7.4) were dialyzed under the same conditions used in the micelle release studies. During
these studies, the biphasic release anticipated if DOX binding to the dialysis membrane was

202

not evident, indicating the use of a rate constant for DOX transport across the dialysis
membrane was sufficient for modeling purposes.
Analysis of ultrafiltration studies is affected by incomplete removal of unconjugated
drug during the centrifugation and washing steps.130,
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In the context of these release

studies, ultrafiltration must remove unconjugated DOX in the aqueous phase from the DOX
remaining in the micelle. This was validated two ways. First, free DOX was dissolved in a
50% methanol:water mixture and underwent the ultrafiltration process described in the
methods section. After the ultrafiltration process, spectrometric analysis determined that
no DOX was present in the concentrate. The second confirmation used two identical block
copolymer solutions. The ultrafiltration was performed on three micelle solutions and
three more solutions that were spiked with free DOX. Comparison of DOX present in the
concentrate after ultrafiltration confirmed complete DOX removal as there was no statistical
difference between the group of solutions that was or was not spiked with free DOX.

7.3.3 Model-predicted micelle instability during storage confirmed by other
experimental methods
Initial modeling of the release profiles of DOX required a fraction of DOX to be
unconjugated, fc, at the beginning of the release studies for the 0.1 and 0.5 mg micelle/mL
solutions unlike the 1.0 mg micelle/mL solutions which indicated 100% of DOX was initially
conjugated. While the DOX release studies at 1.0 mg micelle/mL solutions were conducted
shortly after synthesis (within two weeks), the other micelle solutions were constituted
from freeze-dried block copolymer material that had been stored at -20 °C for
approximately 15 months.
Hydrdazone degradation during storage seemed like a plausible explanation; however,
such degradation has not been previously reported for these micelle systems and was
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unexpected. Confirmation that the model-predicted degradation was indeed a factor in the
discrepancies seen in release profiles at different micelle concentrations was confirmed
experimentally by comparing the DOX concentrations before and after ultrafiltration.
Analysis of drug loading before and after running the stored copolymer material through a
Sephadex column to separate free DOX from the DOX-conjugated copolymer was also
performed as a second validation. Values of the percentage of conjugated DOX (𝑓𝑐 × 100%)
calculated from the results of these methods along with those from mathematical modeling
were similar as illustrated by Figure 7.1. Averaging the values obtained from all four
methods for all three micelle formulations resulted in an average percent of DOX conjugated
of 63 ± 3% (95 % CI) after 15 months of storage. For further regression analysis, this
parameters was fixed for the value obtained from size exlculsion experiments (67, 68, and
69 % for HYD, ABZ, and GLY, respectively) to increase the statistical strength of the fitted

% DOX Initially Conjugated

release parameters.

100

Model, pH 5
Ultrafiltration

Model, pH 7.4
Size Exclusion

80

60

40

20

0

HYD

GLY

204

ABZ

Figure 7.1. The graph above displays the % of DOX conjugated (𝑓𝑐 × 100%)
after 15 months of storage determined by mathematical modeling (under both
pH conditions DOX release was monitored) and two other experimental
methods (see legend at the top). Error bars represent 95% confidence intervals.

7.3.4

Characterization of release kinetics of HYD DOX-conjugated block

copolymer micelles
For the HYD micelles, both release profiles obtained from ultrafiltration and dynamic
dialysis (including all three micelle concentrations, spike experiments, and dialysis of free
DOX only) were simultaneously fit to the mathematical release models described in the
model development section. By fitting these profiles, the effects of DOX transport through
the dialysis membrane and the % of unconjugated DOX present due to hydrazone
degradation during storage could be separated from the intrinsic parameters to be
estimated for the DOX/HYD system. The experimental release profiles along with the
resulting profiles obtained by the model-fitted release parameters (see Table 7.2) are
shown below in Figure 7.2a and b for release in pH 5.0 and 7.4 medium respectively. Based
on the values reported in Table 7.2, the main parameters affected by pH are not the rate
constants, but partitioning (Kp) and the fraction of conjugated DOX in the phase fast phase
(f) at each pH.
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Table 7.2. Values of release parameters fitted to mathematical model to describe DOX
release from micelle formulations at pH 5.0 and 7.4
Micelle pH

𝑘1 (hr-1)

𝑘2 × 102 (hr )

𝑘𝑑 (hr )

𝐾𝑝 × 10−3

f

-1

-1

HYD

7.4

0.24 ± 0.1

0.55 ± 0.1

0.81 ± 0.03

2.5 ± 0.6

0.38 ± 0.06

ABZ

7.4

0.27 ± 0.2

0.36 ± 0.1

0.79 ± 0.03

1.1 ± 0.8

0.34 ± 0.06

GLY

7.4

0.30 ± 0.1

0.46 ± 0.1

0.80 ± 0.03

2.2 ± 1

0.25 ± 0.04

HYD

5.0

0.29 ± 0.05

0.45 ± 0.1

0.80 ± 0.03

0.62 ± 0.2

0.68 ± 0.03

ABZ

5.0

≥ 1.15*

0.59 ±0. 2

0.78 ± 0.03

0

0.36 ± 0.05

GLY

5.0

0.64 ± 0.5

0.82 ± 0.1

0.77 ± 0.02

0

0.20 ± 0.05

Values are reported along with 95% confidence intervals
*Value used for generation of statistics as release of fast phase was rate-limited by DOX
transport through the dialysis membrane

A.
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B.
Figure 7.2. DOX release profiles at pH 5.0 (A) and 7.4 (B) obtained for HYD
micelles. The same symbols are used to describe the micelle concentrations and
methods at both pH conditions. The release profile obtained by ultrafiltration of
a 0.5 mg copolymer/mL solution is shown ( ) in addition to release profiles
obtained by dynamic dialysis of micelle solutions composed of 1.0 (

), 0.5 ( ),

and 0.1 (×) mg copolymer/mL. Additionally, the profile of free DOX (0.12
mg/mL) allowed to dialyze from the cassette ( ) and the DOX release profile
obtained by dynamic dialysis of a 0.5 mg copolymer/mL solution (which had
been dialyzed for 72 hours in release media to remove conjugated DOX) spiked
with 0.1 mg/mL of free DOX (

) are also shown to reflect DOX transport across

the dialysis membrane and the effect DOX partitioning to the micelle has on DOX
transport out of the dialysis cassette respectively. The lines of corresponding
color to the symbols represent the simulated release profiles at those conditions
generated by the fitted parameters reported in Table 7.2 using the mathematical
model developed. The inset at the top right of each plot reflects the entire time
course release was monitored while the initial phase of release is shown in the
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main plot.

Error bars indicate the standard deviation of triplicate release

studies at each time point.
Using both ultrafiltration and dynamic dialysis methods to monitor release, DOX
partitioning could be identified and shown to affect DOX release profiles. Based on the
success of this mechanistic model to describe DOX release from HYD, the same model was
applied to the GLY and ABZ formulations to generate constants which described their
release profiles.

7.3.5 Characterization of release kinetics of DOX-conjugated block copolymer
micelles with GLY and ABZ spacers
Release studies of GLY and ABZ micelles showed similar biphasic release profiles as
those observed with HYD by the dynamic dialysis method. This is illustrated by the release
profiles in Figure 7.3. However, release profiles could not be obtained by the ultrafiltration
method for these micelles. This was likely due to the smaller amount present in the fast
phase for these solutions at pH 5.0 and then worsened by the added effect of DOX
partitioning at pH 7.4. Because ultrafiltration was not possible with these formulations,
DOX partitioning was dependent upon the initial (fast) phase of release in conjunction with
the multiple concentrations studied.
Based on the values reported in Table 7.2, several comparisons can be made between
these spacer-modified micelles and the HYD micelles which lack such a spacer. Like the
HYD micelles, DOX partitioning, Kp, is higher at pH 7.4 than at pH 5.0; however, comparing
the values of each formulation to each other is difficult due the large variability indicated by
the confidence intervals. This is not unexpected as Kp is mainly determined in the fast phase
of release observed during dynamic dialysis. In these micelles, this fast phase is the minor
phase of release. Furthermore, this section of the release profile is also complicated by the
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effects of free DOX present in the 0.1 and 0.5 mg copolymer/mL micelle solutions. Unlike
the HYD micelles however, the fraction of DOX release in the fast phase, f, was similar for
release studied at pH 5.0 and 7.4 for both the GLY and ABZ micelles. In addition, the rate
constants of fast hydrazine hydrolysis, k1, also appear to be pH-sensitive in contrast to the
HYD micelles. For GLY, the value of k1 is higher at pH 5.0 than at pH 7.4, but the variability
of this value is high. This is not surprising as the value estimated is similar to the rate
constant of DOX diffusion through the dialysis membrane (kd) and again its estimation is
complicated due to the significant amount of unconjugated DOX released in the profiles
obtained from the 0.5 and 0.1 mg copolymer/mL solutions. This effect essentially results in
a triphasic release profile in which the phase governed by k1 is reduced due to the fast phase
represented by unconjugated DOX initially present. For the ABZ micelles at pH 5.0, the
exact value of k1 could not be determined as the fast phase of release was rate-limited by
DOX transport. During modeling, it was determined that k1 needed to be at least 1.15 hr-1 to
adequately fit the release profiles. This value is only a lower limit for k1 for for hydrazone
hydrolysis of ABZ under pH 5.0 conditions which indicates that release at pH 5.0 for ABZ is
the fastest of the micelle formulations.
The terminal phase (i.e. slow hydrzazone hydrolysis phase) was similar for all three
micelle formulations at both pH conditions studied. Only DOX release from GLY micelles at
pH 5.0 was different, resulting in a hydrazone hydrolysis rate constant of the slow phase, k2,
to be nearly twice as fast that from the HYD micelles and was statistically different.
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Figure 7.3. DOX release profiles obtained for GLY micelles at pH 5.0 (A) and 7.4
(B) along with those obtained for ABZ micelles at pH 5.0 (C) and 7.4 (D). The
symbols used here indicate the same conditions as those used in Figure 7.2. The
release profiles obtained by dynamic dialysis of GLY and ABZ micelle solutions
composed of 1.0 (

), 0.5 ( ), and 0.1 (×) mg copolymer/mL are shown. The

profiles of free DOX (0.12 mg/mL) allowed to dialyze from the cassette ( ) and
the DOX release profile obtained by dynamic dialysis of a 0.5 mg copolymer/mL
solution solution (which had been dialyzed for 72 hours in release media to
remove conjugated DOX) spiked with 0.1 mg/mL of free DOX (

) are also

shown to reflect DOX transport across the dialysis membrane and the effect DOX
partitioning to the micelle has on DOX transport out of the dialysis cassette
respectively. The lines of corresponding color to the symbols represent the
simulated release profiles at those conditions generated by the fitted
parameters reported in Table 7.2. The inset at the top right of each plot reflects
the entire time course release was monitored while the initial phase of release is
shown in the main plot. Error bars indicate the standard deviation of triplicate
release studies at each time point.

7.4 Discussion
7.4.1 Strengths and limitations of micelle release model and methods used
7.4.1.1 Instability of hydrazone bond under storage conditions identified with mathematical
modeling
DOX degradation under the specified storage conditions was unprecedented and
illustrates a prime example of the usefulness of mathematical modeling of drug release in
nanoparticle systems. Without such modeling, the instability of the hydrazone linkage
would likely not have been identified until much later in the development process if at all.
In addition to identifying this instability, the fact that a single value of fc could be fit to
both fast and slow release phases indicates that the structure of the copolymer material in
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its freeze-dried state does not possess the same domains or microenvironments as those of
the micellar structure formed in solution.
While modeling was able to identify hydrazone degradation, the mechanism behind
degradation was beyond the scope of the model. However, several possible modes of
degradation could be hypothesized. First, DOX could have been hydrolyzed during the
freeze-drying process prior to storage. This is unlikely since all the material was freezedried (including the material used for drug release studies at a 1.0 mg/mL block copolymer
concentration) before any analysis on DOX content was performed. According to modeling,
the percent of DOX conjugated was 100% for the 1.0 mg copolymer/mL release studies
performed shortly after synthesis. If DOX degraded during freeze-drying, the percent of
conjugated DOX would have been similar to that observed by release studies performed
with copolymer material that had been stored for 15 months.
The next logical explanation would be degradation due to trace amounts of water still
present or introduced after the freeze drying process. In a previous study, hydrazone
degradation of a DOX conjugate was shown to undergo degradation after lyophilization
during storage at cooler temperatures (2 – 8 °C).198 In that study, the amount of water in
lyophilized samples was approximately 2% and resulted in 20% degradation of the
hydrazone bond after 12 months. Storage of the copolymer material in this study, however,
was stored over a longer period of time but at colder temperatures. Because PEG is
hydrophilic, the PEG chains here may have retained more water residue than the samples in
this earlier study. Increased water residue in the lyophilized cake could lead to increased
hydrazone degradation. This was surmised to be the most likely scenario but additional
studies are required to elucidate the conditions attributing to degradation.
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7.4.1.2 Probing contributions of DOX partitioning and DOX hydrolysis kinetics on release using
sink and non-sink conditions
The terminal phase of release in these profiles is quite slow and could be the result of
slow hydrolysis kinetics of the DOX-hydrazone bond, DOX partitioning, or a combination of
these effects. Distinguishing these effects using only dynamic dialysis or ultrafiltration
methods to monitor release is problematic. By using both methods for the HYD release
studies, the effects of partitioning and slow DOX release become apparent as the % of DOX
removed is greater in all release profiles obtained from dynamic dialysis (at both pH
conditions studied) than the extent of DOX release monitored by ultrafiltration. This
observation indicates partitioning of unconjugated DOX into the micelle is present for both
micelle formulations but not the sole contributor to the terminal release phase as reflected
by the values in Table 7.2.
7.4.1.3 Concentration effects of conjugated and unconjugated DOX on partitioning
While both methods provide the ability to ascertain hydrazone hydrolysis kinetics and
partitioning effects, the simple model used here is still limited in its description of the entire
release profile due to the complexity of the micelle system. Because DOX is conjugated and
initially a large percentage of the micelle (i.e. high drug loading),83 it is reasonable to expect
that in addition to pH, Kp is also a function of the amount of DOX conjugated and the
concentration of unconjugated, partitioned DOX. Such an effect was previously proposed in
liposomal studies for a different drug and was attributed to self-association effects.197 In the
case of micelles however, these high DOX concentrations (conjugated or unconjugated) may
alter the properties (e.g. charge, hydrophobicity) of the micelle environment itself. This is
evident in both Figures 7.2a and b where the fitted release profiles systematically predict
slower release than that seen at several conditions release studies were performed. This
aging effect is revealed because the Kp estimated from the ultrafiltration profiles relies more
214

heavily on the terminal phase of release. At this stage in the release study, significant
hydrolysis (i.e. release) has occurred as opposed to dynamic dialysis in which the effects of
Kp are more pronounced during the initial burst phase of release. In Figure 7.2b, the release
profiles of DOX at 0.5 and 0.1 mg micelle/mL are initially faster as the amount of DOX
conjugated is much higher; however, the spike profile is simulated well. This supports the
notion of aging effects as the micelle samples used in spike experiments had already
undergone significant DOX release and were ultimately more reflective of the micelle
environment at the end of the ultrafiltration studies.
In the release studies conducted with GLY at pH 7.4 (Figure 7.3b), errors in the initial
phase of release are also present; however, it is not the systematic error of slow release
seen in HYD release studies since ultrafiltration studies were not possible with these
formulations and do not share in this bias. In these release studies, Kp is ultimately
determined by the initial phase of DOX release observed in each profile. This is well
illustrated by the pH 7.4 release profiles where DOX partitioning was indicated to be
significant. In the GLY studies, the initial phase of release observed in the spike experiment
is predicted to be slower by the model due to the slower release seen in this initial phase at
0.5 and 0.1 mg micelle/mL concentrations. This would suggest that DOX partitioning may
become diminished at later time points after significant amounts of DOX have been
released. Similar trends are seen to a lesser extend in the ABZ pH 7.4 release profiles as Kp
is lower for these micelles than the Kp estimated for GLY. Such an explanation also explains
the high error in Kp values since it is averaging micelle formulations with different aging
effects.
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7.4.2 Effect of unconjugated DOX partitioning into micelle on observed drug
release under non-sink and sink conditions
The amount of drug released in non-sink studies will vary depending upon the
partitioning of unconjugated DOX into the micelle (Kp). This effect is shown by Figure 7.4 by
comparing the release profile observed for HYD release at pH 5.0 with a simulation of the
profile if no binding occurred.
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Figure 7.4. Simulation of HYD pH 5.0 release profile under non-sink conditions.
Using the rate constants provided in Table 7.2. The % of DOX remaining in the
ultrafiltered samples analyzed during release (
mechanistic model developed (

) along with the fit using the

) are shown and compared to a simulation of

that profile if there was no partitioning of unconjugated DOX (Kp=0) into the
micelle (

). Based on the values in Table 7.2, the amount of unconjugated

DOX that partitioned into the micelle was also simulated as a % of total DOX
present in the solution (

).
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This partitioning effect in conjunction with the rate of DOX transport through the
dialysis membrane has implications on the pH-sensitive nature of the initial phase of
release observed from dynamic dialysis. This is illustrated by Figure 7.5. Here, the release
profile of 1 mg/mL GLY at pH 7.4 was simulated based on the values reported in Table 7.2
and compared to the simulated profile of drug remaining in the dialysis tube still conjugated
to the block copolymer micelles. It is evident that the lag seen in DOX release is due to the
accumulation of free DOX. This is expected based on previous reports of a similar lag in
drug release seen with liposomal nanoparticles using dynamic dialysis. 63, 118, 197 This effect
is exaggerated at pH 7.4 where all formulations have a higher Kp. The high partitioning of
DOX at pH 7.4 reduces the rate DOX is able to leave the dialysis cassette and thus
contributes to the slower release seen at pH 7.4. This is clearly illustrated by Figure 7.5
which compares the release profile of 1 mg/mL GLY at pH 7.4 with a simulation of this
profile if Kp were zero (i.e. no partitioning). If DOX partitioning was not present, observed
release would be faster.

This is also apparent by the rate of unconjugated DOX

accumulation in the dialysis cassette, 𝑑𝑈
, (also shown in Figure 7.5). Here, the accumulation
𝑑𝑡
phase (when the rate is positive) lasts much longer than it would if there was no binding of
unconjugated DOX.
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Figure 7.5.

The effect of unconjugated DOX partitioning is illustrated for

dynamic dialysis release studies. Here, the initial portion of the DOX release
profile from a 1.0 mg GLY/mL solution at pH 7.4 (
profile generated by the mathematical model (

) is shown along with the
) using the values listed in

Table 7.2. This is compared to a simulation of the expected release profile if
only conjugated DOX was monitored (×). This comparison indicates significant
accumulation of released DOX within the dialysis cassette during the initial
phase of release. Furthermore, when the observed release profile is compared
to the simulated profile which assumes Kp is zero (

), the initial phase of

release is shown to be further slowed by DOX partitioning.

This is also

supported by the differences in the rate of accumulation and depletion of
unconjugated DOX in the dialysis cassette (𝑑𝑈
) during dynamic dialysis of the
𝑑𝑡
micelle formulation. The accumulation phase (positive values) of unconjugated
DOX in the dialysis cassette when binding is considered (
that if there were no binding (

).
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) is over double

These effects can be can be better understood by thinking of the effective rate
constant for DOX transport out of the dialysis cassette as:
𝑘′𝑑 =

𝑎 𝑘𝑑

(16)

𝑎+𝑏𝐾𝑝

which takes into the account the fraction of unconjugated drug that is in the aqueous phase.
The equation uses the volume coefficients of the aqueous and micelle phases (a and b
respectively) and the DOX partitioning coefficient, 𝐾𝑝 .

These effects on 𝑘′𝑑 and

subsequently the effective half-life of DOX transport out of the dialysis cassette in the
presence of block copolymers (𝑡1/2 = ln𝑘′(2)) was simulated in Figure 7.6a and b respectively
𝑑

for several micelle concentrations. Based on the parameters generated by the mathematical
model, 𝑘′𝑑 and 𝑡1/2 are also plotted for the micelles studies at the two pH conditions
employed. As these figures show, increases in 𝐾𝑝 and micelle concentration both decrease
𝑘′𝑑 and increase the half-life of free DOX transport from the dialysis cassette.
Both of these effects can be considered simultaneously by calculating the free fraction in
𝑎
the aqueous phase, 𝑓 𝑤 = 𝑎+𝑏𝐾
. Using 𝑓 𝑤 , a general trend can be surmised for 𝑘′𝑑 and t1/2
𝑝

for all micelle concentrations employed. These trends are illustrated by Figure 7.6c.
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Figure 7.6. The effect of micelle concentration and partioning of unconjugated
DOX (Kp) on the effective rate constant, 𝑘′𝑑 , (A) and half-life, t1/2, (B) of
unconjugated DOX transport from the dialysis cassette.

Lastly, micelle

concentration and Kp can be used to determine the fraction of unconjugated DOX
unbound to the micelle, 𝑓 𝑤 (C). The use of 𝑓 𝑤 results in a more general trend
with 𝑘′𝑑 (

) and t1/2 (

). In these plots, the symbols

,

, and

refer to

the values calcualted for HYD, GLY, and ABZ at pH 7.4 based on the parameters
generated in Table 7.2. Their color corresponds to the conditions designated by
the trend line they are related with. The opened symbols of the same shape
correspond to values calculated from pH 5.0 release parameters.

7.4.3 Intrinsic factors governing micellar DOX release
7.4.3.1 pH-dependent DOX partitioning
The effects of DOX partitioning on observed drug release has already been explained;
however the reason why partitioning is higher for all micelles at higher pH is also significant
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and should be addressed. The partitioning seen here may be due to change DOX speciation
as a function of pH. This is illustrated below in Scheme 7.2. DOX is a weak base with a pKa
of 8.2.107 As the pH is increased over the region studied, the fraction of DOX in its neutral
base from increases over 200 fold. If only the neutral form contributed to binding, the
partitioning DOX in GLY and ABZ micelles at pH 5.0 would be 10 and 5. These values are too
small to affect release kinetics at the micelle concentrations employed in dynamic dialysis
studies, making this a plausible explanation for the considerable difference in DOX
partitioning between pH 5.0 and 7.4 studies.

Scheme 7.2. The ionization states of DOX are governed by its acid dissociation
constant (KA) and the pH of the solution. At higher pH, the neutral base form
(DOXNH2) dominates while its cationic form (DOXNH3+) dominates at lower pH.
7.4.3.2 Biphasic hydrazone hydrolysis kinetics
Biphasic drug release has been observed for many micelle systems, but a consensus has
not been reached on the cause of the two phases.16, 99, 104, 205, 206 The exact reason behind the
biphasic release seen herein has not been confirmed, but the most likely hypothesis relates
to the ability of water/hydronium ion to penetrate the micelle core. Due to the hydrophobic
nature of the core, the penetration of water (and subsequently hydronium ions) would not
be a favorable interaction, but is required for acid-catalyzed hydrolysis of the hydrazone
bond used to conjugate DOX to the micelle core. Based on this line of thinking, most of the
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water/hydronium likely resides at the interface of the micelle core and PEG shell. The
hydrophilic nature of PEG would reduce the hydrophobic effect at this interface relative to
the core of the micelle. Conjugated DOX near this interface is relatively free to interact with
water/hydronium because conjugation occurs on the side chains of the polyaspartate core
rather than the backbone of the copolymer scaffold (i.e. more rotational freedom of DOX).
Due to the high surface-area to volume ratio associated with spherical geometries, the
fraction of conjugated DOX susceptible to fast release, f, would only require the shell/core
interface to extend to 7-15% of the total radial distance of the micelle’s core for values of f
ranging from 0.2 – to 0.38. Even the value of 0.68 obtained for HYD micelles at pH 5.0
would only extend the interface to cover approximately 30% of the core’s total radial
distance. The slow phase of hydrazone hydrolysis kinetics also supports this theory as the
core of the micelle (which is sufficiently removed from the core/shell interface) has less
water to achieve hydrolysis. With less water in this region, the rate constant of this phase,
k2, should be much slower and be less sensitive to changes in pH than that expected by
hydrolysis kinetics in bulk solution over the pH range studied here. 198 This is reflects the
trends observed in all three formulations in regards to k2.
Such a theory also explains the fast hydrolysis kinetics observed for ABZ and GLY
micelles as f nearly remains constant while k1 increases at lower pH. This observation is
consistent with acid-catalyzed hydrazone hydrolysis.198 The HYD micelles however, do not
show an increase in k1 but an increase in f. This would suggest penetration of water
increases but the activity of hydronium does not within the micelle environment as pH is
lowered. While not as straightforward as the ABZ and GLY micelles, HYD micelles may still
conform to the above theory if acid supplied locally by unreacted hydrazide side chains of
the polyaspartate core dominate acid catalysis.
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7.5 Conclusions
DOX release from HYD, ABZ, and GLY micelles was analyzed in both acidic and neutral
conditions. Irrespective of drug release conditions and formulation, micelles exhibited
biphasic DOX release. A drug release model accounting for biphasic release was developed
and parameters were estimated through mathematical modeling.

Modeling results

identified a stability issue with the hydrazone linkage used to conjugate DOX to the block
copolymers stored after freeze drying. This stability issue was confirmed by two other
independent methods. The impact of such a finding is significant as researchers considering
the use of drug conjugation strategies employing a hydrazone linkage should be
cognoscente of these stability issues and give careful consideration to validation of
conjugation stability at the storage conditions selected. Failure to do so could lead to poor
efficacy results in preclinical testing if particles with this stability issue are administered
after a period of time in which drug conjugation has started to degrade.
In addition to the stability issue, mathematical modeling also revealed pH-sensitive DOX
partitioning was present in all three micelle formulations. Due to the complexity of the
micelle system, this partitioning effect also appeared to be dependent upon particle aging.
This was evident because partitioning effects in the initial phase of release observed by
dynamic dialysis of freshly-constituted micelle solutions was different than the partitioning
captured in micelle samples used in ultrafiltration and spike experiments. (i.e. conditions
where significant amounts of conjugated DOX had already been released at the point in
which DOX partitioning was estimated). Future studies which can capture the change in
DOX partitioning with micelle aging may be useful in the development of in vitro/in vivo
correlations for drug release from micelle formulations.
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While the variability in partition coefficient estimation was high, its effect on drug
release kinetics was observed. As the fast hydrazone hydrolysis rate constants for all
micelle formulations were within the same magnitude as rate constant of free DOX
transport across the dialysis membrane, the initial phase of release was slowed due to the
reduction in the fraction of unconjugated DOX available to permeate the dialysis membrane.
This reduction driving force of DOX transport from the dialysis cassette exaggerated the
initial lag in DOX release in a manner similar to that previously reported when monitoring
release kinetics from liposomal formulations using dynamic dialysis.49, 118, 197
In addition to partitioning, hydrazone hydrolysis kinetics were quantified for all three
micelle formulations and shown to be biphasic. This was attributed to the likely scenario of
higher water penetration at interface of the PEG shell and micelle core than at the center of
the hydrophobic core. The insertion of spacers appeared to keep the fraction of conjugated
DOX that underwent fast hydrolysis similar between release studies conducted at pH 5.0
and 7.4. The spacers also appeared to have an effect on the hydrolysis rate constant within
the fast phase of release. This was most evident for DOX release from ABZ micelles at pH
5.0. Hydrazone hydrolysis kinetics of DOX in the fast phase was too fast to be determined
due to rate-limiting DOX transport across the dialysis membrane.
These results illustrate the usefulness of mechanistic mathematical models in the
development process of micellar nanoparticles. The approach used to here develop a
mechanistically-based mathematical that accounts for method-specific effects on observed
drug release profiles should prove to be a useful guide for assessing release characteristics
intrinsic to a particular drug/nanoparticle system.

Copyright © Kyle Daniel Fugit
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CHAPTER EIGHT
Conclusions and Future Directions
Unlocking the full potential of nanoparticles as drug delivery vehicles requires
developing rationally-design formulations with predictable properties in vivo. A paradigm
shift from the current trial-by-error approach used to design nanoparticle formulations to a
more methodical approach will only be facilitated with fundamental knowledge of the
critical physicochemical properties and physiological mechanisms affecting nanoparticle
performance (i.e. drug release kinetics). Mechanistic mathematical models supported by
experimental studies provide a means to study these effects. The studies conducted within
this thesis provide several examples of identifying physicochemical properties and
environmental (sometimes even physiological) conditions through mechanistic modeling of
experiments rationally designed to identify such effects. More importantly, these studies
demonstrate a methodical approach for future nanoparticle formulation design and
development.
The non-sink ultrafiltration method developed in chapter three provided a way to both
quantify drug permeability and binding constants for liposomal drug delivery systems. This
study also provided a quantitative example of the differences in release profiles due to the
presence of non-sink or sink conditions. The interplay of both kinetic and thermodynamics
effects on liposomal release kinetics are clearly illustrated by this study and stresses the
importance for nanoparticle formulators to consider both effects when evaluating
characterization studies of drug release from nanoparticulate drug delivery systems.
The results of chapter four demonstrated the applicability of the non-sink method to
observe the pH-sensitivity of both liposomal topotecan release kinetics and interfacial
binding at the bilayer surface. This study is also the first attempt to develop an extensive
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mechanistic model for topotecan release. Developing this model required further studies to
evaluate the ionization state (i.e. pKa) and kinetics of reversible, pH-dependent, ringopening/closing of topotecan. Adaptation of the model to incorporate opening/closing of
topotecan’s lactone ring identified the rate-limiting effect of ring-closing on release kinetics
and the observed pH permeability profile. The constants estimated by this mathematical
model also laid a foundation for future studies of liposomal topotecan intended to probe
effects on more sophisticated, and commonly studied, liposomal formulations of the drug.
Chapter five probed the effect of ammonia on liposomal release kinetics of activelyloaded (i.e. low intravesicular pH driven loading) topotecan. In the course of this study, a
spectroscopic fluorescence method was developed to monitor liposomal release kinetics
and validated with the aid of mathematical modeling. Consequently, modeling showed
increases in the rate of release with increasing ammonia concentrations. The increase in
release correlated with increases in intravesicular pH due to ammonia influx from the
extravesicular solution. These simulations combined with the ammonia levels measured in
the various release media studied (solutions or plasma) identified a correlation between
accelerated release and increases in intravesicular pH rather than some other physiological
effect present in the plasma samples. The implications of this observation are significant.
Many liposomal delivery systems are actively-loaded and take advantage of low
intravesicular pH to increase loading efficiencies and slow release.

Any of these

formulations will also be sensitive to ammonia influx. This study also warns of the great
care that should be taken when using plasma to study release as its stability can have undue
effects (i.e. acceleration) on release kinetics.
Chapter six built upon the physicochemical properties identified in Chapters 3- 5 to
develop a mechanistic model capable of explaining loading and subsequent release kinetics
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from actively-loaded formulation of liposomal topotecan. Mathematical modeling of active
loading kinetics at 37 °C suggested uptake of cationic topotecan across the bilayer occurred
as an ion-pair with chloride present in the loading solution. This prediction was confirmed
with release studies which showed slower release in the absence of chloride. Using the
transport mechanism suggested by modeling these loading experiments, the effect of
loading temperature on topotecan release was evaluated.

A mechanistic model

incorporating the precipitation of a topotecan HCl salt within the liposome led to the
extended release kinetics observed from topotecan loaded at 60 °C. The mechanism of
transport identified for actively-loaded liposomal topotecan will aid in formulation
optimization. These results suggest alterations in the levels of chloride during loading could
provide a rational way to tune liposomal release kinetics of topotecan.
Lastly, chapter seven extended the approach used to mechanistically model liposomal
drug release to the development of mechanistic models for the characterization of drug
release from polymeric micelle nanoparticles. Experimental release studies of doxorubicin
conjugated to block copolymers via a pH-sensitive hydrazone linkage were mechanistically
modeled. The model-predicted instability of doxorubicin conjugation during storage was
experimentally confirmed. This finding is considerable to the field of nanoparticle drug
delivery systems as because many polymer-based formulations use a similar conjugation
strategy, making them potentially susceptible to this stability issue. Such stability issue
could greatly alter the in vivo performance of these nanoparticle formulations if significant
storage has been incurred between synthesis and preclinical studies. In addition to stability
issues, further modeling of doxorubicin release kinetics using sink and non-sink conditions
revealed biphasic release and partitioning of unconjugated doxorubicin into the micelle
phase. While the stability and partitioning effects complicated the interpretation of release
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kinetics, these studies were still able to illustrate the kinetic and thermodynamic factors
affecting release kinetics under sink and non-sink release conditions.
While the developed models within this thesis sometimes become quite complex, the
same initial approach was used for the development of each model. This approach is
generalized by the equation below:

∑
𝑖

𝑑𝑀𝑖
= ∑ [∑ 𝑘𝑗 (𝑡, 𝑟, ∑ 𝑀𝑖 , ∑ 𝐺𝑖 ) 𝑀𝑖,𝑗 ]
𝑑𝑡
𝑖

𝑗

essentially, any drug species, i, that may undergo transport into or out of the nanoparticle
must be expressed by their respective rate of change,

𝑑𝑀𝑖
𝑑𝑡

, with their sum yielding the net

transport of drug from the nanoparticle. These rates are governed by the sum of kinetic
processes, j, with each process described by a rate constant for that particular driving force,
𝑘𝑗 , which contribute to the rates affecting the release of drug species, 𝑀𝑖 . In some cases, this
is strictly diffusion, but other kinetic factors (e.g. drug interconversion, degradation
kinetics, convection) may also be incorporated as was successfully demonstrated in several
chapters of this thesis. These rate constants may be a function of time, position (denoted by
the variable, r), other drug species in solution (∑ 𝑀𝑖 ), as well as other excipients or solutes
in solution (∑ 𝐺𝑖 ). In addition to these rate constants, the driving force may also be
dependent upon the amount of species i that is susceptible to the kinetic process 𝑘𝑗 (which
is denoted by 𝑀𝑖,𝑗 ). Two clear examples of this effect relate to the transport of only drug
species unbound to the bilayer driving drug diffusion through the bilayer and the driving
force governing drug transport through dialysis membranes in both liposomal and micellar
drug release studies. Equilibrium constants were used throughout these chapters to solve
for 𝑀𝑖,𝑗 in terms of 𝑀𝑖 . These mathematical manipulations also illustrate the mechanistic
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aspect of modeling release kinetics via the incorporation of thermodynamic coefficients
governing drug speciation.
While the terms comprising 𝑘𝑗 appear to be complex functions in the generalized
equation above, they can usually be simplified and assumed to be constant depending upon
the conditions in which they are evaluated. Much of this work assumes constant release
rate constants for the evaluation of these release studies; however, exploration of their
dependence on environmental factors and consequently their dependence upon some of the
variables mentioned above may be of relevance in the future development of
nanoformulations. In the case of liposomal formulations, factors which alter the barrier
properties of the lipid bilayer are of key importance to extending the predictability of
release kinetics under in vivo conditions. In the actively-loaded formulations studied here,
the low intravesicular pH calculated in these formulations may alter bilayer properties as
lipid degradation is acid-catalyzed. The resulting lysolipids, other degradation products, or
the loss of PEG over time may alter partitioning, drug diffusivity through the bilayer,
interfacial drug binding, or a combination of these properties. The first three of these
factors would directly alter drug permeability while the last would alter the concentration
gradient of unbound drug driving drug release. Such changes may be particularly important
for liposomal formulations in which release occurs over several days and remain in
systemic circulation over a similar period of time. Under these circumstances, liposomal
drug release may be more dependent on bilayer degradation due to many of the factors
illustrated to slow release (e.g. self-association, precipitation) within this thesis.
The high concentrations of intravesicular drug observed during active-loading (in these
studies and typically present in other formulations that employ a similar loading process)
may also alter bilayer properties. This was partially illustrated in chapter three which
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illustrated the effect of charge buildup upon the bilayer surface diminishing binding as drug
concentrations increased. In this case, the driving force increases as higher drug loading is
achieved. A similar scenario may also occur for neutral, highly lipophilic compounds which
may exhibit much higher binding constants than topotecan. Such compounds may exhibit
saturable binding if high enough intravesicular concentrations are achieved. Furthermore,
the binding of pharmaceutical agents may alter the structure of the bilayer itself. One can
understand this best by considering such an effect on bilayer chain ordering. Incorporation
of enough drug may have effects similar to the incorporation of cholesterol on bilayer chain
ordering and surface density calculations. The diffusivity of drug as well as the volume
contributions of the membrane and aqueous volume may be significantly altered if enough
drug is incorporated into the bilayer. Such effects may become important and require
further study for liposomal formulations that incorporate more lipophilic agents. Lastly,
these high intravesicular drug concentrations may also increase osmotic stress on the
bilayer.

Considerable effort was made to maintain isotonic conditions during release

studies, but the effect of high intravesicular concentrations of drug were problematic to
address as release or uptake during studies could conceivably alter intravesicular
osmolality throughout the experiment. While these stresses did not seem to change particle
size significantly (which would have suggested ruptured or shriveled vesicles), significant
counter-transport of water across the bilayer may have occurred to compensate for the
changes in intravesicular osmolality due to solute transport. The transport of water across
the bilayer (and consequently its presence within the bilayer) may also alter bilayer
properties and may enhance the partitioning of a TPT-Cl ion-pair within the bilayer.
Enhancing ion-pair partitioning of topotecan and Cl would consequently promote its
transport across the bilayer.
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Developing more mechanistic approaches to modeling drug release for other
nanoparticle formulations should also be explored. For polymeric micelles, identifying the
factors which affect the hydrolysis kinetics of drug conjugated to the copolymers
comprising the micelle may be advantageous. It may also be helpful to perform additional
studies that probe the mechanism governing partitioning of unconjugated drug to the
micelle core and/or its surface. Developing rational ways to test the mechanisms of drug
release in other nanoformulations should also be possible if one is cognizant of the general
transport equation above and correctly identifies the factors likely to govern drug transport
from the nanoparticle under consideration.
As more variables affecting release kinetics are incorporated, evaluating the validity of
these mechanistic mathematical models will also be of greater importance. During the
course of these studies, most of the effort given to regression analysis of these mechanistic
models concerned the achievement of the global minimum for the objective function and
reducing correlation coefficients. Confidence in achieving the global minimum can be quite
difficult when multiple data sets and parameters are fit simultaneously (as was the case in
nearly every chapter of this thesis) due to a high probability of multiple local minima
existing under these scenarios. Such a challenge is best addressed by careful consideration
of the initial values provided for parameters to be evaluated by regression. Sensical initial
values can sometimes be determined by preliminary simulations of the model using a range
of parameter values. Sometimes, logical reasoning based on previous studies in the lab or
from values reported in the literature (e.g. properties of similar particles or drugs) can be
used to provide reasonable estimates for these initial values. At other times, especially in
the case of more complex models, regression may fail when multiple parameters have
similar mathematical (but mechanistically distinct) effects on fitting the data. Chapter four
contains a good example of this situation as changes in both ring-opening kinetics and the
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pKa of topotecan’s phenol could provide similar effects on the drug’s liposomal release
profile. This is one of the main reasons why separate experiments were required to validate
the constants for both topotecan’s phenol ionization and ring-opening/closing
interconversion kinetics. Further evidence of the relationship of these parameters was also
observed by the correlation coefficients obtained during model fitting of these parameters.
Correlation coefficients aid in understanding the limitations of using a particular data
set to provide high statistical confidence for parameters evaluated by regression. High
positive or negative correlation (values approaching 1 or -1, respectively) between multiple
fitted parameters will also result in poor confidence limits for those parameters in most
cases. This issue may require additional experiments to isolate one or more of these
parameters (as already mentioned for chapter four). Another way of circumventing this
issue may be mathematical transformation of the equation or parameters of interest.
Rewriting the rate constants for ring opening and closing in chapter four in terms of the ring
closing rate constant and an equilibrium constant between the ring-opened and closed
forms is an example of such a transformation.
Sometimes mathematical transformations may also allow the removal of bias when
parameters from previous studies are used. Such was the case in chapter six. Here, an
expression for topotecan’s true pKa was rewritten in terms of the previously determined
pKa and its ion pairing association constant with Cl. This effort was made to remove any
bias ion-pairing with Cl may have contributed during the previous study which determined
TPT’s pKa. While such considerations remove some bias, one can argue that any of these
previously determined values (whether from other studies performed by the experimenter
or reported in the literature) are still only a sample mean of a population and therefore
must have a measure of the variance of the sample data too. Fixing certain parameters in
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this manner may lead to underestimates in the uncertainty of those parameters that are
fitted. Perhaps simultaneous regression of those data sets along with the new data sets (e.g.
release profiles) would provide a better assessment of the values of interest for the
population. Currently, however, many of the data fitting software packages available are
not capable of handling multiple data sets during regression analysis. Hopefully, further
advancements in software and processing will allow such a global fit of data to be
achievable.
Perhaps advancements in regression software will also provide a better statistic to
determine the validity of these complex models. Most regression software packages do
have some indicator of the model’s ability to fit the data set. This indicator is illustrated in
chapter six by the Model Selection Criterion (MSC) as it is the calculation made by the
regression program used for these studies to assess goodness-of-fit. MSC, like similar
values reported by other software programs, is only useful as a relative scale in the
determination of whether one model or another is a better fit of a certain data set. It
cannot, however, provide an absolute statistic indicating the probability that the fitted
model accurately explains the data. In this thesis, the validity of a model has been handled
to an extent by using parameters generated by one data set to predict the outcomes of
separate experiments performed under different conditions. Another future test for model
validity might be the analysis of residuals between experimental and predicted values from
the fitted model. Such an analysis would speak to the scatter of data and identify systematic
deviations in the data. Both of these approaches, however, only provide a qualitative
demonstration of the model’s validity. One possible solution may be a lack-of-fit test
performed as part of the analysis of the multiple conditions fitted to the developed models
during regression. This test, however, requires the ability to determine the sum of square
errors attributable to the lack-of-fit (SL) and noise of the experimental method (SE).
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Calculation of these variables, however, requires repeated experiments at the same
conditions to isolate SE., which was not done in many of these studies. It would appear
reasonable for future studies which aim to utilize such a statistical test to have at least one
condition repeated to assess this error and calculate the lack-of-fit F-statistic. Assessing the
sensitivity of this statistic, however, is a more complicated issue. The F-statistic calculated
by the lack-of-fit test (as well as the critical F-value used to judge the probability of a lackof-fit) is highly dependent upon the degrees of freedom associated with the modelevaluated data set. More specifically, the number of parameters, study conditions (e.g.
release studies at different conditions), and total number of observations will alter the
magnitude of both the experimental and critical F-values of the study. High critical F-values
are an indication that the number of fitted parameters is too high for the number of
conditions evaluated in the study (i.e. a statistical false negative would result). Under this
scenario, the lack-of-fit test would be too insensitive for a meaningful evaluation of the
model’s ability to explain the data set in question. Use of this test for the evaluation of
future models will thus require careful consideration of the statistical power necessary for a
meaningful lack-of-fit test.
While this work provides insights that will aid in the optimization of the nanoparticle
formulations studied herein, future work is still necessary to probe the issues mentioned
above. Such studies will aid in the eventual prediction of in vivo nanoparticle drug delivery
systems from in vitro characterization studies.

Even so, these studies illustrate the

advantages of a combined experimental and mechanistic modeling approach to characterize
the physicochemical properties governing release in nanoparticle drug delivery systems.
The studies discussed in this dissertation will provide examples for future approaches to
analyzing drug release kinetics and developing models capable of predicting drug release.
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